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ABSTRACT 
of a Ph. D. thesis (CNAA) entitled 
"Bioavailability studies on orally administered, oily suspensions of drugs". 
by 
Omran M. O. Alhammami 
Bioavailability studies on suspensions of sodium salicylate, 
nitrofurantoin and ampicillin in various oily vehicles, based on 
Fractionated Coconut Oil (FCO), have been carried out in either rabbits or 
rats. In vitro dissolution rate tests have also been performed, together 
with rheological, solubility, adsorption and partition coefficient 
measurements. 
The results suggest that the viscosity of the vehicle plays an 
insignificant role and that most of the observed changes occurring 
in vivo can be attributed to the delaying effects of FCO on the gastric 
emptying rate (GER). The results of this delay depend on the pK ý1 value 
and solubility of the drug. In the case of ampicillin, stimulation of a 
biliary recycling process by the oil also appears to affect the plasma 
concentration versus time curve. 
The inclusion of sucrose in FCO also leads to significant changes 
when the apparent partition coefficient of the drug between FCO and 0.1 
mole/dn-? HCI is high, as it is for sodium salicylate, but not when it is 
low, as with ampicillin. It is suggested that the bioavailability 
increasing mechanism of sucrose is caused by the effect of high osmotic 
pressure on the uptake of water by the GI membrane and is not due to an 
additional delay in GER over that caused by the oil itself. The enhancing 
effect of sucrose on the bioavailability of salicylate is nullified by the 
inclusion of 1% Cab-o-sil and it is suggested that adsorption of the drug 
on to Cab-o-sil is responsible for this effect. 
The in vivo bioavailability parameters correlated poorly with in vitro 
parameters. It is suggested that such correlation indicates that 
traditional dissolution rate tests, such as dialysis and flask-stirrer 
methods, are unsatisfactory as bioavailability indicators when applied to 
dosage forms that cause marked changes in physiological factors like GER 
and biliary excretion. 
(v) 
ACKNOWLEDGEMENTS 
The author wishes to thank 
Dr. John H. Richards, B. Pharm. , Ph. D. , M. P. S. , Reader in Pharmacy, 
Leicester Polytechnic, England, for his encouragement whilst 
directing the work presented in this thesis and many helpful 
discussions. Dr. Richards' patience, encouragement and 
enthusiasm have been constant inspirations. 
My father, Alhaj Moosa Omran Alhammami, for the financial support 
that made this work possible. 
Dr. C. A. Walton, B. Pharm., Ph. D., M. P. S., Head of Pharmaceutical 
Formulation, Glaxo Research Ltd., who acted as my External 
Supervisor. 
Mr. G. Redfern, B. Sc. (Maths), B. Sc. (Stats), M. Phil., F. S. S., 
Head of Statistics, School of Mathematics, Computing and 
Statistics, Leicester Polytechnic, England, for useful discussions. 
Mr. C. Boot, Mr. G. H. Cragg, Mr. L. Patel, Mr. H. Lomas, Mr. M. Edwards, 






I. I.. Definition and significance of bioavailabLL! 
_ýj 
The term bioavailability is usually defined as the rate and 
extent of absorption of a drug from its dosage fo rm into the systemic 
circulation (Blanchard and Sawchuk, 1979). In the context of this 
definition, general circulation refers primarily to venous blood 
(excepting the hepatic blood during the absorption phase) and arterial 
blood which carries the drug to the tissue (Gibaldi and Perrier, 1975). 
According to the above definition, the bioavailability of an 
intravenously administered drug is rapid and complete. However, for 
reasons of convenience and stability, most drugs are administered 
orally after first being formulated into a dosage form (delivery 
system), which is usually a tablet or a capsule. In these circumstances 
the rates and extents of absorption of the drugs in an individual are 
usually not precisely known for reasons that are given later in this 
section. 
Other terms that have identical or similar meanings to 
Ibioavailabilityl have also been referred to in the literature, e. g. 
'physiological availability' (Oser et a], 1945), 'efficacy of 
absorption' (Wagner, 1971a), Ibiophasic availability' (Smolen, 1971), 
'systemic availability' (Barr, 1973) and the more general term 
'biological availability'. 
Since it is generally assumed that the therapeutic effect of a 
drug is a function of the concentration of the drug in a patient's 
blood (or plasma or serum) the importance of bioavailability in drug 
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therapy stems from the fact that the rate and extent of absorption 
of an administered drug can, in principle, affect the patient's 
response to the drug. 
The intensity of pharmacological response elicited by many drugs 
is probably directly related to the concentration or activity of the 
drug in the immediate vicinity of the receptor site in the blood 
(i. e. biophase)- (Ariens, 1964). The term biophasic availability has 
been used by Smolen (1971) to describe the availability of a drug in 
its biophase. Unfortunately, this approach is only useful for drugs 
whose intensity of action can be easily and accurately determined, and 
for the majority of drugs this approach tends to be difficult and of 
limited sensitivity. Furthermore, it is often not possible to measure 
the drug concentration directly by sampling from the biophase, 
therefore the concept of biophasic availability is presently more 
useful than its application, at least for the majority of the drugs 
(Koch-Weser, 1974). 
The clinical significance of bioavailability depends on the 
assumption that an apparent distribution equilibrium is established 
between drug in the blood and receptor compartments. Once this 
equilibrium has been attained, measurement of the concentration of 
drug in the blood is assumed to provide an indirect measure of the 
concentration of drug at the receptor site (Koch-Weser, 1972; Chasseaud 
and Taylor, 1974). Alternatively, urinary excretion of the unchanged 
drug can be measured (Koch-Weser, 1974; Ritschel, 1980c; Gibaldi, 1977a; 
Sjoqvist et a], 1980). Hence, the determination of the blood 
concentration or urinary excretion data of the drug may allow one to 
follow the time course of pharmacological activity. However, this is 
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not always the case, since there is no guarantee that a drug 
reaching the systemic circulation will also reach the receptors 
in adequate concentration. It is possible to identify some instances 
in which systemic availability may not necessarily be the same as 
pharmacologic or biophasic availability. This will occur when the 
biophase is in a poorly accessible region, such as a deep-seated 
infection in a poorly perfused tissue, which does not rapidly reach 
distribution equilibrium with the blood compartment. An example of a 
situation where direct measurements on the biophase do show poor 
initial equilibration is seen inthe work of Sholkoff et a] (1967) on 
salicylate concentration in synovial fluid, since these do not 
parallel plasma concentration. 
In spite of this limitation to the clinical significance of 
systemic availability use is often made of bioavailability measurements 
in the assessment of pharmaceutical products. A knowledge of the factors 
that influence bioavailability is therefore important. Barr (1973) 
reported that the amount of drug reaching the systemic circulation is a 
function of, but not necessarily equal to, the amount of drug available 
for absorption from the gastrointestinal (GI) tract. This function is 
dependent on a number of factors that may consequently affect the 
bioavailability. These can be conveniently classified as either patient 
related or dosage-form-related factors (Barr, 1973; Koch-Wesser, 1974; 
Wagner, 1977; Blanchard and Sawchuk, 1979) or, alternatively, 
following Ritschel's nomenclature (1980c), as factors causing either 
physiologically modified bioavailability or dosage form modified 
bioavailability, respectively. The former factors include, for example, 
the effects of stomach emptying rate, intestinal transit time, bile 
salts, mucin, blood flow to the GI tract, variation in the pH of the 
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GI fluids, intestinal metabolism and recycling processes. The 
dosage-form-related factors include formulation and manufacturing 
variables, in other words physicochemical properties of the dosage 
forms, such as particle size, the chemical form and solubility of 
the drug and the type of the vehicle or excipient that is used. 
Knowledge of these factors is essential for proper inter- 
pretation and evaluation of bioavailability studies since a difference 
found in bioavailability between two different drug products may be 
falsely attributed to dosage form factors when a physiologically 
modified bioavailability is the correct cause, unless the change 
in the formulation causes an alteration in physiological function. 
The possible effects of dosage-form-related factors on the 
bioavailability of drugs has led to the concept of the bio- . 
equivalence of drug products. Thus, if two products containing the 
same amount of the same therapeutically active ingredients in the 
same dosage forms (J. e. chemically equivalent or pharmaceutically 
equivalent) produce different bioavailabilities they are said to be 
bioinequivalent. If the bioavailabilities are similar then the 
products may be described as being bioequivalent. If the comparison 
is made of the therapeutic and/or toxicity effects then it is usual 
to talk in term of therapeutic equivalence or inequivalence rather 
than bioequivalence (Blanchard and Sawchuk, 1979). 
1.2 Methods of assessing bioavailability 
1.2.1 In vivo methods 
The pharmacological responses elicited by some drugs may be 
used to provide an assessment of bioavailability (Koch-Weser, 1974; 
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Wagner, 1975c) ; e-g- the lowering of blood sugar by antidiabetic 
agents and the lowering of blood pressure by hypotensive agents. 
However, this approach cannot be used for many drugs and, consequently, 
most bioavailability assessments are based on the determination of 
the concentration of the drug, and/or its metabolites, in samples of 
blood and/or urine (Gibaldi and Groundhoffer, 1975; Wagner, 1977; 
Dittert and DiSanto, 1978; Sjoqvist et a], 1980), that are taken at 
specified times after administration of the drug or drug product to 
the subje ct, which may be a laboratory animal, a human volunteer or 
a patient. Plots of the resultant data*yield cueves describing the 
time course of the drug in the body fluid and are often referred to 
a blood level curves, urinary excretion curves, etc. 
Comparisons of parameters derived from blood level curves with 
those derived from a similar curve obtained after administration of 
a reference formulation allow an assessment of the bioavailability of 
the drug in the test formulation t6 be made. If the reference 
formulation is an intravenous injection then it is accepted that the 
method yields an absolute assessment but if an extravasally 
administered reference formulation is used, e. g. an orally 
administered solution or standard formulation of proven clinical 
efficacy, then the bioavailability of the drug in the test 
formulation is generally assessed in a relative manner. However, it 
is-poýsible to obtain an estimate of the absolute bioavailability of 
certain drugs without using an intravenous injection as the reference 
formulation by using Lalka and Feldman's method (1974). This method 
is based on the concept of renal clearance and involves perturbation 
of the clearance of a drug by the co-administration of urinary 
acidifying or alkalinizing agents, A modification of this method has 
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been proposed by Barzegar-Jalali (1980), which avoids the need for 
frequent blood sampling. 
The parameters that are usually derived from blood level curves 
and used in bioavailability assessments are M the area under the 
curve (AUC), (ii) the peak time (PT) and (iii) the peak concentration 
( PC). A comparison of AUCs for test and reference formulations yields 
an estimate of the extent of absorption, whereas an analysis of the 
peak times and peak concentrations provides an evaluation of the 
rate of absorption (Gibaldi, 1977a, Kaplan and Jack, 1979). 
The information obtained from the blood level curves of a drug 
may often be supplemented by estimates of drug excreted in the urine. 
In fact, if an assay of the drug in blood is either unavailable or 
ynreliable urinary excretion data may provide the only effective 
measurement of bioavailability, e. g. for nitrofurantoin (Cadwallader 
et al, 1978). It is usually recommended that the amounts of intact 
drug and its metabolites in the urine should be determined. 
However, Ritschel (1980b) has shown that if at least 10% of the 
drug is excreted intact then measurement of this intact drug alone is 
adequate for estimation of the extent of bioavailability. 
Although an indication of the rate of bioavailability can be 
deduced from urinary excretion curves the practical data is often 
not very precise because of the difficulties that arise in the 
collection of samples at given times and frequencies. These 
, difficulties can be overcome by catheterisation of the subject. 
Since the results obtained in an in vivo bioavailability 
assessment will be influencedmarkedly by the biological variability 
between subjects, then an adequate experimental design is essential 
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in order to minimise this influence and allow its effect to be 
taken into account in the analysis of the results. The design of 
comparative bioavailability tests and analysis of their results has 
been reviewed by Westlake (1973 and 1979). 
1.2.2 In vitro methods 
The in vivo methods of assessment that are mentioned in the 
previous section are expensive and time-consuming. Consequently, 
many attempts have been made to develop relatively rapid, inexpensive 
and reproducible methods that can be used either in the development 
of new dosage forms or in the quality control of existing products. 
These attempts have usually bee n concerned with the development and 
use of in vitro models that simulate and describe the dissolution and 
absorption of drugs in vivo. Such models have allowed many useful 
studies to be carried out on the effects of a variety of factors that 
are important in the design and control of drug properties. Examples 
of such studies can be listed as follows: - 
(a) Effects of physicochemical properties of drugs on their 
dissolution rates (Nelson, 1962a; Nelson et a], 1962; Higuchi et 
a], 1965; Wuster and Taylor, 1965). 
(b) Effects of manufacturing processes, excipients and tablet 
coating on the release of drugs from dosage forms (Levy and Hayes, 
1960; Levy et a], 1963; Morrison and Campbell, 1965; Paikoff and 
Drumm, 1965; Wood, 1965). 
(c) Screening potential dosage, forms for bioavailability purposes 
(Yen, 1964), 
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(d) Retrospective studies carried out in attempts to explain the 
clinical failure of a particular dosage form (Keller, 1960; 
Campagna et al, 1963; Levy, 1964). 
(e) Sensitive quality control procedures aimed at the detection of 
changes in drug release characteristics caused by batch-to- 
batch variation, formulation changes or storage conditions. 
(These changes may or may not be detected by a less sensitive 
in vivo method. )(Markus, 1970; Pernarowski, 1970). 
Indication of differences in the in vivo absorption characteristics 
of drugs and provision of a secondary standard to detect dosage 
forms with a potential for poor bioavailability (U. S. P. XVIII; 
U. S. N. F. XVIII). 
The use of in vitro dissolution methods as quality control 
procedures in the latter two examples have somewhat different 
requirements from each other. When they are used as a quality control 
screening procedure, as in (e), to detect batch-to-batch differences 
or changes in the dissolution characteristics during storage of dosage 
forms the principal requirement will be the sensitivity and 
reproducibility of the method to detect small differences. However, 
these differences may or may not be indicative of differences in 
in vivo bioavailability that are the subject of (f). 
There are probably at least 100 or more different types of 
apparatus that have been proposed for the determination of the 
dissolution rates of drugs themselves or drugs from dosage forms. 
Classifications of these types. have been given by Hersey (1969) and 
Swarbrick(1970) and the factors that affect the sensitivities of the 
different methods and extents of correlations between in vitro and 
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in vivo parameters have been reviewed by Wagner (1961); Higuchi 
(1967); Wood (1967); Fincher (1968); Levy (1970); Gibaldi (1977c) 
and Nelson and Miller (1979). 
1.2.3 Correlation between in vivo and in vitro data 
The significance of the in vitro dissolution testing should 
never be overlooked or taken for granted, since the in vitr 
release or dissolution rates do not necessarily reflect La v-! -v-Q 
absorption rates. The La vitr tests of any sort have no intrinsic 
value per se but are useful only to the extent that they correlate 
with quanti. tative in vivo results. This approach can only be 
achieved when the in vitro tests are able to simulate in vivo 
conditions (Filleborn, 1948). 
While there are reports in the literature describing correlations 
between in vitro disintegration and dissolution times and in vivo 
availability, there are also many other reports in which such 
correlation is not observed (Morrison and Campbell, 1965; Wagner, 1971b). 
The limitations associated with in vitro dissolution tests reflect 
the complex physiological mechanisms involved in drug release and 
absorption. Furthermore, it is not generally appreciated that 
components in a formulation may themselves alter physiological 
mechanisms involved in the determination of bioavailability. These 
in vivo factors can mask or distort possible correlations. Currently 
used dissolution tests do not predict the effect of these 
physiological changes. New types of-oral dosage forms, which involve 
the use of osmotic pressure elevators or oily vehicles, can alter 
significantly some of the physiological functions which cannot be 
A 
10 
detected by in vitro tests. These could include variable gastric 
emptying and intestinal rates or changes in GI pH. Dissolution tests 
may indicate the type of the release, but in vivo performance can 
only be determined by in vivo measurement in man. 
However, where physiological factors play no significant role 
in the absorption process, in vitro dissolution tests do have a 
significant predictive value for drugs that exhibit dissolution rate 
limited absorption. Many reports show variations in clinical response 
between two or more orally administered dosage forms containing 
chemically equivalent amounts of a drug, usually of limited aqueous 
solubility. These have been summarised by Barr (1969) and Riegelman 
0969). Frequently, this variation has been traced to differences 
in the dissolution rate of the drug from the dosage form, which, in 
turn, affected the GI absorption of the drug. Thus, solid dosage 
forms (e. g. tablets) exhibiting inadequate clinical activity 
possessed a low dissolution rate relative to those tablets giving the 
expected response or activity. Tablets having an enhanced availability 
or pharmacologic response invariably had a rapid rate of dissolution. 
Wagner (1971c) classified in vivo - in vitro correlations into 
two types: - 
0) Quantitative correlations where the in vivo variable (Y) is 
related to the in vitro variable (X) by an equation such as 
Y= bX, Y=a+ bX, log Y- log Y 
0- 
bX, Y=a+ log X, 
-etc. 
These are obviously the more informative correlations. However, 
such a relationship should probably be derived only when there 
is a theoretical reason for relating the variables as indicated 
by the equation derived. For example, Bates et al (1969) found 
a correlation between the man cumulative percentages of 
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salicylamide (Y) excreted in the urine one hour after 
administration of these dosage forms of the drug and the 
percentage of salicylamide dissolved after 15 minutes in vitro 
(X). The correlation could be expressed as Y-0.47 X+0.07. 
A relation Y=-0.544 + 1.003 log X was established by Maeda 
et al (1979) for three griseofulvin dosage forms. In this 
relationship Y represents the mean plasma level of the drug 
and X is the amount of drug that is released from the dosage 
form within 30 minutes in an in vitro dissolution tests. 
(ii) Rank order correlations, in which (a) Y increases as X increases, 
(b) Y-increases as X decreases or (c) Y decreases as X increases. 
For exampleMacDonald et a] (1969) found a rank order correlation 
between the AUCs for four tetracycline hydrochloride dosage 
forms and the corresponding dissolution half-lives of the drug 
from the dosage forms. The higher the dissolution half-life the 
lower the AUC. In addition, a direct rank order correlation was 
observed between the amount of salicylate excreted in the urine 
after one hour following administration of four aspirin dosage 
forms and the amount of aspirin that dissolved in 10 minutes in 
ýLj ýtro (Levy et aI, 1961 ). 
Some variables derived from in vivo data that have been correlated with 
variables derived from in vitro are: 
A 
peak blood levels, 
area under the blood level curve between time 0 and t, 
absorption rate constant, 
amount. of drug excreted in the urine in a given time, 
urinary excretion rates at given times, and 
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pharmacological responses such as blood sugar lowering, blood 
pressure, pain relief, etc. 
Similarly, variables derived from in vitro data that have been 
correlated with in vivo data include: 
disintegration time, 
time for some percentage of the drug to dissolve in vitro, 
e. g. t50% - time for 50% of the drug to dissolve, 
concentration of solution or amount in solution at a given time, 
intrinsic dissolution rate, and 
first order rate constant of the dissolution process (Wagner, 
1971c). 
The correlation of in vivo with in vitro data has been reviewed 
extensively by Levy (1966), Swarbrick (1970), Wagner (1971c) and 
Barr (1972). 
1.3 Physicochemical factors affecting drug absorption 
1.3.1 pH - partition theory 
The dissociatýloný cons tan t and lipid solubility of a drug, as 
well as the pH at the absorption site, often dictate its absorption 
characteristics. The interrelationships among these parameters are 
known as the pH - partition theory of drug absorption (Gibaldi, 
1977c; Poole, 1979). 
The salient points of this theory are (a) that the epithelium of 
the GI tract and other biologiýal membranes act as lipid barriers, 
which separate aqueous phases; (b) drugs pass from one aqueous phase 
to another by. a process-that involves partition between one of those 
phases and the membrane, diffusion across the latter and finally a 
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second partition between the membrane and the other aqueous phase; 
(c) since partition is of such importance in the transport process 
the membrane: aqueous phase partition coefficient of the drug will 
also be important; (d) many drugs are weak electrolytes and 
consequently will ionize in aqueous solution. The degree of ionization 
will depend on the pKa value of the particular drug and the pH of the 
aqueous phase in accordance with the Henderson-Hasselbalch equations 
for weakly acidic and weakly basic drugs (Eq. 1.1 and 1.2, respectively). 
pKa - pH =. log ( unionized acid (Eq. 1.1) ionized acid 
pKa - pH = log ( 
ionized base 
unionized base 
(Eq. 1 . 2) 
(e) since the unionized form of a drug will exhibit a higher lipid 
membrane: water partition coefficient it follows from (c) above that 
ease of transport in vivo via passive diffusion will be markedly 
affected by the pKa value of the drug an-d the pH of the aqueous phase, 
into which, or from which, partition is. occurring. 
Many investigators (e. g. Travell, 1940; Shore et al, 1957; 
Schanker et a] , 1957 and 1958; Hogben et a] , 1957 and 1959; 
Schanker, 1960; Kakemi et al, 1967; Doluisio et a], 1969a) have 
substantiated the pH - partition theory as indicated in the review 
by Levine (1971). However, application of the theory suggests that 
weakly acidic drugs would be mainly absorbed from the stomach whilst 
weakly basic drugs would be preferentially absorbed from the intestine. 
The extremely larger surface area of the small intestine, compared 
with the stomach, more than compensates for the effects indicated by 
the pH - partition theory, and consequently, the small intestine tends 
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to be regarded as the major site of absorption for all drugs (Levine, 
1971) (see part 1.4-3a of this Chapter). However, the stomach still 
functions as an absorptive site for weakly acidic drugs. For example, 
Nayak and Benet (1974) showed that although salicylic acid is more 
rapidly absorbed from the intestine than from the stomach in 
unanaesthetised rhesus monkeys the extent of absorption appeared to 
be the same from both regions of the GI tract. Thus, it seems 
reasonable to suggest that the contribution of absorption from the 
stomach to the total amount of absorption should not be discounted, 
particularly for weakly acidic drugs when gastric emptying rate is 
delayed. The rate of stomach emptying will, in fact, have a marked 
effect on the rate of drug absorption because this emptying rate will 
govern the rate of appearance of drug at the major absorption site, 
i. e. in the small intestine (see part 1.4. laof this Chapter). 
1.3.2 Drug dissolution and release 
Drugs administered orally in solid dosage forms, such as tablets, 
capsules or suspensions, are not immediately available to the body, 
since they are normally absorbed from solution (Morrison and Campbell 
1965; Cadwallader, 1974). This means that such drugs must dissolve in 
the GI fluids before absorption occurs. A schematic illustration of 
the important processes involved following oral administration of 
dosage forms containing solid drug, i. e. tablets, capsules and 
A 
suspensions, is given below: ý 
Drug in Drug release Drug in Transport Drug in 
solid dosage solution from GI systemic 
form at absorption tract to circula- (. i. e. dissolution) site blood tion. 
1ý (Absorption) 
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Either dissolution or absorption may be the rate-limiting 
stage in the overall process. When dissolution is the controlling 
step absorption is said to be dissolution rate limited. Dissolution 
rate limited absorption may occur even if the drug is given as a 
solution of a water soluble salt. For example, a sodium salt may 
be precipitated as the free acid in the gastric juice (Munzel, 1971) 
but in the form of very fine particles, which favour rapid 
dissolution. Since dissolution precedes absorption, any factor 
affecting the rate of solution also must affect the rate of absorption. 
Consequently, dissolution rate may affect the onset, intensity and 
duration of clinical response. 
A general relationship describing the dissolution process was 
first observed by Noyes and Whitney (1897). The Noyes-Whitney equation 
states that: 
dC 
7t kS (Cs - Ct) Eq. 1.3 
Where dC/dt is the dissolution rate, k is a constant, S is 
the surface area of the dissolving solid, Cs is the concentration of 
drug in the diffusion layer surrounding the solid material and Ct 
is the concentration of the material in the solvent at time t. 
The constant k has been shown to be equal to D/h (Higuchi, 1967), 
where D is the diffusion coefficient of the dissolving material and 
h is the thickness of the diffusion layer. The diffusion layer is 
a thin, stationary film of solution encapsulating the surface of 
the solid. It is saturated with the drug and hence Cs may be equated 
with the solubility of the drug in the solvent. The term (Cs -Cd 
in Eq. 1.3 represents the concentration gradient between the diffusion 
layer and the bulk solution. In dissolution-rate limited absorption, 
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Ct is negligible compared to C5, i. e. so called sink conditions 
exist, and Eq. 1.3 may then be written as: 
dC DSCs Eq. 1.4 i-t =- h 
Eq. 1.4 describes a diffusion controlled dissolution process. It is 
envisaged that when the solid is introduced to the dissolution medium, 
the drug rapidly saturates the volume of liquid immediately adjacent 
to the surface and thereby creates the diffusion layer. Drug molecules 
diffuse from the saturated layer to the bulk (the slow step in the 
dissolution process) but are immediately replaced in the diffusion 
layer by molecules from the solid surface. This is known as the 
diffusion layer model of dissolution. On the other hand, when 
diffusion from the saturated-layer to the bulk is relatively rapid and 
the reaction at the solid/liquid interface is not instantaneous then 
this reaction may become the rate limiting step with respect to the 
mass transport process. This is known as the interfacial barrier model 
of dissolution. 
Eq. 1.4 is an oversimplified representation of the dynamics of 
A 
dissolution. Nevertheless it is qualitatively useful and permits a 
consideration of the effects of many factors on dissolution rate. The 
solubility (C 
s) of many 
drugs increases with increasing temperature 
and is influenced by minor changes in chemical structure (e. g. salt 
versus parent acid or base)., crystal structure, degree of solvation 
and interaction with other ingredients in a dosage form. On the other 
hand, the diffusion coefficient (D) is inversely related to viscosity, 
and dissolution rate decreases as the viscosity of the solvent 
increases. Increasing the surface area (51 of drug exposed to the 
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dissolution medium, by reducing the particle size or by any other 
means, frequently increases the dissolution rate. Changes in the 
above parameters caused by formulation factors or manufacturing 
techniques are obviously important from a bioavailability point of 
view. Consequently, numerous review and research articles concerned 
with dissolution rate - limited absorption and the factors affecting 
dissolution rates and bioavailabilities of drugs have appeared in 
the literature. Some of these are listed below: Nelson (1962b), 
Delgado and Cosgrove (1963), Poole (1969), Schneller (1970), Munzel 
(1971), Monkhouse and Lach (1972), Ritschel (1973), Greenblatt et 
a] (1974), Yamamoto et a] (1974), Haleblian and Goodhart (1975), 
Goodhart and Eichman (1976), Gibaldi (1977c), Nayak et al (1977), 
Maeda et a] (1979), Mathur et a] (1979), Poole (1979), Resetarits 
et a] (1979), Wade (1980) and Notari (1980b). 
Occasionally the choice of formulating a sparingly water soluble 
drug as an aqueous suspension or as a solution or a suspension in a 
non-aqueous organic solvent arises. However, the choice of vehicle 
can affect the bioavailability of the drug. Thus, drugs dissolved in 
non-aqueous solvents that are miscible with biological fluids, e. g. 
glycerin, are usually rapidly absorbed when compared with solid dosage 
forms of any type, since the very fine particles precipitated after 
dilution with the biological fluids favour rapid dissolution rate. 
In the case of drugs that are dissolved or suspended in water- 
immiscible liquids, e. g. an oily vehicle, then an additional phase 
or compartment must be included in any model of the release process. 
In fact, the release of drug particles from such media in vivo may 
become the rate limiting step in the overall absorption process. 
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(The physiological effects of an oily vehicle may also have a 
considerable affect on the bioavailability of the drug - see 
Chapters2 and 3 of this Section). 
The mechanisms involved in the release of solid drugs from 
this type of suspension are complex and detailed information on these 
mechanisms with respect to orally administered oily suspensions is 
not available. However, in vivo and in vitro bioavailability studies 
on fatty suppositories containing suspended drugs (Bevernage and 
Polderman, 1973; Schoonen et a], 1976 and 1979; de Blaey and Rutten- 
Kingma, 1977; Rutten-Kingma et a], 1979a, b, c and d) and associated 
in vitro studies on drugs suspended in liquid paraffin (Crommelin, 
1980a and b; Crommelin and de Blaey, 1980a and b) indicate that the 
following mechanisms of drug release may operate. 
(a) Drug that is dissolved in the oily vehicle is released by a 
process that involves diffusion through the water immiscible vehicle 
and partition at the interface into a surrounding aqueous body fluid. 
(b) If the drug is suspended in the water immiscible vehicle then 
the release process involves movement of drug particles through the 
vehicle to the interface followed either by dissolution at the 
interface into the surrounding aqueous phase, or by complete passage 
of particles through the interface into the aqueous phase, in which 
dissolution then occurs. 
The previously quoted studies show that the relative importance 
of these mechanisms and of each process within them depends on 
factors such as the concentration of drug in the non-aqueous vehicle, 
its solubility in this vehicle and in water, the particle size of 
the suspended particles and the viscosity of the vehicle. For example, 
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in the case of compounds that are insoluble in the non-aqueous 
phase but readily soluble in water, such as sodium chloride, sodium 
salicylate and sodium phenobarbitone, the release was shown to be 
controlled by the rate of transfer of the solid particles through 
the oily vehicle to the interface, since the rates of other 
processes, e. g. dissolution in water, are rapid. In contrast, when 
less water soluble compounds are used, e. g. paracetamol and 
chloramphenicol, then mass transfer to the interface occurs at a 
faster rate than dissolution into the aqueous phase and this laýer 
stage is consequently the rate determining one for the release 
process. 
Although these studies on the bioavailability of drugs 
suspended in fatty suppository bases provide a lot of useful 
information there are several other factors that may affect the 
release process and that still require investigation, e. g. the 
effect of gut motility on the thickness of-layers of water immiscible 
vehicles and on the kinetics of particle movement within those layers, 
and the effect of pH on the overall release process because the 
non-aqueous vehicle inay act as a reservoir for parent acids or 
bases that may be formed when a water soluble salt is released from 
, 
the vehicle into the GI fluids. 
1.4 Physiological factors affecting absorption 
1.4.1 Factors affecting transit to the site of absorption 
(a) Gastric emptying rate (. GER) 
The importance of gastric emptying with regard to drug 
absorption is readily apparent in the light of the pH-partition 
theory. Delay in the gastric emptying, caused by any factor, will be 
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a particularly important determinant of drug absorption in the 
following situations: 
(1) Where the absorption of the drug is favoured by the acidic 
environment of the stomach. 
(2) Where drugs are optimally absorbed from the small intestine. 
In the first category, according to the pH-partition theory, 
acidic drugs are absorbed well from the stomach. Although the surface 
area available for absorption from this organ is small compared to that 
of the small intestine, the extent of salicylic acid absorption 
appeared to be identical from both regions of the rhesus monkeys tract 
(Nayak and Benet, 1974). Significant gastric absorption of aspirin 
was also reported by Truitt and Morgan (1960 and 1964) and Saunders 
(1974a)has stated that acetylsalicylic and salicylic acids are 
absorbed rapidly in the stomach. It appears, therefore, that an increase 
in the time that such drugs reside. in the stomach (delay in gastric 
emptying rate) would lead to an increase in the contribution that such 
absorption makes to the overall extent of GI absorption. In addition, 
the slower release of drug from the stomach may improve the efficiency 
of absorption from the intestine or allow a longer period for drug 
dissolution to occur before transfer into the intestine. Various 
examples of the enhancement of absorption of weak acidic drugs that 
can. be ascribed to delays in the GER have been reported. Peterson and 
Finland (1942) found that the absorption of sulphadiazine is more 
complete, although slower, when it is given after a meal than if it 
is given on a fasting stomach in man. Fatty meals reduced the rate 
but increased the extent of aspirin absorption (Koch et a], 1978). 
The bioavailability of phenytoin was increased markedly when 
coadministered with food (Melander et a], 1979). A more complete 
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absorption, although slower, was found when furosemide was 
administered after a meal than in the absence of food in the rat 
(Chungi et al, 1979). A significant increase in the amount of drug 
absorbed, but not in the rate of absorption, occurred when aspirin 
and salicylic acid were administered in aqueous suspensions with 
different viscosities to the'rabbit (Barzegar-Jalali and Richards, 
1979b). In fact a linear relationship was observed between the log of 
apparent viscosity of the suspending medium at a shear rate of 100 s- 
and 37 0C and the amount of drug absorbed in 9 hr. Cook and Hunt (1970) 
showed that aspirin absorption was decreased ten times in situations 
where the rate of gastric emptying was increased by alkalinization 
the stomach medium. 
In the second category, which applies to the majority of drugs, 
absorption is optimal in the intestine because of (i) the phys i co- 
chemical properties of the drug and the pH environment of this region 
of the tract (e. g. weakly basic drugs), (ii) the presence within the 
intestinal mucosa of "carrier" molecules, which are required for the 
active or facilitated transport of drugs, (iii) the use of enteric 
coated dosage forms, which are formulated so as to prevent drug release 
in the stomach fluid but to allow. rapid drug release in the mildly acid 
fluids of the duodenum or (jv), the large total absorptive epithelial 
surface area of the intestinal mucosa, A delay in the rate at which 
drugs in this category leave the stomach and enter the duodenum may 
have a pronounced effect on the onset of therapeutic effect, the 
overall rate of drug absorption, the intensity of effect, 'and, 
occasionally, the biological availability, The process of gastric 
emptying is also of i. mportance when considering drugs that are prone 
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to chemical degradation in the stomach. 
The terms most frequently used in the literature to quantitate 
emptying are emptying time, emptying half-life and emptying rate. 
Emptying time generally refers to the time needed for the total contents 
initially present to leave the stomach, emptying half-life is the 
time needed for the stomach to empty one half of its initial contents 
and emptying rate refers to the speed with which stomach contents leave 
the stomach. Note that there is an inverse relationship between 
emptying time or half-time and emptying rate. 
It has been suggested that gastric emptying takes place by a 
monoexponential (i. e. first order) kinetic process (Hopkins, 1966; 
Hunt and Knox, 1968a). As a result, a semilogarithmic plot of the 
volume of a liquid meal or dosage form remaining in the stomach versus 
time will provide a straight line relationship, from the slope of 
which the rate constant associated with emptying can be derived. 
However, Wagner (1971d) pointed out that small amounts of liquids 
appear to empty from the stomach at essentially constant (zero order) 
rates whilst larger volumes obey the first order process as mentioned 
above. 
GER is influenced by a variety of factors. The composition and 
viscosity of a meal ingested by a subject may significantly influence 
the rate of gastric emptyi, ng, For example, fats (Davenport, 1971a and b), 
in any form, not only inhibit gastric secretion but have a considerable 
inhibitory effect on gastric emptying. (See Chapter 2 in this Section 
for information on the mechanism of action of fats. ) Proteins and 
starch also inhibit gastric emptying but Bachrach (1959a) suggested 
that their effects are less pronounced than those produced by fat. 
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However, Hunt and Stubbs (1975) reported that isocaloric 
concentrations of triglycerides and carbohydrate gave equal slowing 
of gastric emptying. For example, 4g triglycerides/100 cm' meal 
slowed gastric emptying to the same extent as 9g carbohydrate/100 cm, 
meal and both meals were equivalent to 36 kcal/100 cm'. Amino acids 
reduce the rate of gastric emptying to an extent directly dependent 
upon concentration, probably as a result of osmotic pressure (Cook and 
Moulang, 1972). 
Hypertonic solutions are emptied more slowly than pure water 
or hypotonic solutions . 
(See Chapter 2 in this Section for information 
on the mechanism of action of hypertonic solutions. ) For example, 
the absorption of drugs administered in a concentrated sucrose solution 
was decreased in rabbit and rat, due to delay in the GER (Kato et al, 
1969). Since all the drugs, i. e. aminopyrine, dipyrone, phenobarbitone 
and strychnine, that were investigated by Kato et a] are absorbed 
primarily from the intestine, the gastric emptying hypothesis fits 
their observations. However, Hem (1973) commented that "unfortunately, 
these workers did not study a drug that is absorbed chiefly from the 
stomach. An increased relative availability from such a drug in the 
sucrose vehicle would be strong support for their hypothesis". Malone 
et al (. 1960) reported that addition of sucrose to the vehicle is 
responsible for the delayed absorption pattern of phenobarbitone in 
the rat. The temperature of the meal may be critical in the rate of 
gastric emptying. Davenport (1971b) has indicated that cold meals 
increase and hot meals decrease the emptying of gastric contents. The 
A 
latter phenomena is perhaps an example of a physiologicIl protective A 
action that occurs to prevent possible damage to the intestinal mucosa. 
24 
The viscosity of the ingested meal or that of a liquid dosage 
form of a drug may also affect the emptying of stomach contents. 
Usually, as the viscosity of the gastric fluids is increased, there 
is a corresponding decrease in the rate of emptying (Levy and Jusko, 
1965). Enhancement of absorption of riboflavin occurred when administered 
in a high viscosity(2%wlv)-sodium alginate solution (Levy and Rao, 
1972). On the other hand, increases in the viscosity of aqueous 
vehicles used for nitrofurantoin suspensions led to decreases in the 
rate (Seager, 1968; Soci and Parrott, 1980) and extent of absorption 
(Seager, 1968) in man and in the extent of absorption in the rat 
(Barzegar-jalali and Richards, 1980). 
Gastric emptying may also be influenced by the positioning of 
the individual. In a person lying on his left side gastric emptying 
is reduced because the natural curvature of the gastric pouch gives 
rise to an uphill path leading to the duodenum. However, if the subject 
is lying on his right side, emptying is facilitated (Bachrach, 1959b). 
Significant differences may be observed in the onset of therapeutic 
effect depending on whether a patient is ambulatory or bedridden. The 
emotional state of the patient also may influence the stomach motility. 
Aggressive or stressful emotional states increase' stomach contractions 
and emptying rate whereas depression reduces the rate (Bachrach, 1959b; 
Almay, 1973). 
The highe I acidity of the duodenal contents, the slower the GER 
(Hunt and Knox, 1969). Lower molecular weight acids are more effective 
than those of higher molecular weight. Low concentrations of sodium 
bicarbonate (e. g. 1%) increased the rate of emptying while higher 
concentration decreased it (5hay and Gershon-Cohen, 19341. 
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Fluids or suspensions of small particles empty more rapidly 
than chunks of material (e. g. large granules or tablets), which 
must first be reduced in size prior to emptying (Davenport, 1971a; 
Wagner, 1971c). Intact tablets have been observed in the stomach as 
long as 6 hr after ingestion of an enteric-coated product with a 
meal (Blythe et a], 1959). Gastric emptying is one of the more 
important factors contributing to the usually large intersubject 
variability in the absorption of drugs from enteric-coated tablets. 
As a means of reducing this variability, it has been suggested that 
enteric-coated medication be administered in the form of small, 
individually coated granules that would empty gradually but 
continuously into the duodenum (Wagner et a], 1960). 
Differences in gastric emptying among subjects also contribute 
to the variability in absorption rate of drugs from conventional 
dosage forms. For example, after administration of 1.59 (3 tablets) 
of paracetamol to . 14 convalescent hospital patients, the maximum 
concentration in the plasma ranged from 7.4 to 37.0 pg/cml, and the 
time required to reach the maximum concentration ranged from 30 to 
180 minutes(Heading et a], 1973). Both these indices of absorption 
rate were linearly related to the gastric emptying half-life found 
in each patient. 
Gastric emptying can be prolonged or prompted significantly by 
a number of drugs. For example, the anticholinergic drug 
propantheline significantly reduces the rate of absorption of 
riboflavin and enhances its extent of absorption (Levy et al, 1972). 
Metoclopramide, on the other hand, significantly increases the 
absorption rate of ethanol CGibbons and Lant, 1975), tetracycline 
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and paracetamol (Nimmo, 1973) and the rate of extent of absorption 
of L-dopa (Wade et a], 1974; Mearrick et al, 1974). 
GER is reduced by bile salts (Menguy, 1960; Hunt, 1975). These 
salts were reported to inhibit markedly gastricemptying as well as 
proximal intestinal transit in the rat (Feldman and Gibaldi, 1968; 
Feldman et al, 1968), and it was suggested that these findings would 
be similar in man (Mayersohn et a], 1969). 
(b) Intestinal transit 
Once a dosage form empties from the stomach and enters the 
small intestine, it will be exposed to an environment totally 
different from the stomach. Since the small intestine is the primary 
site of drug absorption, the longer the residence time in this region 
the greater the potential for efficient absorption, assuming the drug 
is stable in the intestinal fluids and will not react with endogenous 
material to form water-insoluble derivatives. 
There are primarily two types of intestinal movements, propulsive 
and mixing. Propulsive movements, generally synonymous with peristalsis, 
propel intestinal contents down the tract at about 1-2 cm/sec (Guyton, 
1971). Thus, under normal circumstances, movement down the tract is 
relatively slow and it takes 3-10 hr to move a meal in the form of 
chyme from the pylorus to the ileocaecal valve (Guyton, -197-1). These 
propulsive movements will primarHy determine intestinal transit rate 
and, therefore, the residence time of a drug in the intestine. This 
time of residence is important since it will dictate the amount of 
time available for the dosage form to release the drug, permit 
dissolution, and allow for absorption, Both release and mucosal 
permeation, stated Hayton (. 19801, must occur before gastrointestinal 
transitremoves the drug from sites of absorption that are located 
IL 
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primarily in the small intestine and particularly in the proximal 
region. For a drug to be considered well absorbed by the oral route, 
release and permeation must occur quickly relative to GI transit. 
Mixing movements of the small intestine are a result of 
contractions dividing a given region of the intestine into segments 
producing an appearance similar to a chain of sausages. These 
contractions result in the mixing of the intestinal contents with 
secretions several times a minute. These movements bring the gut 
contents into intimate contact with the surface epithelium and 
thereby provide a large effective area for absorption. This contact 
and agitatio n provided by the peristalsis waves facilitate absorption 
by reducing the man free diffusion path of the drug molecules to 
the intestinal mucosa. 
Obviously, the slower the intestinal motility, the longer the 
residence time and the more complete may be the process of dissolution 
and absorption. Excessive peristalsis (Propulsive) or intestinal 
motility would be expected to produce the opposite effect. 
. Intestinal motility will be more important for those dosage forms 
that release drugsslowly (e. g. sustained-release products), require 
time to initiate release (e. g. enteric-coated tablets), or contain 
drugs that are dissolved slowly or are absorbed by a special ised 
mechanism only in a certain region of the intestine. 
Propantheline and similar drugs significantly increase transit 
IL 
time, whereas metoclopramide accelerates transit through the small 
intestine. The extent of absorption of drugs that are incompletely 
absorbed may be dependent on intestinal motility. Enhancement of. 
riboflavin absorption in man by preadministration of propantheline 
(Levy et al, 1972) or by administration of the vitamin in a highly 
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viscous sodium alginate solution (Levy and Rao, 1972) has been 
reported. Retention of the vitamin at its specialised absorption 
sites for prolonged time periods because of the increase in the GI 
transit time, brought about by the anticholinergic agent or by the 
high viscosity, was proposed as the rationale for the absorption 
data. Enhancement of the absorption of poorly water soluble drugs, 
such as digoxin (Manninen et al, 1973) and phenolsulphonphthalein 
(Ashly and Levy, 19731 by preadministration of propantheline has also 
been observed. However, decrease in the absorption of digoxin was 
demonstrated in patients receiving metoclopramide (Manninen et a], 
1973). These workers suggested that the increased residence time at 
the site of absorption permitted a better dissolution and absorption 
of digoxin. 
(. c) Recycling processes 
Once absorbed, certain drugs are returned to the GI lumen by 
way of the stomach, bile, or intestine and are then available for 
subsequent reabsorption, These recycling processes may complicate 
the assessment of bioavailability by appearing to extend the time 
necessary for absorption of the administered drug by producing an 
erratic plasma concentratton-time curve. 
Enterogastric and enterointesti. na. 1 recycling processes are not 
particularly important. Nevertheless, because both processes ensure 
an essentially continuous flux of drug between blood and GI contents, 
as viewed from the blood, the. G1. tract may be regarded as just 
another equilibrating tissue, As such, the GI tract will be evident 
in the disposition kinetics of a drug given intravenously and 
-accordingly forms part of its volume of distribution. 
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Enterohepatic recycling potentially offers the greatest 
problem. Earlier comments about blood flow and volume of distribution 
are still applicable, and although the liver receives 25% of the 
cardiac output (Rowland, 1973), accumulation in bile only becomes 
quantitatively important for drugs that are extensively cleared by 
the liver into bile and that possess a relatively small volume of 
distribution. 
A quantitative kinetic description of enterohepatic recycling 
is difficult. Any bile formed is stored and concentrated within the 
gall bladder in man and some animals. Stimuli, especially food and 
fats, enhance the evacuation of bile from the gall bladder (see parts 
1.4.2 b and d of this Chapter) but this evacuation occurs in a 
discontinuous manner, which complicates the picture. If the fraction 
of the dose in the bile is sufficiently great and subsequent 
reabsorption rapid, secondary peaks may appear in the blood 
concentration-time curve. A drug, or more usually a drug conjugate, 
is excreted into the bile and enters the G1 tract where, in the case 
of the metabolite, it may be broken down by enzymes in the gut or 
gut flora to liberate the unchanged, parent drug (Williams et a], 
1965; Plaa, 1975; Routledge and Shand, 1979). Any drug appearing 
,. 
in this way may then be reabsorbed into the body as well as any 
drug which may have appeared in the gut from a recently taken oral 
dose. This might be responsible for the prolonged retention of 
certain drugs and drug metabolites in the body (Williams et a], 1965). 
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1.4.2 Effect of constituents of the GI fluids 
(a). Hydrogen ion concentration and enzymes 
pH varies considerably along the length of the GI tract and 
may have an important influence on drug absorption. Not only is 
it important because it determines the degree of ionization of the 
drug, but it is also an important determinant of the degree of 
solubility, and hence dissolution, of poorly water soluble drugs 
and of the degree of drug degra dation that may occur in the GI 
tract. 
In man, the usual pH range of gastric fluid is 1-3, whilst 
intestinal fluids range from approximately 5-6 in the duodenum to 
7-8 in the proximal jejunum and approach a pH of about 8 in the 
large intestine (Borgstrom et a], 1957; Wagner, 1961). 
Differences in the pH along the GI tract and any changes in 
this pH, that may be caused by several factors, will affect the 
absorption of weakly organic acidic or basic drugs because of changes 
in the extent of ionization, since the unionized moiety of the drug 
is absorbed preferentially as indicated in part 1.3.1 of this Chapter. 
The pH of gastric fluid is subject to a great deal of variationl. 
Gastric secretions have a pH of less than 1, but the pH of gastric 
contents is usually between I and 3 because of dilution and diet. 
The pH of the stomach contents is distinctly but briefly elevated 
after meals; pH values of 5 are not unusual (Gibaldi, 1977b). 
Fasting tends to decrease the pH of gastric fluid to 1.2 - 1.8 
(Martin, 1955). Disease may also influence the pH in the stomach 
(James and Pickering, 1949). Fats and fatty acids have been found to 
inhibit gastric secretion (Menguy, 1959a; Johnson and Grossman, 1969; 
Christiansen et a], . 1976). A major clinical effect of antispasmodic 
drugs, such as atropine and propantheline, is a reduction in gastric 
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secretion. Some anticholinergic activity, including suppýession of 
secretion, is commonly found with many other drugs. A large number 
of antacid products are widely used for the purpose of neutralising 
gastric acidity and elevating the pH of gastric contents (Hurwitz, 
1977). 
These factors may significantly influence the gastric absorption 
of weakly acidic drugs which are usually efficiently absorbed at the 
normal low pH of the gastric fluids. However, Pottage et al (1974), 
reported that the rate, but not the extent, of absorption of aspirin 
is significantly higher in achlorhydric patients than in normal ones, 
due to the higher solubility of the drug in the less acidic gastric 
fluid. 
, 
The pH of the GI fluids may also be an important factor when 
considering the stabilities of drugs in the GI tract. In fact the lack 
of oral activity of certain drugs, when compared to their activities 
following parent! ral administration, can be attributed to some type 
of degradative reaction that is catalyzed by the high acidity and 
enzymatic activity of gastric fluids. The end products of such 
reaction usually possess no activity. Some examples of drugs prone to 
acid catalyzed degradation are certain penicillin derivatives 
(Broderson, 1949) and erythromycin and its esters (Stephens et al, 
1959; Nelson 1962al. 
Drug inactivation in gastric fluid competes with stomach 
emptying and absorption as processes of drug removal from the 
stomach, once solution of the drug has been achieved. That portion of 
a dose, which is emptied into the intestine in an undissolved state, 
can be expected to become available for intestinal absorption. 
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Since GI fluids contain various enzymes essential for the 
digestion of food, it is not unreasonable to expect that these 
enzymes may be responsible for the metabolism of certain drugs. More 
details of this aspect will be discussed later in this chapter (see 
1.4-3d). 
(b) Bile salts 
Bile salts, which are physiological surface active agents, 
may enhance the rate and extent of absorption of poorly water-soluble 
drugs by the following mechanisms: 
(i) Increased drug dissolution rates have been noted in studies in 
vitro in the presence of bile salts (Bates et a], 1966a; Weintraub 
and Gibaldi, 1969) and in the presence of lysolecithin, another 
naturally occurring surface active agent found in duodenal fluid 
(Bates et al , -1967) - 
(ii) Inhibition of gastric emptying and proximal intestinal transit 
and alteration of membrane permeability were the reasons suggested by 
Mayersohn et al (. 1969) who observed enhancement in the absorption of 
riboflavin and flavin mono-nucleotide when bile salt was given prior 
to the drug. In addition to their effect on GER, bile salts are known 
to alter membrane permeability (. Davenport, 1968; Feldman and Gibaldi, 
1968; Feldman et a], 1968; Hori et a], 1977; Richards and Gardner, 
1978). Significant increase in the permeability of the everted 
intestine to salicylate by bile salt has been reported (Feldman and 
Gibaldi, 1969a and b). 
The increased absorption of many drugs administered after a 
fatty meal or together with an oil may be caused not only by the 
resultant delay in GER, but also by the fact that bile is secreted 
into the small intestine in response to the presence of fats (-Jvy, 
33 
1934; Sjovall, 1959; Bates et a], 1966b; Bates and Gibaldi, 1970; 
Bates and Sequeira, 1975; Bates et a], 1977). 
Cavallito and O'Dell (1958) have shown that cholic acid 
(a natural bile acid found in man) and dehydrocholic acid (a 
synthetic bile acid derivative) increase the intestinal absorption 
of several quaternary ammonium hypotensive agents in dog as judged 
from blood pressure lowering measurements. These steroidal acids may 
enhance absorption of quaternary ammonium compounds by increasing 
membrane permeability, by mucolytic. action which reduces the barrier 
effects of intestinal mucins, by forming complex salts having a 
greater ability to penetrate the membrane, or by increasing bile 
secretion which will enhance drug dissolution. 
Based on these findings it is suggested that bile salts, normally 
present in the small intestine, enhance the absorption of poorly 
water-soluble drugs. It follows that in those conditions where there 
is a diminished bile salt concentration in the proximal intestine, 
such drugs will be poorly absorbed. This possibility is supported by 
the findings of Pekanmaki and Salmi (1961), who found that absorption 
of phenolphthalein is markedly decreased when bile drainage into the 
intestine is prevented in the cat. 
Bile salts, on the other hand, have been found to form insoluble, 
non-absorbable complexes with such-drugs as tubocurarine (. Mahfouz, 
1949) and neomycin and kanamycin (Faloon et a], 1966). 
(c) Mucin 
Mucin, a viscous mucopolysaccharide, which lines and protects the 
gastric and intestinal surface epithelium, may retard drug absorption 
by acting as an effective barrier to diffusion or by forming non- 
34 
absorbable complexes with some drugs, e. g. quaternary ammonium 
compounds (Levine et al, 1955; Levine and Pilikan, 1961). With 
respect to this observation, a study cited above (Cavallito and 
O'Dell, 1958) indicated that certain bile acids may potentiate the 
absorption of quaternary ammonium hypotensive agents. A possible 
mechanism would be the mucolytic action of bile acids, which might 
reduce the barrier effect of mucin or conceivably alter the binding 
of quaternary ammonium compounds to mucin. 
Tetracycline has been shown to strongly bind to hog gastric 
mucin (Saggers and Lawson, 1966) and other workers have shown 
reduced tetracycline absorption in the perfused rat intestine in the 
presence of added mucin (Braybrooks et al, 1975) and reduced 
tetracycline dissolution rate in vitro in the presence of mucin 
(Kellaway and Marriot, 1975). It has also been noted (Abbott et a], 
1959)that the disintegration time for tablets is longer in human 
gastric fluid containing mucin compared to the times seen in sim ulated 
gastric fluid. Hunter et al (1980) found that rapidly 
disintegrating hard gelatin capsules when administered with a small 
amount of liquid to fasting subjects did not disperse in the stomach 
compared with non fasting subjects. A possible explanation was given 
that adherence to the viscous mucin retards the dispersion process. 
The capsule shell may become coated with gastric mucin and may not 
dissolve for a longer time. As a result, the drug particles may 
become coated with a gelatinous film, which retards dispersion and 
dissolution (Anon, 19721, 
(d) Food 
Any factor that influences drug bioavailability may do so by 
altering the rate and/or extent of absorption. The following mechanisms 
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appear to be the primary methods whereby food and diet may alter 
drug bioavailability: 
(i) Changes in the gastric emptying and intestinal transit rates. 
(ii) Food-induced secretion of GI fluids, which may act on the drug 
molecule. 
(iii) Physicochemical properties of the drug and composition of food. 
Ov) Food may decrease the amount of biological fluids available to 
the drug, thereby decreasing the dissolution rates of solid 
dosage forms. 
(v) Food may increase the viscosity of the medium and decrease the 
rate of drug diffusion to the mucosal barrier. 
(vi) Food components may compete with the drug for absorption. 
(v) Food components may adsorb or interact with a fraction of the 
dose and reduce the amount of drug available for absorption. 
(viii)Food components may affect metabolic transformation of drugs in 
the GI wall and liver. 
Ox) Food, especially fatty meals, enhancesthe secretion of bile. 
W The increased blood flow through the splanchnic area that occurs 
following a meal would increase the absorption capacity. 
The literature contains numerous instances of the effects of food 
on drug bioavailabilities. For example, inhibitory effects have been 
observed with isoniazid (Melander et a], 1976a), tetracycline (Kirby 
et al, 1961; Neuvonen, 1976), penicillin derivatives (Klein and 
Finland, 1963)and rifampicin (Acocella, 1978), whilst bioavailability 
enhancing effects have been noted for sulphadiazine Weterson and 
Finland, 1942), griseofulvin (Crounse, 1961; Kraml et al, 1962), 
riboflavin (Levy and Jusko, 1966), spironolactone, hydralazine and 
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propranolol and metoprolol (Melander et a], 1977a, b and c respectively), 
erythromycin stearate (Malmborg, 1978) and phenytoin (Melander et al, 
1979). In other cases no consistent effects have been reported, e. g. 
oxazepam and metronidazol (Melander et al, 1977d and e respectively; 
Welling, 1980), and sulphasomidine (Melander et a], 1976b). 
The complex effects of food on the absorption of drugs lead to 
the conclusion that the net effect on a particular drug can only be 
ascertained by clinical studies on that drug and should not be 
derived from studies on other drugs. 
1.4.3 Properties of the site of absorption 
(a). Surface area of the absorption sites 
The major components of the GI tract are the stomach, small 
intestine, and large intestine or colon. The small intestine includes 
the duodenum, jejunum, and ileum. The major segments of the GI tract 
differ from one another both anatomically and morphologically, as 
well as with respect to their secretions and pH. 
The stomach is a pouch-like structure lined with a relatively 
smooth epithelial surface. Extensive absorption of many weakly acidic 
drugs or drugs possessing physicochemical properties consistent with 
the permeability characteristics of the gastric mucosa can be 
demonstrated in the stomach under normal physiological conditions. 
However, under such normal conditions, when gastric emptying is not 
impeded, the stomach's role in drug absorption is much more modest 
due to limited residence of the drug and the limited surface area of 
the stomach. 
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Of all regions of the GI tract the small intestine has the 
greatest available surface, from which absorption can take place. 
This large epithelia] surface area results from the existence of 
(i) folds in the mucosa(i. e. the folds of Kerckring or valvulae 
conniventes); and (ii) finger-like projections, termed villi, 
arising from and being part of the folds of Kerckring. Each villus 
is comprised of many microvilli (Levine, 1971). The irregularities 
in the mucosa surface, caused by the microvilli, villi, and 
submucosal folds, increasethe area available for absorption by more 
than 30 times that which would be present if the small intestine 
were a smooth tube (Granger and Baker, 1950). Based on studies in 
the rat, one can estimate that the effective surface area of the 
small intestine is about 10 times that of the stomach (Crouthamel 
et a], 1971) - It would be more in man, since the latterdiffers from 
the rat in having submucosal folds (Hilton, 1901). Other studies 
conclude that surface area decreases sharply from proximal to distal 
small intestine with almost half of the total mucosal area being 
found in the proximal quarter of the gut (Wilson, 1967). Thus, the 
proximal part of the small intestine has the largest capacity for 
absorption of most drugs as well as for most dietary constituents 
(Booth, 1967). The small intestine is also the most important region 
of the GI tract with respect to carrier-mediated transport. 
Since there are no villi present in the colon, as in the stomach, 
the surface area is quite limited. This segment serves as a reserve 
area for the absorption of drugs that have escaped absorption 
proximally because of their physicochemical properties or their 
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dosage form or physiological factors, such as rapid GI transit. 
Only the absorptive capacity of this segment is significant when 
a drug i. s absorbed by a specialised transport process located in 
this area. Generally, if a significant portion of a dose of a drug 
by-passes the stomach and small intestine, one can anticipate a low 
biological availability for the drug. 
(b) Local blood flow 
The entire GI tract is highly vascularised and therefore well 
perfused by the blood stream that permits efficient delivery of 
absorbed material to the body. Usually, blood flow does not appear 
to play a primary role in drug absorption. 
There are circumstances, however, where blood flow to the GI 
tract may influence drug absorption, e. g. when a considerable change 
occurs in the blood flow. A reduction in the blood flow and therefore 
in rate of oxygen delivery may produce a reduction in the absorption 
of those compounds absorbed by active transport mechanisms, e. g. 
phenylalanine in rats (Winne, . 
1973). 
Absorption of freely permeable compounds through the intestinal 
membrane, (e. g. tritiated water, salicylic acid, and sulphaethidol) 
is very sensitive to blood flow, In contrast, compounds which penetrate 
the epithelia] cells with great difficulty, e. g. ribitol, are 
unaffected by changes in blood perfusion. In between these two extremes 
are a variety of intermediate compounds Ce. g. urea, methanol, etc) 
whose absorption rate is blood flow-limited or dependent at low 
flow rates, but blood flow-independent at higher flow rates (Winne, 
1970; Winne and Remi. schovsky, 1970; Crouthamel et al, 1970; Theý and 
Winne, 1971). 
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Blood flow to the GI tract increases shortly after a meal 
and may last several hours. From the quantitative investigations 
in the rat (Reininger and Sapirstein, 1957), in the dog (Herrick 
et a], 1934) and in man (Brandt et al, 1955) it appears that there 
is approximately a 30% increase in blood flow through the splanchnic 
area following a meal. Digestion processes in general seem to 
enhance blood flow to the tract (Bynum and Jacobson, 1971). McLean 
et a] (1978) suggested that the increase in the splanchnic blood 
flow, typical of those found after a meal, can have a significant 
effect on the availability of the drugs subject to first-pass 
metabolism, and postulated that such variation in the blood flow 
could accountfor the increased bioavai labi Ii ty of single doses of 
metoprolol and propranolol when administered with food compared with 
during the fasting state (Melander et al, 1977c). 
Fasting, on the other hand, was reported to produce emotional 
stress (Kollar et al, 1964; Januszewicz et a] , 1967), which may 
cause some constriction of the splanchnic vasculature and, hence, a 
reduction in intestinal blood flow. Reduction in the intestinal blood 
flow can decrease the absorption of certain drugs (Crouthamel et a], 
1970 and 1975). Doluisio et a] (1969b) fasted rats for periods of up 
to 50 hours, and subsequently performed in situ intestinal absorption 
rate studies with salicylic acid, barbitone, haloperidol, and 
chlorpromazine. They found that the ratesof absorption of the test 
drugs were not affected by fasting until after approximately (17-20) 
hours. As the period of fasting extended beyond 20 hours, there was 
a progressive decrease in therates of intestinal absorption of the 
test drugs. These investigators-have proposed tentatively that 
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prolonged fasting may produce a decrease in blood perfusion of the 
mucosa. As a result, there may be an accumulation of absorbed drug 
in the mucosal cells. The decrease in blood flow may, in effect, 
diminish the concentration gradient across the intestinal mucosa, 
which is required for optimal absorption of drugs transported into 
the blood by a passive diffusion process. 
Variations in intestinal blood flow can alter the rate but are 
unlikely to affect the extent of availability, unless the drug is 
subjected to extensive intestinal metabolism. An interesting clinical 
example is provided by Rowland et al (1972) who observed that aspirin 
absorption ceased promptly when a subject fainted while blood was 
being withdrawn from a peripheral vein and commenced again as the 
subject recovered. However, the extent of availability was the same 
as on another occasion when the volunteer did not faint and absorption 
of aspirin was rapid. 
One more point that should be made is that any potential 
k 
enhancement of drug absorption rate by increase in the blood flow is 
offset by concomitant slowing of gastric emptying (Brandt et al, 1955) 
or binding to or interacting with components of food (McLean et a], 
1978). 
(c). The lymphatic route 
Although the lymphatic route is rarely considered where drug 
absorption is concerned, the fact is that any substance, which is 
transferred through the intestinal epithelium into the lamina propýria, 
has equal access to both blood and lymph capillaries (De Marco and 
Levine, 1969). Also, material which leaves the intestine via lymph 
gains access to the general blood circulation without first passing 
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through the liver, thereby averting potential metabolism prior to 
distribution. 
Ordinarily, a much greater proportion of a small molecular 
species is absorbed via the blood than via the lymph because the 
rate of blood flow is several hundred times that of lymph flow 
(De Marco and Levine, 1969).. For example, these authors have shown 
that only a small percentage of a well absorbed drug, p-amino- 
salicylic acid, or an inefficiently absorbed drug, tetracycline, was 
absorbed via lymph under normal conditions. However, the amount of 
these agents carried away in the lymph was doubled when lymph flow 
was stimulated by administration of tripalmitin. While this increase 
in the amount of absorption via lymph would have little therapeutic 
Consequence in the case of the two drugs just mentioned, such an 
increase might have relevance to the effectiveness of oral therapy 
with agents which are only slightly absorbed at best and which are 
susceptible to hepatic metabolism, In this respect it is well to 
remember that the lymphati'c route is the major pathway for absorption 
of large molecules, such as cholesterol, protein and fatty acids. 
Anticancer agents have been reported to be removed to a great 
extent from the site of administration via the lymph (Takahashi et 
a], 1973; Nakamoto et al, 1975a and b; Hashida et al, 1977a and b) 
when administered as emulsion dosage forms, particularly water in 
oil emulsions. In fact, even with Mitomycin C and bleomycin, which 
have relatively low molecular weights, enhancement of these agents 
was reported and even wi. thout di: scernible change tn lymph flow 
(Nakamoto et a], 1975a and b). The existence of a special transport 
mechanism by which drug and oil were delivered together when injected 
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intramuscularly, intraperitonealy or at the stomach wall was 
proposed. These agents could be transported from the site of 
administration directly into the lymphatic system, either with the 
oil droplet carriers or as free drug after separation at the 
injection site. The significant contribution of the former route 
was suggested from the parallel increased transport of the drug 
and tripalmitin following injection of emulsions. Fig. 1.1 is taken 
from Hashida et al (1977b) to show these possibilities in the case 
of iodohippuric acid. 
CENTRAL LYMPH ( THORACIC LYMPH ) 
OTHER L. N. 11 REGIONAL LYMPH NODE 
OTBER DRUG 
TISSUES 
INJ. INJECTION SITE I 
BLOOD 
Fig, 1,1 Model of lymphatic transfer of iodohippuric 
acid following the injection of emulsion formulations. 
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(d) Intestinal metabolism 
Drugs can undergo metabolic transformation at various sites 
along the GI tract. Drug metabolizing enzymes are present within 
the GI fluids, the microflora (Scheline, 1968), and the intestinal 
epithelia] cells (Barr and Riegelman, 1970a). The importance of 
the metabolic alterations of a drug within the tract in terms of 
bioavailability will depend upon the rate and extent of metabolism, 
the absorbability of the netabolite, and its pharmacological activity 
. relative to the parent 
drug. 
Inte'stinal fluids of the dog and specific components of those 
fluids (e. g. pancreatin, trypsin, etcl and the intestinal mucosa of 
the rat are capable of deacetylating N-acetylated drugs, e. g. 
N-acetylsulphisoxazole (Randall et a], 1954). Various drugs containing 
ester groups may be hydrolysed by specific or non specific esterase 
enzymes present in the GI fluids. Chloramphenicol palmitate is 
hydrolysed by contents of the rat duodenum and by purified lipase 
enzymes (Glazko et a], 1952). The acetoxymethyl ester of benzy] 
penicillin is de-esterified prior to reaching the portal circulation 
in dogs, suggesting breakdown by esterase enzymes in the gut fluids 
or within the intestinal membrane (Agersborg et a], 1966). 
The metabolic potential of the GI microflora has been 
recognised only recently, In normal subjects, the stomach and proximal 
small intestine contain relatively small numbers of microorganisms, 
whi*le larger numbers are seen toward the distal end of the small 
intesti, ne. These mi*croflora, which arise primarily from the 
environment, tend to adhere to the luminal surface of the intestine. 
Within an individual, the microflora population and type appear to 
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remain rather stable over long periods of time (Gorbach et a], 1967). 
The primary factors (Donaldson, 1973) governing the number and kind 
of micro-organisms present in the tract are (i) gastric secretions, 
which limits the growth of these organisms in the stomach and upper 
regions of the tract, and (ii) the propulsive motility of the 
intestine, which is responsible for continually cleansing the tract 
and thereby limiting the proliferation of these organisms. Gastric 
atrophy permits increased numbers of micro-organisms to pass into the 
small intestine. Similarly, reduced intestinal motility results in 
overgrowth of these f lora. 
There have been several reviews of drug metabolism by intestinal 
micro-organisms (Scheline, 1968 and 1973; Smith, 1971; Goldman et a], 
1974). The majority of studies have been done in laboratory animals 
rather than man so that the clinical implications of drug metabolism 
by the microflora are difficult to assess. 
In addition to drugs being metabolised by the GI enzymes and 
gut flora, there are several examples of metabolism within the cells 
of the intestinal membrane. Barr and Riegelman (1970b) have shown 
that salicylamide is glucuronidated by the rabbit intestine and it 
is suggested that this may occur in man (Barr, 1969). A recent study 
in dogs has indicated that approximately 42% of an oral dose of 
salicylamide is metabolised within the intestinal wall (Gugler et a], 
1975). A significant decarboxylation of L-doPa during passage through 
the gut wall was reported( HearriCket a], -1975). 
A variety of factors affect the drug metabolism. As the 
metabolic processes have limited capacities (Mearrick et al, 19711 and 
1975; Wade, 1980), gastric emptying rate, therefore, plays a 
significant role in the case of drugs subject to pre-systemic 
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metabolism (i. e. first pass effect and/or intestinal metabolism). 
Mearrick et al (1974) attributed the increase in bioavailability of 
L-dopa when co-administered with metoclopramide to the more rapid 
delivery to the site of absorption. As the gut metabolism has a 
more limited capacity than the transport mechanism, there is an 
increase in the availability when gastric emptying is stimulated. 
Furthermore, the time to obtain peak plasma concentrations is 
reduced and multiple peaks in the absorptive profile are eliminated. 
Delay in GER has the opposite effect since this increases the 
exposure of the drug to the destruction by enzymes (Wade et a], 1974; 
Mearrick et a], 1974). 
In addition, slow transit rate through the GI tract, by, for 
example, reduction or inhibition of propulsive movement, would 
increase the metabolism of the drugs that are metabolised by 
microflora. This is not only because of increase in the number of 
these microflora but also because the drug may reach the site'of 
metabolism in a form available for metabolism. 
Among other factors affecting drug metabolism are: - age, sex, 
diet, alcohol and other drugs. The most profound age-related differences 
occur between the adult and the neonate. Neonates appear to have a 
low drug-metabolism capacity compared to adults. This deficiency is 
responsible for the serious adverse effects observed after 
administration of chloramphenicol (Weiss et a], 1960). A markedly 
prolonged half-life of tolbutamide has been reported in neonates 
compared with adults (Nitowsky et ai, 1966). 
Drug metabolism within the GI tract, at any of the several sites 
discussed above, offers a plausible explanation for the poor bio- 
availability of certain drugs. 
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CHAPTER 2 
THE REGULATION OF GASTRIC EMPTYING RATE BY FATS AND BY OSMOTIC PRESSURE 
As will be seen from chapter 4 in this section the work described 
in this thesis is concerned with the effects of certain oily 
suspension vehicles on the bloavailabilities of drugs. In addition to 
oil some of these vehicles contain large proportionsof sugar that are 
added to improve the suspension properties of the vehicles. Since it 
has already been indicated that oils and sugars affect GER (see 1.4.1a 
in previous chapter) the mechanisms of these effects are considered in 
more detail in this chapter. 
Shay and Gershon-Cohen (1934) studied the effect of a number of 
solutes on the GER and concluded that the acceptability of the 
gastric contents to the duodenal mucosa provides the primary control 
of gastric emptying. The arrival of the initial portion of a meal 
in the duodenum serves as a test of the acceptability of the gastric 
contents. Thus, the use of the Lintvarev term 'trial portion', as 
described by Shay and Gershon-Cohen (1934), is appropriate. If 
acceptable, this trial portion advances and further gastric 
emptying follows. However, should this portion be unacceptable, 
stimulation of the duodenal mucosa occurs and a reflex is activated, 
which results in pyloric closure, Closure is maintained until the 
trial portion is sufficiently neutralized or diluted to permit its 
passage to the adjacent distal duodenum. Pyloric relaxation then 
takes place and further gastric emptying follows. Shay and Gershon- 
Cohen (1934) stressed their belief that the pyloric state, rather 
than peristaltic movement or gastric tonus, is the most important 
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factor in gastric emptying. Furthermore, they indicated that 
induction of pylorospasm is rapidly followed by a cessation of 
gastric peristalsis, and a return of active peristalsis is not 
usually seen until the agent producing pylorospasm has been removed. 
This latter point has been confirmed by more recent work (Quigley 
et a], 1941; Quigley and Meschan, 1941; Brink et a], 1965; Fisher 
and Cohen, 1973) as will be discussed in part 2.2 of this chapter. 
A receptor theory for the regulation of GER has been proposed 
(Hunt, 1956; and 1963; Hunt and Knox, 1968a and b; Bell et a] , 1972; 
Cooke and Christensen, 1973; Cooke, 1975; Hunt, 1975). The receptors, 
which slow GER in response to the composition of the duodenal contents, 
are located on the wall of the duodenum. There are no grounds for 
supposing that there are duodenal receptors which accelerate gastric 
emptying. Thus, a maximal rate of gastric emptying is assumed to 
correspond to minimal stimulation of duodenal receptors, which 
inhibit peristalsis and raise pyloric pressure. According to the 
above authors there are three types of receptors, i. e. fat, acid and 
osmoreceptors. The remaining discussion is limited to a consideration 
of the first and last of these three types. 
2.1 Osmotic pressure and gastric emptying rate 
On general grounds it would be expected that solutions iso-osmotic 
with plasma would be least. disturbing to a tissue. In addition, it 
is customary to think of the stomach as a protective reservoir for 
the intestine. 
The idea that the osmotic pressure of gastric contents might 
influence GER stems from the observations of Carnot and Chassevant 
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(1905). They found that, in dogs with a duodenal fistula, saline 
of the same osmotic pressure as plasma left the stomach more 
rapidly than more dilute or more concentrated solutions. Isotonic 
solutions produced a series of pyloric openings, which permitted 
the solutions to pass very rapidly by successive jets from the 
stomach to the intestine withoutundergoing great modifications. 
If, however, the solutions were appreciably non-isotonic contact 
of the first portion of the liquid with the duodenum provoked 
reflex closure of the pylorus, which did not reopen until 
proper dilution of this portion had taken place. Since that time 
there has been confirmatory work by Appearly (1926), Johnston and 
Ravdin (1935), Shay (1944), Wells and Welbourn (1950and Jones 
(1951). 
Hunt (1954 and 1956) studied the effect on gastric emptying of 
a selected range of solutes in test meals. In these expe'riments the 
concentration of the solutes in the meal was varied and recoveries 
were made at a constant time after giving the meal by tube. For 
example, the volume of the gastric contents was greater at 30 min 
(Hunt, 1954) and 20 min (Hunt, 1956) with meals containing 35 gm 
sucrose/dM3 than it was with test meals containing no sucrose. 
Additional experiments (Hunt and Pathak, 1960) showed that different 
solutes were all approximately equivalent per osmole in slowing 
gastric emptying, thus suggesting that P single receptor was 
responding to some common property. The finding that many solutes have 
an equal action per osmole makes it difficult to dismiss the idea 
that there is an osmoreceptor which slows gastric emptying (Hunt, 
1961 and 1963). 
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The mechanism by which this osmoreceptor regulates GER stems 
from the observations of Hunt (1961 and 1963) and has been 
reviewed by Bell et a] (1972) and Cook and Christensen (1973). 
It is suggested that the receptor is in the form of a vesicle 
having some of the properties of'a red blood cell, i. e. it is 
deflated by contact with hypertonic solutions. Such deflation is 
p ostulated to cause a signal to be relayed to the stomach where it 
inhibits the peristaltic action of the GI pump. This would allow the 
duodenal secretion to dilute the gastric efflux to a greater extent 
and thus reduce the stimulus to the osmoreceptor. On the other hand, 
inflation of this osmoreceptor with substances that penetrate it 
along with water from the duodenum is postulated to reduce the signal 
that inhibits gastric emptying. Glucose, sucrose and sorbitol are 
believed not to penetrate into the osmoreceptors. Thus, deflation 
of the osmoreceptors gives slow emptying and inflation gives rapid 
emptying of the stomach. 
The site of the osmoreceptor has been reported to be in the 
duodenum and jejunum. (Hunt, 1961,1963-and 1975; Hunt and Knox, 1968a 
and b; Bell et a], 1972; Cook and Christensen, 1973; Cook, 1975). 
Evidence for this supposition arises from the fact that isocaloric 
meals of starch and glucose empty at the same rate and more slowly 
than water. Since hydrolysis of starch occurs beyond the pylorus, the 
osmoreceptor must be there also. 
This mechanism explains and supports the earlier theory and 
observations of Carnet and Chassevant C1905), Appearly (1926), and 
Shay and Gershon-Cohen (1934). Cook and Christensen (1973) believe 
that this osmoreceptor mechanism could be mediated by a humoral effect. 
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2.2 Fatýand Gastric empt ing rate 
It has been known since the first observations of Edwald 
and Boas (1886) that fat introduced into the stomach inhibits 
its secretions and motility. This inhibitory effect was demonstrated 
by Lintvarev (1901), Ivy and Farrel (1925), Farrel and Ivy (1926), 
Kosaka and Lim (1930), Roberts (1931), Waugh (1936), Card (1941), 
Tidwell and Cameron (1942) and Grossman (1950), who recognised that 
inhibition takes place mainly from the duodenum and is a function of 
the chemical nature of the fat rather than its physical properties. 
The effects of many neutral triglycerides on GERwere tested and it 
was concluded that unsaturated fats were the more effective inhibitors. 
The effect was only observed (Roberts, 1931; Quigley et al, 1934; 
Waugh, 1936) after the fat had left the stomach. It was concluded 
that either oil absorption exerts this inhibitory effect on gastric 
motility or some substance, which acts in a similar manner, is formed 
or liberated. This inhibitory substance may be formed in the mucosa 
(Kosaka and Lim, 1930) of both the small and large intestine as a 
result of contact with fat. This provides further evidence to 
substantiate a humoral theory of inhibition. The name enterogastrone 
was suggested for the intermediary substance (Kosaka and Lim, 1930; 
Grossman, 1950). 
The presence of fat in the intestine does not inhibit gastric 
motility or secretion unless both bile salts and lipase are present 
in the lumen of the intestine. This conclusion is based on the 
following facts. Introduction of I cm' of fat into the proximal small 
intestine of intact rats consistently suppressed gastric motility. 
In rats with'diversion of bile from the small intestine this 
inhibition failed to occur unless bile salts were added to the 
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administered fat. When both bile and pancreatic juice were 
diverted from the small intestine, inhibition occurred only when 
oil was mixed with bile salts and lipase prior to injection (Menguy, 
1960). Gastric emptying of fatty meals is significantly more rapid 
in patients with pancreatic insufficiency compared with normal subjects. 
Addition of pancreatic enzyme to fatty meals slowed the gastric 
emptying in these patients. Pancreatic enzyme had no effect when 
added to 5% glucose solution or a fatty meal of normal subj ects. 
These results suggested that the digestive products of fats inhibit 
GER (Long and Weiss, 1974). Bile salts administered parenterally or 
intraperitoneally inhibited gastric secretion and motility in rats 
and dogs (Menguy, 1959a and b; Menguy and Koger, 1959; Menguy and 
Peisner, 1960). Since bile salt secretion is enhanced (see part 1.4. 
2b in the previous chapter) during fat absorption, it was concluded 
that the reabsorbed bile salts could be the humoral agent mediating 
gastric inhibition by fat. The specific inhibitory effect of lipolytic 
products j2er se was ruled out by Quigley et a] (1934). 
More recently it has been reported that the sodium salts of fatty 
acids (Hunt and Knox, 1968c) and digestive products (Hunt, 1975) 
caused the inhibition in GER, since monoglyceride scarcely slows gastric 
emptying. Hunt 0975) showed that fatty acids in the form of soaps 
gave a greater reduction in GER and thus supported the finding of 
Quigley and Meschan(, 1941), who found that the order of retardation of 
gastric evacuation, as a result of pyloric closure and inhibition of 
antral activity, was soap > fatty acids > neutral fats. 
The idea that delay in GER is caused by the digestive products 
of fat has been supported recently. Inhibition occurs within 5 minutes 
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(Moberg and Carlberger, 1974) , which is exactly the same time as 
reported by Farrel and Ivy (1926). The pattern of emptying was 
described by Moberg and Carlberger (1974) as composed of a rapid 
initial phase (5 minutes) followed by a prolonged emptying phase, 
during which a remarkable inhibition of gastric emptying was noted 
with fat containing meals. These findings and others (Moberg et al, 
1974) suggested that the emptying rate during the prolonged phase 
was evoked in the upper small intestine by the digestion and 
absorption of fat. Knox and Mallinson (1971) demonstrated that 
triglycerides must be digested to exert their inhibitory action. 
A relationship has been reported between the GER and digestibility 
and absorbability of the fat (Johansson et a], 1972; Yamahira et a], 
1978). The latter conducted further studies and found that increase in 
the volume of oil caused more delay in GER. 
Having these points in mind, together with the fact that 
earlier studies (Roberts, 1931; Quigley et a], 1934; Waugh, 1936) 
showed that inhibition in GER only occurs when fat leaves the stomach 
and passes through the pyloric sphincter, it can be concluded that 
the fat receptor is located somewhere beyond the pylorus, and that it 
is sensitive to the digestive products of fat. 
Fatty acids are known to decrease GER via sensitive receptors 
located in the duodenum and jejunum (Shay et a], 1939; Hunt and Knox, 
1968a and b; Cook and Christensen, 1973; Hunt, 1975; Cook, 1975). The 
resulting inhibition of GER was found to be correlated to a 
significant inhibition of the propulsive movement in the duodenum by 
sodium myristate (Borgstrom and Arborelius, 1975). Once the gastric 
contents had filled the duodenal bulb, no further emptying occurred 
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before the bulb had been partially or completely emptied by an 
antegrade (i. e. propulsive) peristalsis wave. The authors thought, 
therefore, that duodenal transport rate interferes. directly with 
the GER. Hunt and Knox (1968b) and Weisbrodt et a] (1969) also 
believed that the duodenal contractility and motility regulate GER, 
but in a different way. They thought that the antral contractility 
and duodenal quiescence are intermittent during gastric emptying. 
Weisbrodt et a] (1969) found that the slowest rate of emptying occurs 
when there is a relatively low antral and a high duodenal activity 
and vice versa. 
However, it se ems t-hat the conflicting ideas of these workers 
can be explained as follows. The emptying of material that is 
incompatible with the duodenal mucosa into the duodenal bulb leads 
to enhanced duodenal activity since the normal antegrade (propulsive) 
waves are followed by retrograde peristaltic waves that prevent 
emptying of the duodenal bulb. This leads, in turn, to inhibition of 
gastric emptying, i. e. antral activity decreases. Thus, the resultant 
delay in transport from the stomach to duodenum allows the duodenum 
time to handle the initially incompatible material. When compatibility 
has been ensured duodenal activity decreases and gastric emptying occurs 
because antral activity then increases, i. e. there are intermittent 
periods of antral and duodenal activity. 
However, the above mechanism does not take into account the fact 
that the pyloric sphincter may also interfere with gastric emptying. 
Waugh (19.36) and Gershon-Cohen and Shay (1937)showed, using 
radiological observations, that fat in the duodenum and jejunum 
immediately produced marked atony of the whole stomach, with no 
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peristalsis for 30-90 min, together with pyloric closure. In addition, 
increase in the pressure exerted by the pylorus has been reported 
when olive oil is instilled into the duodenum in the dog (Brink et 
a], 1965) but only after 15-20 min, whereas antral-motility was 
inhibited immediately. The role of the pyloric sphincter and inhibition 
of the peristaltic movement of the stomach in regulating GER have 
been reported in response to fat in the duodenum of the dog (Quigley 
and Meschan, 1941; Quigley et a], 1941) and to olive oil and g. lucose 
in the duodenum of man (Fisher and Cohen, 1973). 
Fisher and Cohen (1973) strongly suggested that the endogenous 
release of cholecystokinin and secretin augment the pyloric pressure. 
Their suggestion, which was supported by the work of Fisher et a] 
(1973), stems from the facts that secretin inhibits gastric emptying 
and secretion in man (Chey et a], 1970); cholecystokinin, the production 
of which is stimulated by fat, (Isenberg and Csendes, 1972), delays 
gastric emptying in man (Chey et al, 1970) and raises pyloric pressure 
in dog (Isenberg and Csendes, 1972); and that olive oil raises the 
pyloric pressure after being introduced into the duodenum (Brink et 
a], 1965). However, enterogastrone, the postulated hormone, has not 
yet been isolated in pure form. It refers to a substance, liberated 
from the duodenum and jejunum by fats, which inýibits both gastric 
emptying and secretion. It is neither cholecystokinin nor secretin 
(Johnson and Grossman, 1969). Its structure has been partly determined; 
it appears to be distinct from other GI hormones (Brown et al, 1970) 
and does not possess any significant cholecystokinin or secretin 
activity (Brown et a], 1969).. 
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In summary, GER has been suggested to be regulated by receptors 
that are located in the duodenum and jejunum and that are sensitive 
to osmotic pressure and the digestive products of triglycerides, 
namely fatty acids. As a result of stimulation, enterogastrone 
would be released and this mediates the delay in GER through myogenic 
activity of the GI tract, i. e. the pyloric pressure region is 
raised and the GI peristaltic motility is altered. 
The relative effectiveness of this inhibition has been reported. 
For example, the following test meals would decrease the GER to the 
same extents; 500 millimoles of glucose and 8 mmole myristic acid 
per litre (Hunt and Knox, A968b; Cook, 1975); 9 gm carbohydrate/100 CM3 
and 4 gm triglycerides/100. CM3 , both equal to . 36 kcal 
/100 W. 
(Hunt, 1975; Hunt and Stubbs, 1975). 
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CHAPTER 
THE ENHANCEMENT OF INTESTINAL ABSORPTION OF DRUGS BY FATS AND OILS 
In addition to the major effect of oils in delaying GER, which 
was the subject of the previous chapter, the formation of bile salt- 
fatty acid-monoglyceride mixed micelles, that are formed during the 
digestion of fats and oils (Senior, 1964; Dawson, 1967; Hofmann and 
Small, 1967; Carey and Small, 1970; Holt, 1972; Ockner and 
Isselbacher, 1974), has been reported recently to have a significant 
effect on the enhancement of intestinal absorption of drugs which 
are normally, poorly absorbable, e. g. streptomycin and gentamycin 
or nonabsorbable, e. g. heparin. The following mechanisms have been 
proposed to explain this effect; (a) direct interaction of the drug 
with the mixed micelles, (b) the enhancement in the absorption Js 
related to the digestibility and absorbability of the lipids, (c) 
alteration of the mucosal membrane permeability. 
Based on in situ absorption studies in the rat, using intestinal 
loops closed at proximal and distal ends, Inui et al (1976) and 
Tokunaga et a] (1978) suggested that the mixed micellar solution 
enhanced drug absorption by mechanisms (a) and (c). Using the same 
method of study Mura'nishi et al (1977 and 1979) and Muranushi et al 
(1980a) suggested that the enhancement of absorption was unlikely 
to be due to (a) and (b). The alteration of the mucosal permeability 
was examined by exorption studies using sulphanilic acid, and by 
pret. reatment of the intestinal loop with buffer solutions as controls, 
with micellar solutions of bile salts and mixed micellar solutions. 
A close correlation was found between the enhancing effect and the 
alteration of the mucosal membrane permeability. It was concluded that 
the enhancement of intestinal absorption of drugs by the addition of 
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mixed micelles is mostly due to an increased permeability of the 
mucosal membrane caused by the incorporation of the lipid component 
of the mixed micelle (Muranushi et al, 1980a). 
Since the mixed micellar solution significantly enhanced the 
absorption over that of a bile salt micellar solution alone 
(Muranishi et al, 1977 and 1979; Muranushi et al, 1980a), it was 
thou ght that the lipid of the mixed micelle played a critical role 
in this enhancement (Taniguchi et a], 1980; Muranushi et al, 1980a and 
b). This led Taniguchi et a] (1980) to conduct further experiments- 
using different lipids and different surfactants, including bile 
salts, to study the effect of surfactant mixed micelles. Although 
bile salt micellar solution did not cause a marked increase, an 
addition of mono-olein or oleic acid to that solution resulted in an 
induction of the absorption. Mono-olein and oleic acid caused a 
remarkable effect irrespective of the surfactant present. Another 
interesting finding by the same authors was the ineffectiveness of 
triglycerides, such as triolein and trioctanoin, so the great efficacy 
of absorption of oleic acid plays an important role in the improvement 
of heparin absorption. 
Furthermore, polar lipids, administered as adjuvants, can also 
be absorbed from the intestine, penetrating through the epithelia] 
cells. The disappearance of-mono-olein or oleic acid from the 
intestinal lumen was remarkably rapid and occurred within -15 min. 
This disappearance appears to be highly correlated with the absorption 
rate. of heparin. In addition, the absorption oV heparin was higher 
from mono-olein-bile salt solution than from monoýolein-HCO 60 solution 
(HCO 60 is a non-ionic surfactant, i. e. the polyoxyethylene 
derivative of hydrogenated castor oil), and concomitantly mono-olein 
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itself was absorbed in higher amounts from the bile salts solution 
than from the HCO 60 solution (Taniguchi et a], 1980). The authors 
suggested that some relationship exists between the penetration 
of polar lipids into the epithelial cell membrane and the delivery 
of heparin moleculesinto the cell. It follows, therefore, that 
polarity and digestibility of the lipid play a critical role in 
the absorption of the drugs (Bloedow and Hayton, 1976; Yamahira et 
al, 1979). 
Further studies were conducted by Muranushi et a] (1980b) on 
the mechanism of the intestinal absorption of drugs in the presence 
of mixed micelles using the liposomal membrane as a biomembrane 
model. The effect of incorporating various lipids on the permeability 
of drugs through the liposomal membrane was investigated. A close 
correlation was observed between the enhancement of intestinal 
absorption of drugs induced by the mixed micelles and the altering 
of the permeability of the liposomal membranes by the incorporation 
of the lipid component of the mixed micelles. Namely, lipids which 
enhanced the intestinal absorption increased the permeability of 
liposomal membranes, and lipids, which did not cause an increase of 
the drug absorption, did not alter the permeability of liposomal 
membrances. Furthermore, the degree of the enhancing effect of various 
fatty acids on the permeability of liposomal membranes corresponds 
to the extent of the enhanced intestinal absorption in the presence 
of fatty acids mixed micelles. 
The-role of bile salts, however, should not be neglected 
particularly with regard to their contribution in altering membrane 
pe rmeability and their involvement in fat absorption. The principal 
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role of the bile in 
the products of lip 
in true solution in 
mixed micelles. The 
through the monomer 
Based on these 
facilitating lipid absorption is to solubilise 
id digestion. Fatty acids then exist as monomers 
equilibrium with the fatty acid within the 
actual process of fatty acid absorption occurs 
phase (Westergaard and Dietschy, 1976). 
facts, the mechanism for the inducement of 
intestinal absorption of poorly absorbed drugs by mixed micelles is 
speculated by Muranushi et a] (1980b) as follows: " The micellar 
state may facilitate the incorporation of the lipid component of 
mixed micelles into the mucosal membrane. The incorporated lipid 
interacts with the polar region of the membrane phospholipids and 
enhances the fluidity and permeability of the mucosal membrane. 
Consequently, poorly absorbed drugs can transfer across the mucosal 
membrane easily. " 
Finally it should be mentioned that all the above studies were 
conducted using closed intestinal loops. Therefore, the major effect 




SCOPE OF THE THESIS 
S. uspension dosage forms are important classes of pharmaceutical 
products. These dispersion systems present many formulation, stability, 
manufacturing and packing challenges. 
Oralpharmaceutical suspensions have been known and used for a 
long time. Besides being the dosage form that is favoured by the 
very young and by elderly people, who find it difficult to swallow 
tablets or capsules, several other reasons exist for the use of 
suspensions (Ansel, 1976). 
Oral pharmaceutical suspensions are comprised of a physiologically 
active ingredient(s) and the vehicle. The vehicle is generally 
comprised of a liquid plus density and viscosity enhancing agents, 
flavouring agents and preservatives. Water has usually been the 
preferred liquid. The physiologically active agent is present as 
dispersed particles, the size of which is usually very small. The 
solubility of the active agent in the liquid is very low. 
The oral pharmaceutical suspension is contrasted with the oral 
pharmaceutical solution in which the physiologically active agent is 
dissolved in the liquid. Where certain drugs are chemically unstable 
when in solution the oral suspension improves chemical stability 
whilst permitting liquid therapy (Ansel, 1976). 
In many cases, however, the physiologically active agent is not 
chemically stable in either a water-based oral pharmaceutical 
suspension or an oral pharmaceutical solution. In such cases it is 
impossible to prepare a satisfactory liquid pharmaceutical dosage form 
ut, ilising water as the base for the preparation. Even when the drugs 
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are supplied as powders to which water can be added immediately before 
use, drug degradation may still occur during daily use by patients. 
Consequently, the use of a non-aqueous vehicle, e. g. an oily vehicle, 
would seem reasonable in these cases. 
Although an oily vehicle is not well accepted because of its 
taste, Stephens and Su (1975) claim the following advantages; 
(a) it is useful for preparing oral pharmaceutical liquid dosage forms 
of water degradable physiologically active ingredients, (b) it has 
good flow properties, and (c) it shows resistance to the settling 
and caking of suspended particles. In addition, oily vehicles may 
enhance the GI absorption of drugs, as indicated later in this chapter. 
Some oily vehicles for pharmaceutical formulations have been 
the subject of various patents. For example, an oily vehicle patented 
by Stephens and Su (1975) is composed of refined fractionated 
coconut oil containing hydrogenated castor oil, lecithin, aluminium 
stearate and an oil insoluble excipient, such as sucrose, to adjust 
the viscosity of the vehicle. Preservatives and flavouring agents can 
be added to modify the oily taste. Another oily vehicle discovered 
by Lin and Pramoda (1978) is composed of sesame oil, silica gel 
(Cab-o-sil) and sucrose. However, these patents were concerned mainly 
with the physical and chemical stabilities of given suspensions 
rather than with their bioavailability aspects. Although Lin and 
Pramoda (1978) conducted simple crossover studies to compare the 
bioavailabtlity of a permanent suspension of amoxicillin in their 
novel oily vehicle with that in the commercially available aqueous 
suspension, their studies were limited. However, extensive stability 
tests confirmed that the novel oily suspensions exhibited excellent 
62 
stability, with shelflives exceeding five years in some cases (as, 
for example, with ampicillin) with minimal oil separation. Similar 
stabilities were reported by Stephens and Su (1975) in the assessment 
of their vehicle, together with claims that oily taste was not 
apparent and that the vehicle has a good 'mouth feel'. 
Little information is available on the factors that may affect 
the bioavailability of drugs administered orally as a suspension, 
particularly in oily vehicles. Although it is well known that fat 
enhances the bioavailability of many drugs most studies have been 
conducted by coadministration of fatty meals with drugs in man 
(Crounse, 1961 and 1963; Kabasakalian et al, 1970; Bates et a], 1974b; 
Rosenberg and Bates, 1976; Melander et a], 1977a, b and c; Melander 
and Wahlin, 1978; Koch et a], 1978; Melander et al, 1979). Other 
studies have demonstrated the enhancement of bioavailability of 
drugs from emulsion dosage forms in man (Wagner et a], 1966; Bates 
and Sequeira, 1975; Bates et a], 1977) and in the rat (Kaiser et a], 
1967; Carrigan and Bates, 1973; Chakrabarti and Belpaire, 1978; 
Ogata and Fung, 1980). However, the GI absorption of drugs 
administered orally to intact animals in oily suspension dosage forms 
has received very limited attention, e. g. in mice (Feinstone et al, 
1940), and in rat (Carrigan and Bates, 1973; Bloedow and'Hayton, 1976; 
Chakrabarti and Belpaire, 1978). No studies have explored the various 
factors that affect the drug release and absorption from oily 
suspension dosage forms, apart from that of Bloedow and flayton (1976). 
Even this study was limited to the use of a simple dispersion of 
the drug in the oil, i. e. no attempts were made to consider the 
effects of other pharmaceutical adjuvants, which are necessary in 
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the production of commercial oily suspension dosage forms. 
In view of the above comments the work presented in this 
thesis was carried out in order to investigate the effects of oil 
on the bioavailability of sodium salicylate, ampicillin trihydrate 
and nitrofurantoin in either rabbits or rats. In addition, the 
effects of the different pharmaceutical adjuvants and different 
concentrations of the suspending agents, that are specified in the 
two patents mentioned above, were investigated, individually and in 
combination, on the bioavailabilities of the three drugs. 
With the factors that influence the dissolution and absorption 
of drugs in mind (see parts 1.3 and 1.4 of Chapter 1 in this Section) 
some of the physicochemical properties of the drugs have been 
st udied, e. g. solubility of the drug in the oil and in 0.1 mole/dm' 
HCI, apparent partition coefficient between the oil and the acid. 
Rheological properties of dispersions of each ingredient and 
combinations of all the ingredients specified in the above mentioned 
patents, together with different concentrations of the suspending 
agents were also studied. The possibility of adsorption of the 
drugs from ýolution in the oil onto the insoluble suspending agent 
(Cab-o-sil) ujcLs studied in an attempt to explain the effect of this 
suspendi-ng agent on the bioavailabilities of the drugs. Finally, in 
order to investigate the extent of the effect of viscosity on the 
results obtained using the oily vehicle in vivo and the possibility 
of correlating the in vivo results with in vitro measurements two 
classical in vitro dissolution methods, i. e. flask-stirrer and 
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CHAPTER 1 
RHEOLOGICAL STUDIES ON OILY VEHICLES 
1.1 Introduction 
The rheological Properties of a pharmaceutical dosage form, 
which can range in consistency from liquid. through semisolid to 
solid, can affect its patient acceptability, physical stability, and 
the biological availability of the active ingredient. 
With respect to the physical stability of suspension dosage 
forms, i. e. the ability of the suspension medium to retain insoluble 
particles in a suspended or substantially suspended easily 
redispersed state, the viscosity of the suspension vehicle is an 
important factor as indicated by Stokes' law, which is described 
by Eq. 1.1 
d2 (1p, - A, ) 
18 1? Eq. 1.1 
where -V = the sedimentation rate, g- gravitational constant, 
d- the diameter of the particle, P, and A are the densities of 
the particle and dispersion medium, respectively and o? is the 
vi. scosity of the dispersion medium. 
According to Stokes' law, an i. ncrease in the mean particle size 
or in the differences between the densities of the solid and liquid 
phases will produce a faster rate of sedimentation, while an 
increase in the viscosity of the liquid medium will decrease the 
sedimentation rate (Richards, 1972). 
In addition to viscosity, other rheological properties of the 
-suspens. ion medium, such as thixotropy and yield value can be related 
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to suspension stability. For example, Foernzler et al (1960) found 
a direct relationship between the sedimentation rate and the 
reciprocal of the thixotropic area of zinc oxide suspensions and 
Meyer and Cohen (1959) reported suspensions of some drugs suspended 
in a plastic medium to be permanent when the medium exhibited a 
critical minimum yield value, irrespective of the apparent viscosity. 
These rheological properties, i. e. thixotropy and yield value, 
have been used to promote prolonged drug action in vivo. For example, 
Ober et a] (1958) reported that concentrated (40-70% w/v) aqueous 
procaine penicillin G suspensions are highly thixotropic and possess 
exaggerated yield values. This yield value was the key to the 
sustained action of the injectable products of Ober et al. Suspensions 
possessing high yield value were very thixotropic, and the authors 
found that these suspensions first became fluid as they passed 
through the hypodermic needle, then quickly recovered their structure 
to form a complete depot in the muscle, thereby providing prolonged 
therapeutic blood levels. 
The rate of structural recovery was found by Ober et al to be 
important and, in fact, is of significance in all suspensions where 
thixotropy is employed to achieve stability. This is the case with 
oily thixotropic aluminium stearate gels (Buckwalter and Dickison, 
1948 and 1958) as will be discussed later in this introduction. 
Therefore, rheology is of a great importance with respect to dissolution 
and release in vitro as well as drug release and bioavailability in vivo. 
Whilst the rheological aspects of aqueous suspension media have 
received considerable attention with respect to drug release and 
dissolution in vitro (Kabre et al., 1964; Braun and Parrott, 1972; 
Florence et al_, 1973; Bachynsky et al, 1976; Shah and Sheath, 1976; 
6.7 
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Barzegar-Jalali and Richards, 1979a) and drug release and bio- 
availability in vivo (Levy and Jusko, 1965; Hewitt and Levy, 1971; 
Levy and Roa, 1972; Barzegar-Jalali and Richards, 1979b; Marvola et 
a], 1979a; Soci and Parrott, 1980), little attention has been paid 
to these aspects in the case of non-aqueous vehicles. In addition, 
the small number of publications concerned with the effects of the 
rheological properties of such vehicles have been limited to 
dermatological products, e. g. Kostenbauder and Martin (1954), Billups 
and Sager (1964)i Whitworth and Stephensons (1971), Asker and Whitworth 
(1974) and Davis and Khanderia (1980), or to injectables, e. g. 
Buckwalter and Dickison (1948 and 1958) and Phadke (1975). Thus, 
there is no apparently available information concerning the effects 
of the rheological properties of non-aqueous vehicles on the bio- 
availabilities of orally administered drugs. In fact, there is even 
little information on the rheological properties of such vehicles. 
Aluminium stearates have been used as a suspending agent and 
gelling agent in oily vehicles intended for intramuscularly injected 
repository forms of pen. icillin by Buckwalter and Dickison (1948 and 
1958). Appropriate rheological properties were included in the list 
of requirements suggested by these workers, e. g. the injection should 
(a) be capable of easy withdrawal into a syringe and administration 
at room temperature, (b)- retard the release of drug from the site of 
injection and (ýc) prevent the sedimentation of suspended drug 
particles. Buckwalter and DickisQn 0948 and 1958) indicated that 
the rheological properties of the oily gels depend on the type of 
aluminium stearate that is used (J. e. mono, di- or tristearate), on 
the'nature of the oil and on the conditions under which the gel is 
prepared. They concluded that gelled vehicles that satisfied their 
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list of requirements were obtainable. Later work by Phadke (1975) 
showed that the sedimentation rate of procaine benzy1penicillin 
in sesame oil gelled with aluminium stearate correlated well with 
the duration of penicillin blood levels in the rabbit. In fact, this 
worker suggested that sedimentation rate would provide a reasonable 
index of batch quality and might provide a substitute for blood 
level measurements. 
Aluminium stearate (50: 50 mixture of mono- and distearates) is 
also an essential ingredient in the oily vehicle patented by 
Stephens and Su (1975) for use as a suspension medium for orally 
administrated drugs that are water degradable, such as erythromycin, 
penicillin-v, tetracycline, cephalexin and others. The patent claims 
that the drug suspensions possess good physical stabilities and 
infers that the vehicle exhibits appropriate rheological properties. 
However, direct assessment of these properties is not described. 
Colloidal silica has also been used as a thickening agent for 
non-aqueous vehicles and Lin and Pramoda (1978) have patented such 
a vehicle for use with orally administered drugs that are not stable 
in aqueous suspensions, e. g. amoxicillin and ampicillin. Zia et a] 
(1974) also showed that the stability of penicillin G in peanut oil 
thickened with silica could be improved by reducing the surface 
acidity of the silica. The effect of this suspending or gelling agent 
on the in vitro release of methylsalicylate from n-dodecane and 1- 
dodecanol has been studied by Sherriff and Enever (1979). 
In spite of the importance of the rheological properties of 
vehicles gelled with either aluminium stearate or colloidal silica 
these properties were not specified for the oils and gels used in 
the above studies except for the systems investigated by Sherriff 
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and Enever (1979). Previous work on the flow properties of aluminium 
soap-hydrocarbon systems has been reported (Shiba, 1960; Stephens, 
1971) but these studies were limited to systems containing liquid 
paraffin and many aspects of the rheological behaviours of these 
systems were not fully explained. 
In contrast to most of the previous studies the flow curves of 
the oily vehicles used in the present work are described in this 
chapter. 
1.2 Experimental 
1 . 2.1 Materi aIs 
Fractionated Coconut Oil (FCO) B. P. C. 1968, was obtained from 
Alembic Products Ltd. The acid and saponification values of the oil 
were checked every two weeks during the course of the whole 
investigation to ensure that they remained within the limits 
described in the B. P. (1973). Colloidal silica (Cab-o-sil) and 
lecithin 90% (refined grade) were obtained from B. D. H. Chemicals Ltd. 
Aluminium mono-and distearates were obtained from Witco Chemical Ltd. 
Hydrogenated castor oil was obtained from Akzo Chemie U. K. Ltd. 
Sucrose (. Icing sugar) was obtained from the British Sugar Corporation 
Ltd. and xanthan gum (Keltrol-food grade) was obtained from Kelco 
Ccr., U. S. A. 
1.2.2 Methods 
(i) freparation of the dispersion media 
In addition to the FCO alone, the following three types of 
systems were investigated in the assessment of the rheological 
behaviours of 24 different vehicles, 
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Type 1 vehicles 
Vehicles of this type relate to that described by Stephens 
and Su (1975). 
(a) 0.5% w/v, 1% w/v, 1.5% w/v, 2% w/v, 2.5% w/v, 3% w1v, 3.5% w/v, 
4% w/v or 5% w/v of a 50: 50 mixture of aluminium mono- and 
distearate dispersions in FCO. 
(b) solution of 0.7% w/v lecithin in FCO. 
(c) dispersion of 0.35% w/v of hydrogenated castor oil in FCO. 
(d) dispersion of 0.5% w/v aluminium stearate + 0.7% w/v lecithin 
+ 0.35% w/v. hydrogenated castor oil + 20% w/v sucrose in FCO. 
(e) dispersion of 0.5% w/v aluminium stearate + 0.35% W/v 
hydrogenated castor oil + 20% w/v sucrose in FCO. 
M dispersion of 0.5% w/v aluminium stearate + 0.7% w/v lecithin 
+ 0.35% w/v hydrogenated castor oil + 30% w/v sucrose in FCO. 
Vehicles d and f were prepared according to the patent of 
Stephens and Su (1975) by dissolving the lecithin in a portion of 
the FCO. Dissolution was facilitated by heating the FCO to about 
90-1000C and agitating the mixture thoroughly until all the solids 
were dissolved. To this solution, with the heat maintained, the 
aluminium stearate and hydrogenated castor oil were added and the 
resulting mixture was mixed well until the I. atter two ingredients 
weýre thoroughly dispersed. Then the sucrose, previously sieved to a 
mesh size of 63-75gm, was added and the resulting dispersion was 
mixed thoroughly with the temperature at 90-100 0C for 3 hrs. 
The resulting dispersion was cooled to room temperature with 
mixing. The remainder of the FCO was then added to bring the 
dispersion up to the volume. Care was taken to avoid the entry of 
any moisture into the container, since preliminary studies showed 
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that water affects the structure of the gel. The remaining vehicles 
(a), (b), (c) and (e) were prepared in accordance with appropriate 
stages in the above method. For example, vehicles of type I(a) were 
prepared simply by adding the required amounts of aluminium stearate 
to a portion of the FCO in a flask and heating in a water bath 
(90-100)OC for 3 hrs with thorough agitation. For vehicles (b) and 
(c) the require. d amount of the ingredient was added to a portion of 
the oil and mixed thoroughly at a temperature of 90-1000C until the 
solid was dissolved in the case of (b) or thoroughly dispersed in (c). 
Vehicles (a) (b) and (c) were then cooled to room temperature and 
the remainder of the oil was added as mentioned above. 
Type 2 vehicles 
Vehicles of this type relate to that described by Lin and P ramoda 
(1978) 
(a) dispersions of (i) 20% w/v or (ii) 30% w/v of sucrose in FCO. 
(b) M 0.3% w/v, 00 0.5% w/v or Ciii) 1% w/v of Cab-o-sil in a 
20% w/v dispersion of sucrose in FCO. 
Cc) 1.25% wIv Cab-o-sil + 30% w/v sucrose in FCO. 
(d) 1% w/v Cab-o-sil in FCO. 
Vehicles (b) and CO were prepared according to the patent of 
Lin and Pramoda (1978) by adding the sugar in successive portions to 
a-portion of the FCO in a suitable container and stirring until the 
system was suitably dispersed and suspended. The Cab-o-sil was then 
added and stirred until dispersed. Sufficient additional oil was 
added and stirred to obtain a uniform dispersion. Although it was 
not specified in this patent, the sucrose was sieved and the portion 
corresponding to a mesh size of 63-75 1= was used in the preparation 
of the vehicle. Precautions were taken to avoid the entry of moisture 
into the container for the same reason mentioned above, 
72 
The vehicles that contain only dispersions of sucrose in the 
oil (a) or Cab-o-sil in the oil (d) were also prepared according to 
this patent simply by adding the sucrose or Cab-o-sil to the oil and 
stirring until complete dispersion was obtained. 
Type 3 vehicles 
These aqueous vehicles were included for use in comparative 
in vivo and in vitro studies. 
(a) 0.25% w/v xanthan gum in di*stilled water. 
(b) 0.25% w/v xanthan gum + 20% w/v sucrose in distilled water. 
(c) 30% w/v sucrose in distilled water. 
100 cm3 quantities of the dispersions were prepared by wetting 0.25 gm 
of gum with 2 cm' of 90% v/v alcohol and then adding 75 CM3 of distilled 
water or 20% w/v sucrose solution to prepare (a) and (b) respectively. The 
dispersions were allowed to hydrate for 24 hrs. The volumes were made up 
to 100 CM3 with appropriate vehicle. 
All vehicles of every type (except 3c) were then homogenised for 
one minute using an Ultra-Turrax mixer at a fixed speed and stored 
overnight. On the following day the dispersions were stirred gently and 
0 warmed to 37 C before use. 
(H) Rheological measurements 
A Rotovisko, viscometer (Haakel fitted with concentric cylinder 
sensors and a temperature controlled water jacket at 370C was used. 
The NV measuring cup and bob with measuring head 500 were selected; 
this combination was suitable for the viscosity range studied. 
The measuring cup was filled with a dispersion, previously 
warmed to 370C, and the bob immersed. The dispersion was allowed to 
remain undisturbed for 2 min to allow temperature equilibrium to 
be re-established. The bob was set in motion at the lowest shear rate, 
ýnd a reading was taken at the end of 30 seconds. The rotational speed 
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of the bob was then increased to the next setting at 30 second 
intervals until the highest shear rate was reached, then decreased 
at the same rate to the lowest shear rate and scale readings were 
recorded at the end of each 30 seconds period. The total time for 
each measuring cycle was therefore 5 minutes. 
1.3 Results 
The rate of shear (D) that is applied to the system under test 
at a given speed of rotation of the bob in the Rotovisko viscometer 
is given by Eq. 1.2 
B 
D-s Eq. 1.2 
u 
where B is a constant that depends on the dimensions of the 
concentric cylinders and U is a speed factor. 
The scale readings (S) observed on the instrument can be 
converted into shear stress (--r) values by Eq. 1.3 
-r - AS N m- 
2 Eq. 1.3 
where A is a constant (the stress factor) that depends on the 
dimensions of the sensor system that is used and on the torsional 
constant of the instrument. 
Tables of results that listed the values of the instrument 
parameters, observed scale readings and derived shear rates and 
stresses were prepared for each system that was studied. Table 1.1 
is an example of such a table and shows the results obtained for 
FCO. 
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Table 1.1 Rheological parameters for FCO at-370C 
Sensor - NV, Measuring head - 500 
D(s- 
I) 
-L -2 r(N m 
162 
81 0.31 32 0.6 
54 0.50 49 0.9 
27 1.00 97 1.8 
18 1.38 146 2.5 
9 2.75 291 5.0 
6 4.25 436 7.8 
3 8.38 873 15.3 
2 12-75 1310 23.3 
1 25-00 2620 45.8 
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Rheograms or flow curves, i. e. plots of shear rate versus 
shear stress, for all the systems studied in this chapter are shown 
in Fig. 1.1 - 1.4. These figures describe the "upcurves" only 
and extend to a maximum shear rate of 436 s- 
1 for the sake of clarity 
at the lower shear rates. With the exception of the linear (i. e. 
Newtonian) flow curves that were obtained for FCO alone (curve(l) 
in Fig. 1-1), 0.7% w/V lecithin in oil (curve l(b) in Fig. 1.2) and 
30% w/v sucrose in water, the remaining rheograms indicated varying 
degrees of pseudoplastic behaviour of the oily dispersions referred 
to in Fig. 1.1 - 1.3 and the aqueous systems referred to in Fig. 1.4. 
In addition to pseudoplastic behaviour, systems containing 
concentrations of aluminium stearate greater than 1% w/v in FCO also 
exhibited a slight thixotropy. The complete rheograms (i. e. upcurves 
and downcurves) for 1% w/v and 5% w/v aluminium stearate in FCO over 
the complete range of shear rates that was used and that for vehicle 
type 1(f), which corresponds to the vehicle described in Stephens 
and Suls pate nt (1975), are shown in Fig. - 1.5 and 1.6'respectively, 
in order to illustrate the hysteresis loops that denote thixotropic 
behaviour in these systems. 
The apparent viscosities at an arbitrarily chosen low shear rate 
of 100 s- 
I 
of a series of aqueous vehicles have been correlated with 
the bioavailabilities and in vitro release rates of a series of drugs 
(Barzegar-Jalali and Richards, 1979 a and b). The apparent viscosities 
of the systems used in the present work were calculated at the same 
shear rate and their values are listed in Table 1.2. 
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Table 1.2 Apparent viscosities ( 77app ) of the vehicles ;Aa s*hear rate 
0 of 100's and temperature of 37 C 
The Vehicle MN sm -2 
Disti I led water (D. W. ) 0.695 (a) 
30% w/v sucrose in D. W. 2.32 
Fractionated Coconut Oil (FCO) 17.5 
0.7% w/v lecithin solution in FCO 23 
0.25% w/v xanthan gum in D. W. 33 
0.5% w/v aluminium stearate in FCO 37 
0.25% w/v xanthan-gum + 20% w/v sucrose in D. W. 38 
0.35% hydrogenated castor oil in FCO 40 
1% w/v aluminium stearate in FCO 50 
20% w/v sucrose in FCO 51 
1% w/v Cab-o-sil., in FCO 58 
1.5% w/v aluminium stearate in FCO 59 
30% w/v sucrose in FCO 64 
2% w/v aluminiu m stearate in FCO 69 
2.5% w/v aluminium stearate in FCO 81 
0.3% w/v Cab-o-sil + 20% w/v sucrose in FCO 83 
3% w/v aluminjum stearate in FCO 92 
0.5% w/v Cab-o-sil + 20% w/v sucrose in FCO 98 
3.5% w/v aluminium stearate in FCO 104 
0.5% w/v aluminium stearate + 0.35% W/V 
hydrogenated castor oil + 20% w/v sucrose 
in FCO i. e. type 1 vehicle-e (le) 105 
vehicle (le) + 0.7% w/v lecithin i. e. (1d) 120 
1% w/v Cab-o-sil + 20% w/v sucrose in FCO 131 
vehicle (ld) using 30% W/V sucrose 
i. e. vehicle 0f) 140 
4% w/v aluminium. stearate in FCO 144 
1.25% w/v Cab-o-sil + 30% w/v sucrose in FCO 150 
5% w/v aluminium stearate in FCO 176 
(a) Liley et a] (1963). 
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Fig. 1.1 Rheograms of FCO and the dispersions of aluminium stearate 
in FCO (Type la vehicles). 
(i) FCO 
00 0.5% w/v aluminium stearate in FCO 
(iii) l% W/v 
(iv) 1.5% w/v (v) 2% w/v 
(vi) 2.5% w/v 
(vii) 3% w/v 
(viii) 3.5% w/v 
(ix) 4% w/v 
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Fig 1.2 Rheograms of oily vehicles Type l(b)-(f) and Type 2 (a) 
at 37'C. 
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Fig. 1.3 Rheograms of oily Type 2(b)-(d) vehicles at 37 0C 
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Fig. 1.4 Rheograms of aqueous Type 3 vehicles at 370C 










-2 tý) .2 tk) 
81 
10 15 20 25 
Shear Stress N m- 
2 
Fig. 1.5 Rheograms of oily dispersions of 1% w/v and 5% w/v aluminium 
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1.4 Discussion 
The Newtonian behaviour exhibited by FCO, 0.7% w/v lecithin 
solution in the oil and the syrup, i. e. 30% w/v sucrose in distilled 
water is as expected for simple liquids and true solutions (Martin 
et a], 1964 and 1973). Dispersions of aluminium stearate, 
hydrogenated castor oil, Cab-o-sil and sucrose in FCO, together with 
those oi ly vehicles specified by the patents of Stephens and Su 
(1975) (type 1 vehicles, d and f) and Lin and Pramoda (1978) (type 
2 vehicles, b and c), exhibited pseudoplastic behaviour. These 
findings are in agreement with those reported in the literature 
concerning Cab-o-sil (Lin and Pramoda, 1978), and sucrose(Martin et 
a], 1964 and 1973). Furthermore, aluminium stearate, 1% w/v and above, 
and the oily vehicle type I (d and f) exhibited thixotropic 
pseudoplastic behaviours. The thixotropic property of oily gels of 
aluminium stearate has been reported previously (Buckwalter and 
Dickison, 1948 and 1958; Phake, 1975). 
When classifying materials according to the types of flow and 
deformation, it is customary to place them in one of two categories; 
i. e. Newtonian or Non-Newtonian systems. The choice depends on whether 
or not their flow properties are in accordance with Newton's law of 
flow (Martin et a], 1973). According to this law the higher the flow 
resistance or viscosity of a liquid the greater is the force required 
to cause the liquid to flow. The force per unit area, -r, imposed on 
the liquid is called the shearing stress. The velocity gradient of 
the liquid produced by this force is referred to as the rate of 
shear, D. 
In Newtonian systems the vehicle exhibits a constant 
proportionality between (-r) and (D) and consequently obeys Newton's 
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law, which is expressed by Eq. 1.4 or 1.5 
Y= 41 Eq 1 
or Eq 1 
where '7 is the coefficient of viscosity, ordinarily called by the 
shortened term, viscosity. The Sl unit of viscosity is Ns m- 
2 
Examples of Newtonian fluids include water, glycerin and true 
solutions, such as syrup (Martin et al, 1964 and 1973). Their 
viscosities do not depend on shear stress or rate of shear. The flow 
curves or rheograms of Newtonian liquids are straight lines which 
commence at the origin. Viscosity is the reciprocal of the slopes 
of such a line (D vsr) or the cotangent of the angle it makes with 
the horizontal axis (Martin et a], 1973). 
The addition of dispersed particles and/or suspending agents 
to a Newtonian vehicle often produces non-Newtonian properties. For 
example, the addition of the suspending agent xanthan gum to the 
water (Fig. 1.4) or aluminium stearate. (Fig. 1.1), hydrogenated castor 
oil (curve I(c) in Fig. 1.2), sucrose (curves 2(a) in Fig. 1.2) and 
Cab-o-sil (Fig. 1-3) to the oil produced non-Newtonian systems. 
Non-Newtonian flow behaviours do not follow Newton's law, i. e. 
Eq. 1A'. The non-Newtonian property may be plastic, pseudoplastic or 
dilatant behaviour. These behaviours may be either time independent 
or time dependent, i.. e. thixotropic. Dilatant and plastic behaviours 
are not encountered in this study, therefore, only pseudoplasticity 
and thixotropic pseudoplasticity will be discussed here. 
Unlike systems that exhibit plastic behaviour pseudoplastic 
materials do not p*ossess a yield value, but instead are characterised 
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by rheograms which begin at the origin, (or at least approach it 
at low rate of shear), as in the case of Newtonian liquids. 
However, unlike the curve for a Newtonian material, the pseudo- 
plastic flow curve is not linear, as shown by nearly all of the 
rheograms in Fig, 1.1 - 1.4. Another way of expressing this fact 
is to say that the shear stress, -r, does not increase linearly with 
the shear rate, 0, i. e. pseudoplasticity involves a decrease in the 
proportionality factor of shear stress: shear rate with increase 
in shear stress so that the viscosity apparently decreases as the 
shear stress or shear rate increases. This behaviour cannot be 
expressed quantitatively by fundamental equations but an empirically 
derived equation (Eq. 1.6) is often applicable (Krieger and Maron, 
1951; Kabre et al, 1964). 
n F =7 D Eq. 1 .6 
when n and 1' are constants for a given system. n is greater 
than I and the higher the value of n the greater the degree of 
pseudoplasticity. The viscosity coefficient -q", that is defined in 
Eq. 1.6, is a constant for a particular material, but, unlike 
Newtonian viscosity . -I ' 
it is difficult to assign any physical 
meaning to it. (Note. an equation similar to Eq. 1.6 may be used to 
describe the flow of dilatant systems, which exhibit behaviour 
opposite to that of pseudoplastic systems; i. e. "2 
app 
increases 
with increase in shear rate. In these cases the constant n in Eq-1.6 
is less than 1). 
Since the viscosity of 6 pseudoplastic substance decreases with 
increasing rate of shear, an apparent viscosity, I app 
is commonly 
used to denote the viscosity of the system at a particular shear 
stress or shear rate. It can be expressed as either the reciprocal 
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slope of a line joining the appropriate point on the flow curve 
with the origin of the graph (Green, 1949; Martin et a], 1973) or 
as cotangent to the flow curve at the specified point (Fischer, 
1950; Martin et al, 1973). The former method has been used to express 
the apparent viscosity of the vehicle dispersions at a shear rate 
of 100 5- 
1 
throughout this study. 
The decrease in the I app with 
increasing shear results 
. 
from 
the breakdown, under the influence of shearing force, of structures 
within the system. The structural features of these systems involve 
gel formation, e. g. aluminium stearate (Shiba, 1960; Stephens, 1971) 
and Cab-o-sil in the oil (Sherriff and Enever, 1979); or the 
intertwining of macromolecules and entrapment (immobilisation) of 
solvent molecules within the entanglements as in an aqueous dispersion 
of xanthan gum (Martin et al, 1964 and 1973). Breakdown of these 
structures occurs under the influence of shear, i. e. gel networks are 
disrupted or macromolecules tend to become aligned with their long 
axes parallel to the direction of flow so that intermolecular 
intertwinings are reduced and entrapped solvent molecules are 
released. The viscosity of the system consequently decreases with 
i*ncrease in the rate of shear. For this reason pseudoplastic materials 
are sometimes called "shear thinning systems". When structural 
break0own i's complete the lapp becomes constant, i. e. further increase 
in shear rate will not cause any additional decrease in viscosity. On 
removal or reduction of the shear force reformation of the structural 
units occurs under the influence of Brownian motion. If this 
reformation occurs immediately, the flow curve obtained at decreasing 
shear rates Cthe downcurve) is therefore superimposable on that 
- obtained from measurements made at increasing shear rates 
(the 
upcurvej. This is the case with the oily dispersions of sucrose 
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(curves 2(a) in Fig. 1.2), Cab-o-sil alone (curve 2(d) in Fig. 1.3)and with 
su6roso (curves 2(b) and (c) in Fig. 1-3) and aqueous dispersions of 
xanthan gum (Fig. 1.4). This type of pseudoplastic behaviour is called 
time independent pseudoplastic behaviour. 
However, there are instances where the downcurve is not super- 
imposable on the upcurve, i. e. the reformation of structure is not 
immediate when the stress is removed or reduced, and the downcurve is 
therefore displaced to the left with regard to the upcurve. For this 
reason such flow behaviour is called time dependent or thixotropic 
pseudoplasticity (Martin et a], 1964 and 1973). 
Thixotropy, therefore, may be defined as "an isothermal and 
comparatively slow recovery, on standing of a material, of a 
consistency lost through shearing" (Martin et a], 1973). This is 
due to the fact that if the suspension is viscous or the particles 
are large and heavy their Brownian motion is too slow to restore 
broken interparticular links or to regain the former state of 
entanglement of macromolecules "instantaneously". If the rate of link 
restoration by Brownian motion is. lower than the rate of link 
breakdown by shear the sy app 
decreases even while the system is under 
constant shear. 
The extreme behaviour is an isothermal, reversible so]l'W- gel 
transformation produced by shear and by rest, respectively. For 
example, higher concentrations of aluminium stearate, e. g. 4% w/v and 
5% w/v (fig. 1.5), and the oily vehicle (-type I vehicles d and f) 
(Fig. 1.6), form gels after preparation when unstirred, but flow and 
can be poured more easily after they had been stirred vigorously. 
After a period of about I hour they revert to gels as the Brownian 
motion rebuilds their gel structure, 
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It has been suggested that the area enclosed by the hysteresis 
loop in the rheogram of a thixotropic system can be used as a 
relative measure of the degree of thixotropic breakdown. In addition, 
thixotropy can be represented quantitatively by the decay of shear 
stress or apparent viscosity as a function of time at a constant rate 
of shear (Fischer, 1950; Martin et a], 1964 and 1973) or by a 
coefficient of thixotropic breakdown, i. e. the loss in shearing stress 
per unit increase in shear rate (Martin et al, 1973). Using the 
trapezoidal rule that is commonly used in bioavailability studies, the 
areas of the hysteresis loops of the oily vehicles (type I vehicles, 
d and f) and the oily dispersions of aluminium stearate systems were 
calculated by subtracting the smaller area under the curve from the 
larger one. These areas (thixo tropic indices) are shown in Table 1.3. 
Fig. 1-5 illustrates the thixotropic nature of oily dispersions 
of 1% w/v and 5% w1v aluminium stearate. The hysteresis loops obtained 
for other intermediate concentrations lie between these two curves 
but have been omit ted from the figure for the sake of clarity. However, ' 
their thixotropic indices are given in Table 1.3. Fig-1.5 and Table 
1.3 show that the degree of thixotropy increases with increase in the 
aluminium stearate concentration, The apparent viscosity at a given 
shear rate also increases in an approximately-linearmanner as 
indicated by Fig. 1-7. 
There is a disagreement in the literature concerning the time 
dependency of the flow behaviours of aluminium soap-hydrocarbon systems. 
Complete recovery was reported by Goldberg and Sandvick (j947), and 
Carver and Van Wazer (1947). However, Evans and Matthews (. 1954) and 
Shiba 0960) stated that the change caused by the applied shearing 
-stress is not thixotropic but appears to be a permanent change in the 
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Table 1.3 Thixotropic indices of the oily vehicles thqt formed 
hysteresis. loops 
Vehicle Type Concentration of Thixotropic index 
aluminium stearate N s-Im-2 1x 103_ 
















structure of the gel. Although no evidence of recovery was observed with 
a 9% w1w gel-- gradual recovery did occur with a 3% w1w and this 
lattersystem was therefore thixotropic (Stephens, 1971). The author 
suggested that recovery may, in fact, occur with the 9% w1vi gel, but at 
an extremely slow rate due to the viscosity of the system. 
However, the discrepancies between the results obtained by 
different workers can be ascribed mainly to differences in the 
experimental conditions (Shiba, 1960); for example, the rate of shear, 
temperature, concentration and the properties of aluminium stearates, 
which are not always pure substances. Although the above discrepancies 
have been reported, Shiba (1960) thought that the paraffin gels were 
thixotropic at high temperature or under low rates of shear. 
On the basis-of differences in experimental conditions and 
nature of the oily phase it is possible, thereforei to explain why 
aluminium stearate exhibited pseudoplastic flow behaviour in the FCO 
in this study, whereas plastic behaviour in liquid paraffin was 
reported previously (Shiba, 1960; Stephens, 1971). Furthermore, 
these differences are also likely to be responsible for the fact that 
0.5% w/v aluminium stearate produced a gel in FCO (curve 2 in Fig-1.1) 
and 1% w/ v produced a gel with thixotropic properties (Fig-1-5) 
whereas 1.5% w/w aldmihium stearate appeared to be required 
in liquid paraffin to produce the same sort of effects ($tephens,. 
1971). 
Dispersion of sucrose (20% w/v and 30% W/V) in FCO also exhibited 
non-Newtonian properties, but these were limited to pseudoplastic 
behaviour since no evidence of thixotropy was observed. 
In systems containing 20% w/v sucrose plus different concentrations 
-of Cab-o-sil the pseudoplastic viscosity increased with increasing 
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concentration of Cab-o-sil (curves 2(b) in Fig-1-3). Pseudoplasticity 
was also exhibited by 1.25% w/v Cab-o-sil plus 30% w/v sucrose as 
well as by 1% w/v Cab-o-sil in the oil alone (curves 2(c) and 2(d) in 
Fig. 1-3 respectively). The effe cts of Cab-o-sil have been reported by 
Lin and Pramoda (1978). The action of Cab-o-sil as a viscosity 
enhancing agent may be largely attributed to the ability'of the very 
small silica particles to form a network structure throughout the 
medium by interparticular hydrogen bonding via the silanol groups on 
the silica surface. In addition to these particle interactions, there 
is possible bonding between the silanol groups and other components 
that are also capable of hydrogen bond formation (Marshall and 
Rochester, 1975). No thixotropic properties were detected in the 
Cab-o-sil systems and it is suggested that the recovery and reformation 
of the structural units, upon removal or reduction of shear force, 
occurs immediately under the influence of Brownian motion. 
The effects of the other pharmaceutical additives that are 
included in type I vehicles on the rheological properties of the oil 
are shown in Fig. 1.2 (curves 1(b), (c), (d), (e) and (f)). A 0.7% w/v 
solution of fecithin in FCO was still Newtonian although the viscosity 
Was increased slightly as indicated in Table 1.2. 
The omission of 0.7% lecithin from type 1 vehicles d and f 
resulted in a decrease in the apparent viscosity as shown by Table 1.2 
and the loss of the thixotropy that is exhibited by vehicles of 
type 1 (f and d). Thus the thixotropic structure in these latter 
vehicles depends on the presence of lecithin, a'Ithough on its own in 
FCO. this compound appears to act as a simple Newtonian solution. The 
tendency for lecithin to form reasonably stable complexes with other 
substances, especially other lipids, proteins and carbohydrates, 
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provides a probable explanation for the formation of a thixotropic 
system (West et a], 1966). Thus the type 1 vehicles (d and f), that 
are described by the patent of Stephens and Su (1975), probably 
consist of dispersion of sucrose and hydrogenated castor oil particles 
that are coated with adsorbed aluminium stearate and lecithin 
molecules and the thixotropic structure results from interparticular 
bridges formed by the combined effects of lecithin and aluminium 
stearate when their concentrations are adequate. Alternatively, or 
additionally, the lecithin and stearate may, if their combined 
concentrations are sufficient, form a gel network through the system 
and the insoluble sucrose and hydrogenated castor oil particles are 
simply suspended in this network. 
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SECTION 3 
IN VIVO STUDIES 
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CHAPTER 1 
A COMPARATIVE BIOAVAILABILITY STUDY ON AN AQUEOUS SOLUTION AND AN 
OILY SUSPENSION OF SODIUM SALICYLATE IN THE RABBIT 
1.1 Introduction 
(a) Physico-chemical properties 
Sodium salicylate is the sodium salt of a weak acid (salicylic 
acid, SA) with a pK aof3. 
lt has the following chemical structure: 
Coo Na 
OH 
and exists as almost odourless, colourless, small crystals or shiny 
flakes, or as a white crystalline powder, with a salty-sweet taste. 
0 It is soluble at 20 C in I part of water and in 11 parts of alcohol 
(British Pharmaceutical Codex, 1973). 
Munzel (1971) pointed out that "the most effective means of 
attaining high dissolution rates is to use a highly water-soluble 
salt of a weak acid instead of the free acid itself. The dissolution 
rate of the sodium salt of a weak acid in an acidic dissolution 
medium under certain circumstances may be 1000 times higher than 
the dissolution rate of the weak acid itself, Even if the free acid 
precipitates subsequently from the sodium salt in the bulk phase of 
an acidic solution such as gastric fluid, it will do so usually in 
the'form of very fine particles. The large surface area of the drug 
thus precipitated favours rapid dissolution as additional fluid 
becomes available or as some of the dissolved drug is removed by 
absorption". 
(b) Action and uses 
Sodium salicylate has antipyretic and analgesic actions. When 
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given by mouth, it is absorbed readily and rapidly throughout the 
GI tract and rapidly excreted; frequent doses are therefore required 
to maintain a satisfactory concentration in the blood. The usual 
dose is 0.6 to 2g (British Pharmaceutical Codex, 1973). 
Sodium salicylate is a gastric irritant and sodium bicarbonate 
is often given with it to reduce this effect; however, the bicarbonate 
also increases the rate of excretion and thus lowers the concentration 
of salicylate in the blood to less effective levels. 
The pharmacology of salicylates and related compounds has been 
reý, iewed extensively by Smith (1960). Salicylates in general, exert 
their antipyretic, action in febrile patients by causing dilatation 
of the skin vessels and some perspiration and the increased loss of 
heat results in a fall in body temperature. The principal use of 
sodium salicylate is*in the treatment of acute rheumatic fever; a 
dosage of 1.3 g may be given by mouth every 2 hr., or 2g every 3 hr., 
until the temperature is reduced. For acute rheumatism, it is given 
in a daily dosage of 5 to 10 g in divided doses (British 
Pharmaceutical Codex, 1973). 
Salicylate must be used with care in patients with acute renal 
disease. The prothrombin time may be prolonged after repeated large 
doses. 
(c) Absorption, distribution and elimination of salicylate 
Although the small intestine is now regarded as. the major site of 
absorption of most drugs from the GI tract, because of the large area 
of the intestinal mucosa (, see Part 1.4.3a in Section 1), several 
reports suggested that absorption from the stomach may account for an 
appreciable fraction of the total dose absorbed in the case of 
ýalicylates, aspirin and SA (Levy, 1961; Levy et a], 1961; Truitt and 
Morgan, 1960 and 1964; Rowland et a], 1967; Saunders, 1974a; Nayak . 
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and Benet, 1974) 
The rate of absorption is limited by the low solubility of the acids 
at the gastric pH values (Saunders, 1974a). Earlier indication of the 
gastric absorption of SA was provided by Carnot et a] (1932), who 
reached the conclusion that"absorption of sodium salicyl. ate was 
positive when the stomach contents were acid and negative when the 
gastric contents were neutral or alkaline". The absorption in the acid 
stomach was so rapid that salicylate was detected in serum from the 
tbird minute after the salt solution was introduced into the dog 
stomach ligated at both ends. 
Rowland et al (1972) reported that the absorption of salicylate 
appears to follow first order kinetics. The general picture, however, 
is that the salicylate and related compounds penetrate the intestinal 
blood barrier by passive diffusion of the un-ionized molecule across 
a membrane having lipid characteristics. In absorption from the stomach 
the low pH of the contents means that an anionic drug is almost 
completely un-ionized whereas at the average plasma pH (7.4) most 
anionic drugs are highly dis. sociated. There is, therefore, a concentration 
gradient of un-ionized form which provides a gradient for diffusion 
(Saunders, 1974a). 
There appear to be three principal variables, among others, which 
can affect the results of comparative salicylate absorption studies 
from orallyadministered dosage forms; the physical dosage form, 
intragastric pH and gastric emptying time (Truitt and Morgan, 1964; 
Levy et a] , 1961). 
The initial rate of salicylate absorption is proportional to the 
dissolution rate of the drug in its particular dosage form. Dissolution 
is, in fact, the rate controlli. ng process in aspirin absorption (Levy 
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et al, 1961). Absorption is rapid when salicylate is administered 
in solution; maximum plasma aspirin levels are achieved within 15- 
25 minutes after oral dosing. The absorption rate from solution 
varies among individuals and appears to be influenced by physiological 
conditions in the GI tract (Rowland et al, 1967). The absorption rates 
were similar when aspirin was administered as a solution of sodium and 
choline. salts, but these rates were significantly higher than that 
obtained with aspirin tablets (Levy et al, 1961). This result was 
attributed to the fact that both sodium and choline salicylates being 
essentially fully ionised sal ts of the same weak acid, revert to 
un-lonised SA in acidic gastric fluid. It is'the un-ionised SA, rather 
than its salts, which is absorbed by the process of passive diffusion 
from the GI tract. These observations and suggestions are in 
agreement with the earlier conclusion of Carnot et al (1932), who used 
sodium salicylate. Levy (1961) studied the absorption rates of a 
number of commercial aspirin prep arations in vivo and found that the 
relative absorption rates were proportional to in vitro dissolution 
rates of aspirin from the preparations. Absorption of sodium salicylate 
and aspirin from solution is much more rapid than from solid tablets. 
However, antacids lower the rate of absorption from solution by 
reducing the amount of undissociated aspirin present but increase the 
rate of absorption from solid tablets, because their effect in 
increasing the rate of dissolution of solid aspirin outweighs the effect 
due to decrease of un-ionised aspirin (Truitt and Morgan, -1964).. 
Increase in the gastric emptying rate (GER) leads to 
enhancement in the absorption rate of salicylate as a result of rapid 
appearance of the drug to the major absorption site, i. e. the small 
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intestine (Lolli and Smith, 1946; Sleight, 1960; Moore et al, 1960) 
(see Part 1.4.3a, Section 1). However, Cook and Hunt (1970) pointed 
out the importance of GER on the absorption of aspirin. They 
found that, after 10 min., there was at least 10 times less absorbed 
when aspirin was administered in a buffered solution compared with an 
unbuffered one. It was suggested that the reason for thi§. was that 
the higher the pH the faster is the gastric emptying and hence the 
shorter the time for absorption. According to the pH partition theory 
(see Part 1.3.1, Section 1), for aci'dic drugs, like salicylates, the 
stomach is the optimal site of absorption. Thus, the longer the 
gastric residence time the higher will be the absorption. The 
bioavailability of salicylate and related compounds from different 
dosage forms has been extensively reviewed by Saunders (1974a) and 
Mayersohn et al (1977). 
Since the metabolite of aspirin, i. e. SA, is pharmacologically 
active, its distribution in the body is important and in bioavailability 
studies on dosage forms containing salicylate derivatives SA levels 
in the body must be taken into account (Mayersohn et al, 1977). Once 
the salicylate dertvative is converted to SA, it follows the metabolic 
pathway of the latter. The metabolic products of SA are indicated by 
Florey (1979) and major ones are salicyluric acid and salicyl 
glu curonide, which are formed by conjugation with glycine and glucuronic 
acid respectively. 
The elimination of salicylate occurs mainly by the parallel 
processes of renal excretion. of unchanged SA and metabolism. However, 
the major metabolic pathways are easily saturated in the usual dosage 
range that is used for the treatment of inflammation (Levy et al, 
-1972). Thus, metabolic conversion of salicylate becomes less 
efficient as the dose of sali. cylate increases. Therefore, since the 
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fraction of the dose of a salicylate, e. g. aspirin, that is excreted 
as unchanged salicylate increases with dose (Mayersohn et al, 1977), 
thqcontribution of metabolism to the overall elimination process is 
reduced for large doses. Consequently, elimination of salicylate 
appears to be a first-order process because the contribution of the 
zero-order process is too small to be noticeable, except. during the 
terminal phase of salicylate elimination (Levy, 1965). 
With the pH-partition theory in mind (see Part 1.3-1, Section 1) 
and the fact that good gastric absorption of salicylate occurs it is 
obvious that GER plays a vital role in salicylate absorption. Since 
the GER is known to be delayed by lipid (see Chapter 2, Section 1), 
it was decided to study the bioavailability of sodium salicylate 
administered in oily vehicle. Sodium salicylate was used as a model 
compound which possesses a low solubility in the oil but a high 
solubility in water. This chapter is limited to a consideration of a 
simple oily suspension of sodium salicylate in order to study the 
effect of the oil alone on the bioav6ilability of sodium salicylate. 
In the subsequent chapter the effects of pharmaceutical additives on 
the bioavailability of sodium salicylate administered in oily 
suspension are considered. 
1.2 Experimental 
(a) Materials 
Sodium salicylate and the reagents used in the determination of 
blood salicylate concentrations, i. e. Analar ferric nitrate and 
mercuric chloride, were obtained from B. D. H. Chemicals Ltd. and 




Sodium salicylate was sieved and the 100/120 portion (mesh size 
125-150 9m) was used to prepare the dosage forms as either 4% w/v 
solutions in distilled water or 4% w/v suspensions in Fractionated 
Coconut Oil. The suspension was homogenised for one minute using 
an Ultra-Turrax mixer at a fixed speed. Both dosage forms-were stored 
overnight. On the following morning the suspension was stirred 
Vigo I rously before the required dose volume was withdrawn. 
Adult male flew Zealand white rabbits, weighing 3.94-4.69 kg 
and fed with a standard diet,, were used in this study. Doses of 
120 mg/kg body weight (equivalent to a dose volume of 3 cW /kg body 
weight) of sodium salicylate were administered as either of the 
above hientioned dosage forms by mans of a catheter and syringe 
directly into the stomachs of rabbits that had been fasted for 20 hr. 
The catheter was flushed out with 1/3rd of the dose volume of the 
appropriate vehicle, i. e. water or oil, before removal from the rabbit. 
The dose was based on the work of Lessel and Cliffe (1964) and a 
2-way-cross-over design utilising-8 rabbits was used for the study. 
Fasting was continued during the first 9 hr of each experiment. Blood 
samples (0-7 cri? ) were taken from the marginal ear vein, using a 
1 cm 3 heparinised syringe, tmmediately before administration of the 
drug and at specified times during the 24 hr post-administration period. 
The samples were placed in heparinised tubes and stored in a 
refrigerator until the next day when they were assayed. The total 
blood sallcyla te content in each sample was determined by Trinder's 
method (Trinder, 1954), which was carried out as follows: 
0.7 cn-P of blood was placed in a cylindrical centrifuge tube and 
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3.5 cd of Trinder's colour reagent* were added. The tube was 
shaken during the addition and shaking was continued for a few 
seconds to ensure that the precipitated protein was finely dispersed. 
After centrifugation at 2000 g for 5 minutes the supernatant was 
withdrawn gently using a Pasteur pipette and its absorbance was 
determined at 540 nm in a Unicam SP 500 spectrophotometer against a 
blank solution con taining 0.7 crrP of water and 3.5 cO of Trinder's 
reagent. The concentration of salicylate in each sample was calculated 
from a calibration curve obtained by measuring the absorbances of a 
series of known concentrations of salicylate in rabbit blood, after 
treatment with Trinder's colour reagent. The Beer-Lambert law was 
obeyed over the concentration range used for the calibration curve. 
The concentrationsand absorbances of these solutions are given in 
Table 1.1. 
Table 1.1. Data for calibration cuývp of snditim salicy-late in rabbit 
blood at 540 nm 






*Trinder's colour reagent: 
40 g of A. R. mercuric chloride were dissolved in 850 cm' of distilled 
water with the aid of heat. The solution was cooled and 120 cm of HCl 
(I mole/dM3 ) and 40 g of ferric n1trate (Fe(NO )3,9H 0) A. R. were 
added. When all the ferri, c ni. trate had dlssolvýd the 
ýol'ume 
of the 
solution was made up to _1000 CM3 with 
distilled water. This solution 
is stable for long periods. 
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The regression coefficient (b) of this curve was calculated and the 
concentrations of salicylate in the blood samples were obtained 
using the following equations, 
Y-Y=b (X - X) Eq. 1.1 
or x= (y +bR Eq. 1.2 
b 
where X and-Y are the blood salicylate concentration and 
absorbance, respectively and R and ý are the mean values. Inserting 
the values for R, ý and b into Eq. 1.2 gives Eq. 1.3. 
y+0.0015 x-0.01805 Eq. 1.3 
All the studies were initiated at the same time of day in order 
to eliminate possible circadian variation. The design of this 
study based on a 2-way cross -over design utilising 8 rabbits, is 
described in Table 1.2( Wagner, 1975b). 
Table 1.2 2-way cross-over design 
Group Subjects per group., Time Periods 
number of rabbits I If 
1-4AB 
2 5-8 BA 
The formulation (dosage form) contained sodium salicylate 4% w/v 
Wsuspended in Fractionated Coconut Oil and(B)dissolved in distilled 
water. 
1.3 Results 
The mean concentrationsof salicylate in the blood samples that 
were obtained at various times after oral administration of sodium 
salicylate are given in Table 1.3 and plots oft. hese data are shown 
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in Fig. 1.1 for each formulation. The values of the three commonly 
used bioavailability parameters, i. e. area under the blood 
concentration versus time curve (AUC), peak blood concentration (PC) 
and the time at which this concentration is reached (PT), were 
obtained from plots of the blood concentration versus time curves 
for each rabbit and each formulation and are given in Table 1.4. The 
AUCs for the 0-24 hr. post-administration period obtained from 
individual experiments were calculated by the trapezoidal method 
(Notari, 1980'a). Thus, the (AUC 0) 
24 






) 0.5 + (C 0.5 + CI)0-5 + 
(CI +C 2) 
2 2- 2 
+ (C 2+C 3) + 
(C3 +C 4) + (C4 +C5+ (C 5+C 6) 
2222 
+ (C 6+C9 )3 + (C 9+C 2015 
22 
where C represents the concentration of drug in the blood at the 
time in hours denoted by its subscript. 
Table 1.3 Mean blood concentrations (mg/100 cm3) in rabbits following 
administration as a single dose (120 mg/kg body weight) of sodium 
salicylate in two formulations. Each value is the average of 8 
experiments. 
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The statistical analysis of the bioavailability parameters was 
carried out according to the method given by Wagner (1975). As an 













I Week II 
I Sum = 3.5 
0.5 
5 2 1 
6 2 Week 1 12 Week 1 
27 4 Sum - 12 1 Sum 
8 4 3 
T1 21 T2= 10.5 
Ave 2.6 Ave = 1.3 
Wl 9+7= 16 Gl 9+3.5 12.5 









Sum =N- 31.5 
Correction 
factor = (31-5) 
2 
T6- 
C. F. = 62.02 
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. 
Sum of Squares 
Group Subject AB 
1 
24 
Sum - 25 Sum = 3.25 
34 
4 16 0.25 
54 
264 Sum = 40 4 Sum = 15 
7 16 1 
8 16 9 
Sum = 65 + 18.25 = 83.25 = Total 
uncorrected sum of square. 
Sum of squares total, SS total 
83.25 62.02 a 21.23 
SS 
treatments = (2 1)2 + (10.5 )2 62.02 6.89 
8 
SS 
subjects i-- (2) 
2+ (3) 2 -+ (3) 
2+ (4-5) 2 +(3) 
2+ (4) 2+ (5) 2+ (7) 2_ 62.02 
2 
= 8.61 SS 
weeks = (16) 













residual = 21.23 - (6.89 + 8.61 + mi) 5.72 
SS 
groups - (12-5) 







groups 8.61 - 2.64 = 5.97 
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Table 1.5 ANOVA 
(a) 
of PT of sallcylate in blood following 
administration of two formulations of sodium salicylate 
Source of variation df 
(b) 
SS MS(C) F 
(d) 
Total 15 21.23 1.42 1.5 
Subjects: 7 8.61 1.23 
(e) 
1.30 
Groups 1 2.64 2.64 2.78 
Subj/Group 6 5.97 1.00 1.05 
Weeks 1 
. 
0.01 0.01 0.01 
Treatments 1 6.89 6.89 7.25 
Residual (Error) 6 5.72 0.95 
The critical value of F 1,6 at 5%-probability level is 5.99. Thus, 
there is a significant difference between the mean values of the 
peak time because the critical value is less than the F 1,6 of the 
treatment, i. e. 7.25, given in Table 1.5. 
(a) ANOVA = Analysis of variance, (b) d. f. degree of freedom, 
(c) mean of squares,. MS = 
ý-S 
I(d) 
F= MS of treatment, subject etc. d. f. MS error. 
(e)-The F ratio for subjects (rabbits) of 1.3, (v, =7'vM 6) where 
F,, 6 at 5% probability level is 4.21, is not significant 
hus 
iI cating homogeneity in the animals. However, in some instances in 
this thesis similar F values are significant, but because of the 
experimental design this in no way invalidates the conclusiens drawn 
about the significance of the treatments. 
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Similar statistical analyses were carried. out for the AUC 0 
24 
and PC values and the results are summarised in Table 1.6 together 
with those for PT. 
Table 1.6 Mean values of peak time (PT), peak concentrations (PC) and 
24 the area under the curve (AUC 0) after administration of sodium 





PC (mg/100 c&) 
AUC 
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Any two means not underscored by the same line are significantly 
different (P.,, '0.05). Any two means underscored by the same line 
are not significantly different. 
1.4 Discussion 
Examination of the curves in Fig. 1.1 and the mean PT values 
given in Table 1.4 suggests that a statistically significant delay 
occurred in the attainment of the peak blood concentration following 
administration of the oily suspension when compared with the aqueous 
solutioh. It should be pointed out that the precision with which the 
PT values can be derived from those plots relating to the oily 
suspensions is lower than that obtainable for the aqueous solutions, 
because the latter produced relatively sharp peaks in the blood 
concentration versus time . profiles whereas the oily suspensions gave 
rise to broader peaks. This reservation should be borne in mind 
ill 
if the above mentioned difference in PT values is interpreted as an 
indication that the rate of bioavailability of salicylate from the 
oily suspension is reduced in comparison to that from the aqueous 
solution. However, although the difference between the mean PC 
values shown in Table 1.4 is not statistically significant the trend 
towards a lower value for the oily suspension is in keeping with I 
such interpretation. Furthermore, it is to be expected that the rate 
of availability will be faster in the case of the aqueous solution 
since greater initial concentrations of salicylate are more likely to 
be produced in the aqueous GI fluids when this formulation is 
administered. It should be borne in mind that the low gastric pH 
may cause precipitation of salicylic acid. In the event of such 
precipitation the solid particles that are produced are considered 
to be sufficiently small to provide relatively rapid rates of 
subsequent. d issolution (Munzel, 1971). Enhancement of rate of 
absorption of acidic drugs by the administration of water soluble 
salts of the parent acids has been demonstrated for tolbutamide 
(Nelson et a], 1962), p-aminosalicylic acid (Wan et a], 1974) and 
aspirin (Levy, 1961; Leonards, 1962). 
When an oily suspension of sodium salicylate is administered 
then additional processes must be included in the bioavailability 
pathway. For example, the drug must either first dissolve in the oil 
and then partition into the aqueous fluids of the GI tract or 
ýransference of the undissolved drug particles f rom oil to aqueous 
phase followed by dissolution must occur. The situation will be 
further complicated by the ease with whtch SA, formed by hydrolysis 
of the sodium salt in the gastric acid, repartitions into the FCO. 
The following scheme illustrates these possibilities. 
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Scheme 1. Stages in the bioavailability pathway for sodium salicylate 
administered orally as, a suspension in an oily vehicle 
suspension of Na Sal. 
particles in oil dissolution 
TT 
phys i ca I 
separation (2) 
Na Sal. in 
solution in diffusion 
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The effect of conversion of the sodium salt. to salicylic acid 
in the acidic aqueous phase on the distribution of salicylate in such 
a system is indicated by the relatively high apparent partition 
coefficient (38.6) of sodium salicylate between FCO and 0.1 mole/dM3 
HCI at 370C. This coefficent is contrary to that expected on the 
basis of the solubilities of sodium salicylate in the oil-. (16.85 mg/ 
100 c M3 ) and in 0.1 mole/ OM3 HCI (306 mg/100 cO ) (see Chapter 2, 
Section 4). The pathway (2) in S cheme I is more likely than pathway (1). 
This is probably related to the ease of the physical separation of solid 
drug particles from the oil followed by the rapid dissolution process. 
This probability is supported by in vivo and in vitro studies on highly 
water soluble drugs administered as suspensions in a non-aqueous 
vehicles, e. g. fatty suppository bases and liquid paraffin, e. g. 
sodium salicylate in fatty suppository bases (Schoonen et al, 1976,1979, 
and 1980), phenobarbitone sodium and sodium chloride in fatty 
suppository bases (Rutten-Kingma et al, 1979a and c) and sodium chloride 
in liquid paraffin (Crommelin and de Blaey, 1980a). 
Absorption of drugs administered as solutions in lipids is 
considered to involve liberation of the drug from the vehicle into the 
aqueous luminal fluid, followed by passage through the GI wall. 
Armstrong et al (1979) determined in vitro rates of release and 
distribution coefficients of a range of benzoic and phenylacetic acids 
between either isopropyl myristate or octanol and water, and compared 
them with the bioavailabilities in rat. Absorption in vivo followed an 
inverse rank order to lipid solubility, but was related to the in. vitro 
solvent-water transfer-rate constant, rather than the distribution 
coefficient. The inference was, therefore, that availability depended 
on the amount (Kakemi et a], 1972a) or concentration (Grisafe and 
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Hayton, 1978). of the drug in solution in the GI fluids, which 
in turn was dependent on the rate of supply from the oily phase. 
In other words, in situations where this is slow in comparison with 
the rapid absorption from the aqueous phase, as in the case of salicylate, 
6a 
lipid and aqueous phases in vivo may notLin equilibrium, and the' 
transfer from the oi, l to water becomes the rate-determining process 
(Armstrong and James, 1980). Furthermore, Grisafe and Hayton (1978) 
have shown that the absorption rate of dissolved griseofulvin from 
the rat intestine decreases in the presence of triglyceride digestion 
products because the drug concentrates in the micellar and oil phases 
and negligible absorption occurs from these phases. Ogata and Fung 
(198o) reported that nitroglycerin absorption appeared slower from 
a sesame oil 6mulsion vehi., cle compared with aqueous solution. The 
authors suggested that, "because of-high partition coefficient between 
the oil and water at. 370C DO., the organic nitrate resides principally 
in the oily i'nternal phase of the emulsion vehicle, thus possibly 
delaying its release into i*ntestinal fluids". 
Therefore, tt is likely that the sal icylic. acid formed in the" acidic 
medium of the s-tomach., resi. 'des principally in the otly phase in the 
GI tract and the oi-l wi'll probably provide a reservoir for the uptake 
of the salicylic acid and so reduce the amount of drug initially 
available for absorption by controlling its release to the-GI fluids 
(, Bloedow and Hayton, 1976; Ogata and Fung, 1980; Armstrong and James, 
1980). Since the ini'tial absorption of salicylate occurs from the 
stomach, and since the rate of this absorption is proportional to the 
amount of salicylate. dissolved in the gastric Huids, the in vivo 
dissolution rate of sali., cylate in the stomach would be reflected by the 
-initial absorption rate (Levy, 1961). Indeed, this appears to be the 
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case in this study, since the results of salicylate absorption in the 
initial phase parallels the in vitro release of the drug at 37 0C 
using 0.1 mole/dm3 HCI as the dissolution medium (see Chapter 1, 
Section 4). Furthermore, similar correlations between in vivo and in 
vitro results were not obtained when using drugs with very small 
oil/0.1 molelde HCI partition coefficients, e. g. ampicillin trihydrate 
and nitrofurantoin (see Chapter 1, Section 4). These results suggest 
that the viscosity of the oil plays an insignificant role in delaying 
the rate of absorption but its role as a reservoir for lipid soluble 
drugs is important. Thus, the more lipophilic the drug the more 
reluctant it will be to migrate to the GI fluids (Armstrong and James, 
1980). 
The rate of absorption of salicylate will also be affected by the 
fact that oil delays the emptying rate of the stomach (see Chapter 2, 
Section 1), and consequently decreases the rate of appearance of the 
drug in the small intestine. This latter site is regarded normally as 
the optimum site of absorption for most drugs; even if the drugs are 
readily absorbed from the stomach such as aspirin and related drugs 
Levy, 1961) and even if the drug is ionised in the intestine and 
non-ionised in the stomach (. Benet, 1973). It has been recognised that' 
acceleration of gastric emptying can increase the rate of aspirin . 
absorption (Lolli and Smith, 1946 Sleight, 1960). Moore et a] (1960) 
found that faster stomach emptying increased the toxicity and shortened 
the onset of action of sodium salicylate. 
Although the rate of absorption is reduced by the administration 
of sodium salicylate as a suspension in oil the AUC values given in 
Table 1.4 show that the amount of salicylate absorbed is signifi'cantly 
greater than in the case of the aqueous solution. A variety of factors 
ýould be possible for'this enhancement, e. g. (i) delay in GER caused by 
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the oil; (ii) decrease in gastric secretion and hence increase in 
gastric pH; (iii) enhancement of the uptake of the drug by the 
stimulation of the lymph flow; (iv) formation of mixed micelles; 
(v) viscosity of the oil. 
0) Although salicylates are mainly absorbed under normal conditions 
from the small intestine appreciable gastric absorption-of aspirin and 
salicylate has been reported (Truitt and Morgan, 1960 and 1964; Nayak 
and Benet, 1974; Saunders, 1974a). It appears, therefore, that an 
increase in gastric residence time might lead to an increase in the 
contribution that such absorption makes to the overall extent of 
absorption. In addition, the slower release of drug from the stomach 
may, improve the efficiency of absorption from the intestine or allow 
a longer period for drug dissolution to occur before transfer into the 
intestine. It is suggested, therefore, that the increase in extent of 
absorption of salicylate, that is obtained when sodium salicylate is 
administered in an oily suspension rather than as an aqueous solution, 
may be ascribed to the reduction in stomach emptying rate that is 
caused by the presence of oil (see Chapter 2, Section 1). Various 
examples of the enhancement of absorption of weak acidic drugs that can 
be ascribed to delays in the GER have been given in Part 1.4.1a, 
Section 1. 
0i) Intragastric dissolution would also be enhanced by any increase 
In stomach pH that results from the reduct. ion in gastric secretion 
caused by the presence of oil in the duodenum (Johnson and Grossman, 
1969; Christiansen et a], 1976). Changes in gastric pH, brought about 
by the administration of antacids (Hurwitz, 1971) or by achlorhydria 
(Pottage et al, 1974), have been shown to have significant effects on 
, 
the absorption of weak acids and these . effects are ascribed to the 
relationship between the solubilities -of these compounds and pH. 
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Factors that affect dissolution rate may be of significance in 
the case of poorly soluble drugs administered as solids. However, 
they offer less likely explanations of the present results, where 
the lower extent of bioavallability is exhibited by an aqueous 
solution, unless the effects of precipitation of salicylic acid in 
the stomach from solution of sodium salicylate have a greater 
importance than realised hitherto. 
Oi) Bloedow and Hayton (1976) suggested that the absorption of 
lipophilic drugs might be enhanced by the coadministration of lipids 
due to absorption of these drugs via the lymph by incorporation in 
the chylomicrons. The existence of a special transport mechanism, by 
which drug and oil are transported together into the lymphatic system 
when injected into the stomach wall, has been reported (see Part 1.4.3c, 
Section 1). 
Fatty acids containing 14 or more carbon atoms are considered to 
be taken up in the lymph through chylomicron formation and those 
containing 8-12 carbon atoms enter the systemic circulation through 
the portal vein (Bloom et a], 1951). It has been suggested that 
lipophilic drugs follow one or both of these routes, depending on the 
nature of the drug (Bloedow, 1974) and the nature of the oil (Bloedow 
and Hayton, 1976). It is unlikely, therefore, that salicylic acid would 
be absorbed through the lymphatic route in this study since FCO 
possesses hydrocarbon chains with 8-10 carbon atoms and will 
consequently be absorbed mainly through the portal vein. Supporting 
evidence for this suggestion is provided by Palin et al (1980) who 
found that the absorption of very lipid soluble-DDT was enhanced when 
administered in fractionated coconut and arachis oils and suggested that 
this enhancement was due to the effect of the oils on the total gut 
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transit rate in spite of the fact that DDT is preferentially absorbed 
via the lymphatic route. Furthermore, De Marco and Levine(1969) 
reported that the stimulation of lymph following the coadministration 
of tripalmitin would have little effect on a well absorbed drug. 
Its effect would be significant with the agents that are only slightly 
absorbed at best. Therefore, the effects of enhanced lymph flow are 
unlikely to provide an explanation of the results obtained in this 
study. 
Ov) Enhancement of the absorption of a variety of non-acidic drugs, 
e. g. heparin and streptomycin, by administration in oily formulations 
has been reported recently. The formation of mixed micelles, composed 
of lipids and bile salts, and their effects on the permeability of the 
absorbing membrane have been suggested as a possible. mechanism 
(Muranishi et a], 1977 and 1979; Taniguchi et a], 1980; Muranushi et 
al, 1980a and b). This mechanism offers a less likely explanation of 
the present results since the delay in GER keeps the salicylate in the 
stomach_for a longer period of time and according to the pH-partition 
theory SA is well absorbed from this site. However, the effects of 
mixed micelle formation may become significant after the drug is 
transferred to the small intestine where the mixed micelles are formed. 
(v) Although the viscosity of the oil is higher than water 
0.7-5 vs 0.695, mN s M-2 respectively) (see Section 2), this appears to 
have a negligible influence on the extent of absorption because 
further increase in the viscosity by incorporation of 1% w/v and 
4% w/v aluminium stearate-(see next Chapter) had no significant effect 
on the extent of absorption of salicylate. It is suggested that the 
delaying effect of the oil on GER predominates and masks the effect of 
viscosity. 
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The conclusions made in the previous paragraphs concerning the 
effect of oil on the extent of absorption of salicylate are based on 
the assumption that the AUC values can be used as estimates of the 
relative amounts of drug absorbed from the two different formulations. 
This assumption is only correct if the shape of the blood level curve 
can be described in terms of linear pharmacokinetics. The above 
conclusions can therefore be criticised because, as pointed out in the 
introduction to this chapter, it is known that a capacity limited 
metabolic-pathway is involved in the elimination of salicylates from 
man (Levy, 1965; Levy et. al, 1972). However, many bioavailability studies 
on salicylate dosage forms have ignored the non-linearity of the 
kinetics (e. g. Truitt and Morgan, 1960 and 1964; Nayak and Benet, 
1974; Wan et a], 1974; Orozco-Alcala and Baum, 1979 and Barzegar- 
Jalali and Richards 1979b), including in vivo/in vitro correlation 
studies, such as those of Levy (1961), Levy et al (1961) and Nayak 
and Benet (1974), which are among the best known correlations of this 
type. Furthermore, although Mayersohn et al (1977) reported that 
AUC values could be used to provide valid assessments of the extent 
of salicylate absorption in man provided a dose of 500 mg was not 
exceeded, Nayak et al (. 1977). used single doses of 650 mg and obtained 
a reasonable fit of their experimental data to a linear one 
compartment model in spite of the fact that they were aware of a capacity 
limited metabolic pathway. 
One test of the non-linearity of pharmacokinetic data as Indicated 
by Wagner 0975a) involves the administration of a drug at two or 
more dose levels. Each concentration on the respective blood 
concentration versus time curves is then divided by the dose or 
normalised dose and these ratios aria replotted against time. If 
I 
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the curves are not superimposable or nearly so then one may expect 
some-type of non-linearity. In addition, the AUC 00 values for the 0 
initial blood level curves should show a similar ratio to the doses 
if linear pharmacokinetics are applicable. This approach was tried 
using the data presented in this chapter for the suspension of 
sodium salicylate in FCO that was administered at a dose of 120 mg/kg and 
datapresented in the next chapter for the same formulation (Formula A) 
but administered at a dose of 60 mg/kg. The normalised blood level 
curves for these two sets of data are approximately superimposable 
from t=0 to t-9 hr, which is the last sampling time used in 
the experiment described in the next chapter. In addition, estimated 
values of AUC 00 were obtained using Eq. 1.4, 0 
AUC 00 AUC t(last) +c t(last) Eq. 1.4 00 k 
t( I as 0 where. AUC is the'area under the blood level curve from zero 0 
time unt il the last sampling time (t(last)) as determined using the 
trapezoidal rule, C t(last) is the concentration of salicylate in 
the blood at the last sampling time as estimated from the linear 
portion of a semi-log plot of concentration versus time and 
k is the mean slope of the linear portions of the individual 
semi-log plots of the data presented in this chapter for the 
suspension of sodium salicylate in FCO. 
The values of AUC 00 obtained for the two dose levels were 582 0 
and 262'mg hr/100 cn-P respectively. Their ratio is 2.2, which is 
close to the ratio of the two doses, i. e., 2.0. 
The closeness of the normalised blood level curves and the 
agreement between the AUC 00 ratio and dose ratio suggest that the 0 
system can be described approximately by linear pharmacokinetics. 
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In view of all the above comments it seems reasonable to suggest 
that the possible criticism of the use of ALIC values as indicators 
of the relative extents of salicylate absorption from the different 
formulations is not very severe. 
In conclusion, it is suggested that the enhancement in the 
extent of salicylate absorption obtained in this study can be 
attributed largely to the effect of oils on total gut transit time. 
In addition, it is suggested that the reduction in the rate of 
absorption is due partly to the action of the oil as a reservoir 
that controls the release of salicylic acid and partly to the delay 
in the appearance of salicylate in the small intestine because of the 
decrease in the GER. 
If oily suspensions of sodium salicylate do provide a means of 
reducing the. rate of salicylate absorption whilst enhancing the 
extent of absorption then such formulations may be of value in the 
treatment of chronic rheumatism by allowing a reduction in either the 
dose or its frequency of administration. However, it should be pointed 
out that the volume of oil used in the present studies is relatively 
high when compared with the dose volumes that would be used normally 
in humans and Yamahira et a] 0978). have demonstrated that dose 
volume is an important factor in determining the effects of lipids on 
the bioavailability of an anti-inflammatory agent in rats. Thus, 
the results obtained In the present study. may have more significance 
in relation to the effects of fatty meals on drug bioavailability. 
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CHAPTER 2 
BIOAVAILABILITY STUDIES ON DIFFERENT OILY FORMULATIONS OF SODIUM 
SALICYLATE IN THE RABBIT 
2.1 Introduction 
In the previous chapter, the. bioavailability of sodium salicylate 
from an oily suspension was compared with that from an aqueous solution. 
However, rarely is a drug alone or in a simple vehicle used in therapy. 
It is usually administered in a pharmaceutical dosage form which contains, 
besides the active ingredient, the necessary pharmaceutical adjuvants or 
excipients, such as suspending agents, surface active agents(surfactants), 
colouring and sweetening agents etc. 
There is now considerable evidence that the bioavailability of a 
drug can be markedly affected by the physical state of the drug and the 
dosage form in which it is administered. Formulation factors may affect 
the onset, intensity and duration of patient response, and also the 
incidence and intensity of side effects, most frequently due to 
differences in the rate at which the active ingredient or ingredients 
become available for absorption. This availability for absorption may 
be a function of formulation variables (Hirst and Kaye, 1971), a 
dissolution rate limited absorption process (Yamamoto et a], 1974), the 
effect of oil (Carrigan and Bates, 1973; Bates and Sequeria, 1975; Bates 
et a], 1977; Chakrabarti and Belpaire, 1978; Ogata and Fung, 1980), 
effect of osmatic pressure (Kato et a], 1969; Marvola et a], 1979b), ' Ov- 
effect of viscosity (Levy and Jusko, 1965; Marvola et a], 1979a; 
Barzegar-Jalali and Richards, 1979b and 1980; Soci and Parrott, 1980). 
Hirst(1976) in his review "Formulation and bioavailability", 
summarised the effect of formulation as follows: 
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"Any reduction in the bioavailability of a drug is, in effect, 
a reduction in the dose of drug administered. Different formulations 
of the same drug cannot be assumed to be therapeutically equivalent 
simply because they contain the same amount of drug and comply with 
official standards. Any change, however small apparently, cannot be 
assumed to have no effect on the bioavailability of the drug. Many 
minor changes to drug formulations and methods of manufacture have in 
some instances had a disastrous effect on the bioavailability of the 
drugs included in the preparations". 
Non-aqueous vehicles for oral pharmaceutical suspensions of water 
degradable physiologically active agents are the subjects of patents 
(Stephens and Su, 1975; Lin and Pramoda, 1978) (. see Chapter 4, Section 
Although the Vatterpatent infers that the bioavai labi I ities of drugs 
suspended in the oily vehicle are equal to those of aqueous suspension, 
0 nly data relating to the bioavailability of amoxicillin are presented. 
No further studies were conducted to evaluate the effect of the different 
additives on the bioavailability of drugs. In addition, no mention of 
the effect of the oily vehicle on bioavailability was made in the patent 
of Stephens and Sa 0975). 
Therefore, it was the purpose of this study to investigate the 
effect of the different pharmaceutical additives used in the above 
mentioned patents, individually and in combination, on the bioavailability 
of sodium salicylate in the rabbi. t. 
2.2 Experimental 
a) Materials 
Details of the sources of the. materials and methods of preparation 




The same method was used as in Chapter 1 in this Section, except 
that a dose of 60 mg of sodium salicylate per kg body weight was used 
in this study in a dose size of 1.5 cO /kg body weight. An 8 by 8 
latin square pattern of experimental design was employed and finally 
no 24 hour blood samples were taken in this study. The experimental 
design is shown in Table 2.1 and the 8 formulations are represented 
by the letters A-H. Formulations B, D and E were prepared according to 
the meth. od described by Lin and Pramoda (1978) and the remainder 
according to the method described by Stephens and Su (1975) (see 
Section 2). 
All studies were initiated at the same time of day in order to 
eliminate the effect of circadian variation. 
2.3 Results 
The mean concentrations of salicylate in the blood samples that 
were taken from the 8 rabbits at various times after oral administration 
of the sodium salicylate suspensions are given in Table 2.2. Plots of 
the mean concentrations versus time are shown in Fig. 2.1. 
The mean values of (AUC)9 , 
PC and PT are given in Table 2.3, 0 
which also shows the apparent vi'scosity of each formulation at a shear 
rate of . 100 s- 
1. The AUCs were calculated by using the trapezoidal rule 
as described in the previous chapter. 
Since rabbit number 7 died In the last time period (J. e. time 
period 8), the missing values for the three bioavailability parameters 
(PT, PC and AUC9 ) were calculated according to the eouation 2.1 0 
(Davis, 1954). 
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6 7 8 
1 A B c D E F .G H 
2 B D H F c A E G 
3 c H E B G D A F 
4 D F B H A G c E 
5 E c G A H B F D 
6 F A D G B E H c 
7 G E A c F H D B 
8 H G F E D c B A 
The suspensions contained sodium salicylate 4% w/v in 
A. fractionated coconut oil (FCO). 
B. 20% w/v sucrose in FCO 
C. 1% w/v alum'inium stearate (50: 50 mixture of mono- and distearates) 
in FCO 
D. 20% w/v sucrose + 0.3% w/v Cab-o-sil in FCO 
E. 20% w/v sucrose + 1.0% wIv Cab-o-sil in FCO 
F. 0.5% w/v aluminium stearate + 0.7% w/v lecithin + 0.35% w/v 
hydrogenated castor oil + 20% w/v sucrose in FCO 
G. 0.5% wjv aluminium stearate + 0.35% w, /v hydrogenated castor oil 
+ 20% w/v sucrose in FCO 
H. ' 4.0% w/v aluminium stearate in FCO- 
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Table 2.2 Mean blood salicylate concentration (mg/100 cO ) at 
various times after administration of eachoily suspension of 
sodium salicylate. Each value is the average of 8 experiments. 
Time (h r) 2 
Formy In I 
\(a) 
A 7.9 9.8 11.7 11.3 11.5 10.7 10.1 . 8.6 
B 10.2 12.1 14. o A. 1 13.2 12.7 11.6 9.9 
c 7.6 9.9 11.4 12.4 11.9 11.7 11.5 10.3 
D 6.9 9.1 12.0 12.7 13.2 12.7 12.5 11.3 
E 5.2 7.3 9.5 10.9 11.1 11.0 10.6 9.5 
F 6.3 8.9 12.2 12.3 12.5 12.5 12.0 10.4 
G 5.7 7.9 10.0 11.5 11.3 11.4 11.6 10.5 
H 6.5 8.5 9.9 10.6 10.4 10.4 10.3 9.2 
Key: (a) The formulations are as specified in Table 2.1 
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Fig. 2.1 Mean blood concentration of salicylate versus time 
following oral administration of different formulations of 
sodium salicylate as a single dose of 60 mg/kg body weight 
in 8 rabbits. 
9-9 A, o=B, +=C, *----*= D, E 
G, and H. 








Table 2.3 Mean peak blood concentrations (PC), peak times (PT) 
and area under blood level versus time curve (AUC)9 following oral 0 
administration of different formulations of sodium salicylate as 
a single dose of 60 mg/kg body weight. 
n Fo rmu IABcDEFG 
(a) 
Parameter 
PT hr 2.8 2.8 3.3 4.6 4.3 4.0 5.5 4.5 
PC mg/100 cm, 12.8 14.7 12.8 13.9 12.0 13.8 12.7 11.4 
AUC9 mg hr/100 
.0 
cm 3 . 
89. 
-8 
106.0 97.0 102.8 86.1 99.0 91.9 85.4 
MN s m- 
2 
PP (b) 17.5 51 50 83 131 120 105 144 
Key: 
a. The formulations are as specified in Table 2.1 - 
b. 'q 
app' 
apparent viscosity, from Table 1.2, Section 2. 
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(m-1) (m-2) X=m (R+C+T) - 2. S Eq. 2.1 
where R- total of known values in row containing X 
total of known values in column containing X 
total of known values in treatment values 
containing X 
total of all available values 
m- number of treatments, columns or rows 
X- missing value 




and S =249 
(8-1) (. 8-2) X=8 (25+39+18) -2x 249 
42 X= 158 
X=3.8 hr -\, 4 hr 
using the same procedure the calculated values of the PC and AUC9 were 0 
15.7 m-qllOO CM3 and 1-17.9 mg hr/100 W, respectively. 
A nalysis of variance (ANOVA) of the results was carried out 
according to Schefler (1979). to determine the significance of the 
differences between the mean values of the three bioavailability 
parameters, PT, PC and 
. AUC9 The analysisof variance of the PT is 0 
given below as an example. 
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Table 2.4 Individual values of peak time (PT) of salicylate in the blood 
following oral administration of the 8 formulations according to the 
Latin square desigrv in Table 2.1. 
formulation 
rabbit No. 
A B c D E F G H 
Total 
Row 
1 1 2 3 4 3 4 4 6 27 
2 2 3 1 2 5 2 9 3 27 
3 4 3 3 4 4 6 3 6 33 
4 4 3 3 9 5 6 3 5 38 
5 2 1 6 6 6 2 9 3 35 
6 4 3 4 4 4 2 3 2 26 
7 2 4 3 4. 2 4 4 6 29 
8 3 3 3 4 5 6 9 5 38 
Total Column 22 22 26 37 34 32 44 36 253 
Correction factor (C. F. )'= 




Sum of squares total, SSTota 1= x2_C. F. 







2_ woo. 14i 
1225 -1000.141 = 224.859 
SS (27) 2- (27)2 (33 )2 (38)2 (35 )2 (26 )2 (29 )2 (38)2 
- 1000.141 Row ++ -F +++++ 
1022.125 - 1000.141 21.984 
Ss Column (22 )2 
(22) 2 (26 )2 (37)2 (34 )2 (32 )2 (44 )2 (36 )2 1000.141 
8+ -8 + -8 + -8 + -8 +8 +-8 +8 
1053.125 - -1000.141 = 52.984 
SS Error Ss Total SS Row + 
SS 
ColumnI 
224.859 (21.984 + 52.984) - 149.891 
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Table 2.5 AN OVA 
(a) 
of PT of salicylate in blood following administration 
of oily formulationsin 8 by 8 Latin square design. 






Rows (rabbits) 7 21.984 3.141 1.06 
Columns (treatments) 7 52.984 7.569 2.424 
Error 48 149.891 3.123 
Total 62 224.859 
The critical value of F 7,48 af 5% probability level is 2.21. 
Thus. there is a significant difference between the mean values of the 
peak times because the critical value is less than the F of the 7,48 
treatment, i. e. 2.424, given in Table 2.5. 
(a) The meanings of the symbols are given in Table 1.5 in the previous 
Chapter. 
In order to ascertain the statistical significance of the differences 
between individual mean peak times it was necessary to carry out further 
analysis of the results. 'Therefore Duncan's multiple range test (1955), 
was applied as follows: 
Standard error of a varietal mans, 
Sm MS error 
0.625 
n 
The sample size (2) ý0) (4) (5) (6) (7) (8) 
The significant studentized 2.86 3.01 - 3.10 3.17 3.22 3.27 3.3 
freedom obtained from 
Duncan's Table 
The shortest significant 
range, pxSm= Rp 1.788 1.881 1.938 F. 981 . 2.013 2. o44 2. o63 
Means of peak time in ABCFEHDG 
rank order: 
ranges, P, for a 5% level 





4   
2.8 2.8 3.3 4.0 4.3 4.5 . 4.6 5.5 
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The differences between the individual means are set out in the 
following order: the largest minus the smallest, the largest minus 
the second smallest, up to the largest minus the second largest; then 
the second largest minus the smallest, the second largest minus the 
second smallest, and so on, finishing with the second smallest minus 
the smallest. Each difference is significant if it exceeds the 
corresponding shortest significant range; otherwise it is not significant. 
For example, because G-A is the range of eight means, it must exceed 
R8=2.063, the shortest significant range of eight means, to be 
significant; because G-B is the range of seven means, it must exceed 
R7=2.044, the shortest significant of seven means, to be significant; 
and so on. An example is given below to illustrate the picture: 
G-A = 5.5- - 
G-B = 5.5 - 
G-C = 5.5 - 
G-f = 5.5 - 
G-E = 5.5 - 
G-H = 5.5 - 
G-D - 5.5 - 
The results 
2.8 = 2.7 > 2.063 
2,0. - 2.7 > 2.044 
3.3 = 2.2 > 2.013 
4.0 - 1.5 < 1.981 
4.3 = 1.2 < 1.938 
4.5 - 1.0 < 1.881 
4.6 = 0.9 < 1.788 
can be summarised 
therefore significant at 5% level 
therefore significant at 5% level 
therefore significant at 5% level 
therefore not significant at 5% level 
therefore not sign. ificant at 5% level 
therefore not significant at 5% level 
therefore not significant at 5% level 
3s: 
PT (h r) ABCFEHDG 
probabilitY< 0.05 
where any two means not underlined by the same line are significantly 
different, and any two means underlined by the same line are not 
significantly different. 
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Using the same methods of analysis for PC and AUC9 values, the 0 
following results were obtained: 
PC (mg/100 cm, ): HEGACFDB 
probability < 0.05 




The AUC values given in Table 2.3 reflect the relative amounts of 
salicylate absorbed within 9 hr. A comparison of the AUCs obtained with 
formulations A and B indicates that the presence of sucrose in the oily 
vehicle leads to a significant increase in the amount of salicylate 
absorbed, P< 0.05. It is suggested that this increase is caused by the 
osmotic effect of the sucrose after it is released from the oily phase 
and dissolves. in the aqueous fluids of the GI tract. This osmotic effect 
could involve two mechanisms, i. e. it could produce an extra delay in the 
GER (see Chapter 2, Section 1) or it could reduce the loss of water from 
the GI tract into the tissues (Parsons et a], 1958; Mayersohn and 
Gibaldi, 1971) thereby producing a greater volume of water into which 
salicylate can partition. 
With regard to the first mechanism osmotic pressure has been shown 
to have a significant effect on the bioavailability of aminopyrine and 
diP'yrone in the rabbit, phenobarbitone and strychnine in the rat (Kato 
et a), 1969) and sulphafurazole in the rat (Marvola et a], 1979b). 
Malone et a] (1960) attributed the delay in phenobarbitone absorption, 
when administered with sucrose solution, to the viscosity of the solution. 
However, Kato et al (1969) reported that 1% carboxymethylcellulose, which 
has, 6 viscosity simiJar to 50% sucrose but a much lower osmotic pressure, 
134 
has the same GER as water and 50% sucrose caused a delay in the GER. 
It was. concluded that this delay in GER was due to the osmotic effect 
of sucrose. 
For a highly lipophilic drug, e. g. salicylic acid, the drug 
availability is dependent on the concentration of drug in solution in 
the GI fluids, which, in the present system, is in turn dependent on 
the rate of supply from the oily phase. Grisafe and'Hayton (1978) have 
indicated that the direct absorption of griseofulvin from micellar and 
oil phases is negligible when compared with absorption from the aqueous 
phase of an emulsion formulation. Kakemi et a] (1972 a and b) also 
suggested that drugs, (e. g. salicylamide), dissolved in the oil phase 
of. an emulsion and oily solution are absorbed mainly via the aqueous 
phase and that the transference to this phase from the oil may be the 
rate limiting step. These workers considered a variety of drugs with 
different oil : water partition coefficients (i. e. <1,1 and >1) and 
concluded that the amount of drug in the aqueous phase, rather than its 
concentration, is a critical factor in determining the absorption of 
drugs from emulsions. Since this amount will depend-on the relative 
volumes of the oil and. water phases the absolute volume of the aqueous 
fluids is also a critical factor. The importance of the total volume 
of water was stressed by Kakemi et al 0972a). particularly in relation 
to drugs with oil : water partition coefficients of more than unity. 
Since the apparent partition coefficient of sodium salicylate between 
oil and 0.1 mole/dm3 HCl is -38.6 
(see Chapter 2, Section 4) it seems 
that the second possible effect of osmotic p'ressure, i. e. on the loss 
of water from the Gl'tract by membrane uptake, may be important with 
regard to the bioavailabi'lity of salicylate from oily systems-. Further 
evidence that the i'mportance of this second effect is related to the 
partition coefficient of the drug in question is provided by the results 
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obtained with ampicillin suspensions (see Chapter 4 in this Sect. ion). 
It is suggested, therefore, that the enhancement of salicylate 
absorption produced by the inclusion of sucrose in the oily suspensions 
of sodium salicylate is mainly due to the effects of osmotic pressure 
on. the uptake of water by the GI membranes and not to any additional 
delay in GER over that caused by the oil itself. 
The in vivo effect of sucrose on the absorption of salicylate from 
the oily suspensions is paralleled by its effect on the in vitro release 
of salicylate from the same formulations when using a dialysis method 
(see Chapter 1, Section 4). The presence of sucrose caused the influx of 
water into the oily product inside the dialysis sac after an initial lag 
period. The rate of release of salicylate from the dialysis sac was 
observed to increase after this lag period. 
A comparison of the AUC values for formulations A, C and H suggests 
that the inclusion of 1% aluminium stearate in the FCO increases the 
amount of salicylate absorbed but 4% aluminium stearate decreases the 
amount. However, these differences were not statistically significant. 
The AUCs for B and Hd iffer significantly thus indicating that sucrose 
enhapces salicylate absorption when compared with aluminium stearate. 
It should be noted that the apparent viscosities of both formulations 
are greater than that of the simple oily suspension A, but the apparent 
viscosity of H is the greatest. The effect of sucrose cannot, therefore, 
be ascribed to tlýe viscosity of the product unless there is an optimum 
viscosity beyond which the amount of salicylate decreases as the 
viscosity is further increased. 
A consideration of the AUC values for A, B, D and E suggests that the 
presence of 1% Cab-o-sil nullifies the effect of'the sucrose whereas 
0.3% Cab-o-sil allows the effect to be retained. Two plausible 
rnechanisms might be suggested to explain this effect of Cab-o-sil. The 
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first of these is based on the relatively high apparent viscosity of 
. 
formulation E which may retard partitioning of the drug between the 
oily and aqueous phases. The second mechanism arises from the fact 
that the very small particles of Cab-o-sil produce a large interfacial 
area and the capability of these particles to form hydrogen bonds', via 
the silano'l groups on their surface, with other compounds (Marshall and 
Rochester, 1975), e. g. methyl salicylate (Sherriff and Enever, 1979), 
may lead to a marked adsorption of the drug and so hinder its release 
and subsequent absorption. Incorporation of 5% colloidal silica 
(Aerosil) resulted in no release at all of sodium salicylate from fatty 
suppository bases (Schoonen et a], 1976). In fact, the second mechanism 
is suggested to be the most likely explanation, since the in vitro 
adsorption studies verified this phenomena (see Chapter 2, Section 4). 
Since there is a finite number of silanol groups in the gels, a point 
will be reached where they will be all involved in particle-particle 
or drug-particle interactions when the concentration of the colloidal 
silica is too small (Sherriff and Enever, 1979). This may explain why 
0.3% Cab-o-sil was not able to retard the bioavailability of sodium 
sa licylate in formulation (D). 
Final ly, it should be noted that the amount of drug absorbed from 
formulation F, wh1ch corresponds to the vehicle described in the patent 
assigned to Eli Lilly and Co-(Stephens and Su, 1975), is intermediate 
between formulations A and B and is not significantly different from 
either of them. 
The results of Duncan's test show that none of the PC values 
obtained with formulations containing additives (. i. e. B-H) were 
significantly different at p, *0.05 from the simple suspension in oil 
(i. e. formulation A). The significant differences that are observed 
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are similar to some of those obtained in the case of the AUC values. 
Thus: 
a comparison of B and E suggests that the increased amount of 
absorption caused by the presence of sucrose is nullified 
by the ificlusion of 1% Cab-o-sil. 
(ii) 20% sucrose with or without 0.3% Cab-o-sil (formulations 
B and D, respectively) leads to a significant increase in PC 
when compared with the effect of 4% aluminium stearate 
In addition, formulation F produced a higher PC than H. 
In several cases the formulations produced blood salicylate 
concentration v. time curves with broad peaks. It was consequently 
difficult to determine individual values for the peak time (PT). This 
was particularly so in those curves where the maximum concentrations 
were obtained at the six hou r and nine hour sampling times. In spite 
of these difficulties no significant differences at P> 0.05 were 
detected between any of the mean PT values for the different - 
formulations with the exception of formulation G, which contained all 
the ingredients of the Eli Lilly Patent except lecithin (see Table 2.1). 
However, if the PT and I 
app 
values in Table 2.3 are compared it would 
seem that the PT appears to increase from approximately three hours to 
four or more hours when the apparent viscosity exceeds approximately 
80 mN s m- 
2. The effect is only significant with formu'lation G as 
pointed out above. 
It is expected that an increase in viscosity would cause a decrease 
in the rate of release of sodium salicylate from the oily phase. Ashley 
and Levy (1973) showed, that the absorption of phenolsulphonphthalein 
was reduced during the first hour after administration when viscous 
sodium alginate solution was used as the vehicle and Buckwalter and 
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Dickison(1948 and 1958) reported that peanut oil or sesame oil 
gelled w ith aluminium stearate delays the absorption of included 
drugs when compared with either the oil alone or oil plus beeswax. 
A comparison of the AUC, PC and PT values of formulations F 
and G in which lecithin is respectively present or absent, shows 
that although the differences were not significant (at p >0.05), 
lecithin appears to increase the amount and rate of absorption of 
sodium salicylate. The apparent viscosity of the lecithin containing 
product is the higher. However, it may be suggested that the surface 
activity of lecithin promotes absorption either by affecting the 
permeability of the mucosal membrane or by aiding the emulsification 
of the oily vehicle in the aqueous GI fluids so that the increase in 
area of contact between oil and water allows more efficient transfer 
of drug to the aqueous phase. 
The most important. conclusion that can be drawn from this study 
is that the inclusion of 20% sucrose alone in the oily vehicle improves 
the absorption of sodium salicylate in the rabbit. However, this 
formulation does not provide very satisfactory physical stability of 
the suspension. Formulation F (Eli Lilly Patent) appears to offer a 
suitable compromise between absorption and stability characteristics. 
The present results also suggest more attention should be paid to the 
osmotic pressure of drug solutions or suspensions, since the osmotic 
pressure of hypertonic solutions, particularly, might modify the 
absorption of drugs from their dosage forms. 
It should be borne in mind that the commentsmade in this Chapter 
concerning the extent of abLsorptton of salicylate from the various 
oily formulations are based on AUC masurements that range only from 
0 to 9 hours. Bioavailability assessments should really be based on 
AUC 00 values and shorter time values are only useful if it can be shown 0 
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00 '00 that they are linearly related to AUC 0 values. 
Estimation of AUC 0s 
using Eq. 1.4 that is given in the previous chapter is not very 
satisfactory because the data presented in the present chapter do 
not allow the value of k el 
to be determined with a good degree of 
-accuracy. However, if the mean k el value 
(0.048 hr. that is 
determined from the results obtained for the oily suspen-qion of sodium 
salicylate in Chapter I of this Section is used instead then the 
derived AUC 00 show a reasonably linear correlation with the AUC9 values 00 





(a) Physico-chemical properties 
Nitrofurantoin is N-(5-ni. tro-2-furfurylidene)-l-amino 
hydantoin or 1- 
1 (5-nitrofurfurylidene )amino I hydantoin having 
the following chemical structure 
0 
02 N' 





Nitrofurantoin is described as lemon-yellow, odourless crystals 
or fine powder having a bitter taste. (t4artindale, 1977a.; Cadwallader 
and Hung Won Jun, 1976). The drug is a weak acid with a pKa value 
of 7.2 and a m. p. of 270-272 0C (The Merck Index, 1976), possessing 
low aqueous and oil solubility characteristics. Its solubility in 
water at various temperature and pH conditions has been reported 
together with its solubilities in different organic solvents by 
Cadwallader and Hung Won Jun (1970. For example, the solubility in 
peanut oil is (2.07 mg/100 cm') and at 370C the solubility in water 
is 17.41 Mg/. 100 CM3. This latter solubility is pH dependent; e. g. 
15.4 mg/100 CM3 and 37.4 mg/100 CM3 at pH 1.2 and 7.2, respectively 
(Bates et a], 1974a). 
Nitrofurantoin and its solutions are discoloured by alkali 
and by exposure to light, and are decomposed upon contact with 
metals other than stainless steel and aluminium. Since the drug 
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solutions are photosensitive, all analytical operations must be 
conducted under subdued light. In a ddition, well-closed, light- 
resistant containers should be used for the storage of nitro- 
furantoin and its preparations. A shelf-life of 5 years is claimed 
for tablets and suspensions when stored at room temperature in 
regular glass containers (Cadwallader and Hung Won Jun, 1976). 
As might be exp ected of a compound with limited water 
solubility, the dissolution of nitrofurantoin is particle size 
dependent (Stoll et al, 1973), and is also affected by the pH of 
the dissolution medium (Bates et a], -1974a). Its rate and extent 
of absorption have been shown to be influenced by the particle size 
(Paul et a], 1967; Conklin et a], 1969). The dissolution and 
absorption rates of a . 1: 5-molar ratio nt. trofurantoin-deoxycholic acid 
co-precipitate were found to be more rapid than those of the drug 
alone or of its physical mixture with deoxycholic acid (Stoll et a], 
1973). 
(b) Action and uses 
Nitrofurantoin is an antibacterial agent used extensively in 
the treatment of urinary tract infections (Saunders, 1974c; 
Cadwallader et a], 1978),. Having a broad spectrum of activity, it is 
effective against a]-] strains of E. coli, S. aureus and enterococci. 
Antimicrobial concentrations are not reached in the blood but the 
drug is concentrated in the uri. ne and bactericidal concentrations are 
achieved. Therefore, urine levels and recoveries, rather than blood 
levels, are important indicators of bioavailabtlity (Conklin, 1972; 
Cadwallader et a], . 1978Y. It is most active in acidic urine and 
if the pH exceeds 8 most of the antibacterial activity is lost. It 
is given orally in a dose of 50--150.. n-q 4 times a day (, Martindale, 
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1977a) - 
Nitrofurantoin occasionally causes nausea, vomiting, drowsiness 
and headache (Martindale, 1977a). The crystal size of the drug has 
been found to affect the degree of emesis and the rates of GI 
absorption and urinary excretion following oral administration 
(Paul et a], 1967). Nitrofurantoin should be used carefully in 
patients with marked renal failure. 
(c) Absorption, distribution and elimination 
Nitrofurantoin is readily absorbed after oral administration 
(Conklin et a], 1969). The small intestine is the primary and chief 
site of absorption and high plasma levels are provided within minutes 
(Buzard et a], 3961; Conklin, 1972). Some absorption also occurs in 
the colon but none can be demonstrated from the stomach (Buzard et al, 
1961). Absorption of nitrofurantoin from the small intestine is 
rapid and appears to follow the pH-partition thea ry with little 
indication of gastric absorption. Only limited drug absorptionoccurs 
when nitrofurantoin is administered rectally (Conklin, 1972). 
The bioavailability of nitrofurantoin has received a considerable 
attention in recent years. The general characteristics and 
experimental criteria for bioavailability testing of nitrofurantoin 
were discussed in the monograph presented by Cadwallader et al (1978). 
One of the criteria is-that urinary excretion data should be used for 
assessment of the bioavailabi. lity because of the relatively low 
nitrofurantoin blood levels that result from the very high and rapid 
excretion of the drug in the-urine. In addition, the urinary tract is 
the'actual site of the therapeutic activity. In fact, a linear 
relationship between the blood levels of nitrofurantoin and its rate 
of urinary excretion was demonstrated in man (McGilveray et a], 1973). 
Hence it is possible to determine the rate and extent of absorption 
of this drug by measuring the rate of appearance and cumulative 
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amount of unchanged drug in the urine expressed as a percentage of 
the dose administered. Results obtained from numerous studies, as 
indicated by Conklin (1972), show that similarities or differences 
between nitrofurantoin formulations are readily discernible using 
this approach. Several studies have indicated bioavailability 
problems associated with the use of commercial nitrofurantoin tablets 
(McGilveray et. al, 1971 and 1973; Meyer et a], 1974). In fact, some 
products, that met the official compendia] requirements, were less 
bioavqilable than the other products studied (Meyer et a], 1974). 
Particle size of the drug affects the absorption and excretion rates. 
For example, Paul et a] (1967) found that larger crystals of the 
drug caused less emesis in dogs and slower absorption and excretion 
in man and rats. Absorption of the drug from tablet formulations is 
increased considerably in n on-fasting as compared to fasting subjects. 
Nitrofurantoin is readily and immediately distributed into the 
extracellular and intracellular compartments and has a half-life in 
blood of about 20 min. (-Buzard et a], 1961; Conklin, 3972; 
Cadwallader and Hung Won Jun, -1976). The disappearance from the blood 
apparently follows first-order kinetics. Also there is little 
evidence for any prolonged binding of nitrofurantoin to either plasma 
proteins or tissues CConkli. n, -1972). The one compartment open model 
appears to be adequate for describing the kinetics involved in 
nitrofurantoin absorption and elimination (Conklin, 1972; McGilveray 
et a], -1971). 
Between 30-50% of an orally or intravenously administered dose 
of nitrofurantoin can be recovered i'ntact from the urine of man and 
animals (Cadwallader et al, 19.781. These values suggest that nitro- 
furantoin undergoes metabolic transformation in the body to a 
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signiftcant extent. The possible metabolic pathways of nitro- 
furantoin are not completely elucidated in the literature. However, 
it would follow somew6t similar pathways in metabolism to that 
for nitrofurazone. which undergoes reduction of the nitro group 
and hydrolysis of the azomethane linkage. It is degraded by all 
tissues of the body (except blood) into inactive metabolite, which 
may colour the urine brown (Cadwallader et a], 1978). Nitro- 
furantoin is excreted in the kidney by glomerular filtration and 
is both secreted and reabsorbed in the tubules. Nitrofurantoin 
clearance i'n the kidney is handled by a weak-acid transport system., 
which is influenced by pH. Urinary recovery of nitrofurantoin is 
linearly related to creatinine clearance, and little or no drug 
is excreted by patients with marked renal failure. Urinary excretion 
and biotransformation appear to be mainly and equally responsible for 
the elimination of nitrofurantoin (. Buzard et a], 1961; Conlin, 1972; 
Cadwallader et a], 1978Y. Nttrofurantoin is also excreted to a 
lesser extent in the bile (Conklin and Wagner, 3971). 
3.2 Experimntal 
(a) Materials 
Detai'ls of the sources of the materials and the methods of 
preparation of the vehi-cles are gi. -Yen in Section 2. Nitrofurantoin 
powder was obtained ý. rom S, i'qma CHemi: cal Co., England. 
(b) Methods 
Nitrofurantoi, 'n powder was steyed and the 240.130.0 portkon 
(53-63 ým) was used to prepare 0,1% w/v suspensions in the following 
8 vehicles using the same. methods and experimental destgn as those 
described for sodium salicylate in Chapters 1 and 2 in this Section, 
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respectively. The 8 formulations (vehicles) are presented by the 
letters A-H. 
A Fra ctionated Coconut Oil (FCO) 
B 20% w/v sucrose in FCO 
C 0.25% w/v xanthan gum in distilled water 
0.25% w/v xantha'q gum + 20% w/v sucrose in disti I led water 
E= 1% w/v Cab-o-sil in FCO 
F=0.5% w/v aluminium stearate (50: 50 mixture of mono and di- 
stearate + 0.7% w/v lecithin + 0.35% w/v hydrogenated castor oil 
20% w/v sucrose in FCO 
G= 20% w/v sucrose + 0.3% w/v Cab-o-sil in FCO 
H= 20% w/v sucrose + 1% w/v Cab-o-sil in FCO 
Xanthan gum was used in the aqueous vehicles (C and D) to prevent 
flocculation of nitrofurantoin. A low concentration (0.25%) was used 
in order to avoid a high viscosity relative to that of the oily 
suspension (A). These suspensions were placed in flasks, which were 
covered by aluminium. foil to provide protection from light and left 
overnight at room temperature. On the following morning they were 
shaken before removal of the required dose volume into a syringe. 
A dose of . 10 mg/k_g 
body weight (equivalent to a dose volume of 
1 CM3, /l OOg body weight). was administered to adult male Wistar rats 
(body weight range 380-569 g), via a catheter inserted into the 
stomach. The choice of this dose was based on the work of Conklin and 
Hollifield (1965). The catheter and syringe were flushed out with 
1/3 of the dose volume of oil or water, according to the formulation 
used, before removal-from the ani. mal. The rats were starved for 
20 hr wi'th free access to water before dosing and were kept in 
metabolic cages. At the end of this period the collecte-d urine was 
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used as zero time sample. During the first 10 hr after dosing, the 
animals had free access to water followed by a liquid diet 
containing 5% w/v glucose and 0.05% w/v sodium chloride for up to 
about 36 hr. This was the maximum period over which nitrofurantoin 
was detectable in the urine obtained from any of the rats. 
The design of this experiment was based on an 8x8.1atin 
square identical with that employed for the sodium salicylate sus- 
pensions in the previous chapter4 A mini um "wash-out" period of 7 days 
was allowed between successive experiments. 
Due to the difficulties of obtaining urine samples, it was 
decided to collect them over the following periods: 0-4,4-8,8-24, 
24-27,27-30,30-32,32-34,34-36'hrs after dosing. Samples were 
collected during the later periods only if the previous sample had 
been shown to contain any nitrofurantoin. All samples were assayed 
immediately after collection by the method of Conklin and Hollifield 
(1965) and all studies were initiated at the same time of day in 
order to eliminate the possible effect of circadian variation. 
The assay method of Conklin and Hollifield(1965) was as follows: 
To 1 CM3 Of urine and 4 cm3 of HCI (0.1 rmle/dm3 ) in a test tube 
10 CM3 of nitromethane (B. D. H. ). were added. The contents of the 
tube were mixed vigorously for 2 min. and centrifuged. 4 cm' of the 
nitromethane (bottom layer) were removed and transferred to another 
test tube. At this p9int some of the samples may be cloudy in 
appearance. If so, the tube containing the solvent was placed under 
warm tap water for-about 1-min. To the nitromethane extract 0.5 CM3 
of 0.04 mole/dM3 Hyamine in absolute methanol (Packard Instrument 
Co., Inc. ) was added and the contents were mix ed and allowed to stand 
for at least .1 min. The concentration of the nitrofurantoin-Hyamine 
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complex was. determined by direct spectrophotometry at 400 nm using 
nitro. methane, that had been run through the procedure with 1 crro of 
water and 4 CM3 of HCI, as a blank. The absorbance of e ach sample 
was determined within 30 min. after the addition of the Hyamine 
solution. 
The drug concentrations in the urine samples were determined 
using a calibration curve prepared by the addition of known amounts 
of nitrofurantoin to rat urine as follows: 
50 mg of nitrofurantoin were dissolved in 50 cn? of N, N-dimethyl- 
formamide (Sigma Chemical Co. ) and further dilution of the solution 
was made with water to obtain different concentrations. i cff? of each 
of these standard solutions. was mixed with 1 cn-P of rat urine and 
3 cm' of HCI (0-1 mole/dn? ) and the rest of the previous procedure 
was followed. Table 3.1 shows the concentrations and the corresponding 
absorbance values of the standard solutions. 
Table 3.1 
Concentration Absorbance A-Ao 
pg/cm, (A) 
0 0.025 
5 0.065 0.04 
10 0.098 0.073 
20 0.176 0.151 
30 0.25 0.225 
60 0.474 o. 449 
80 0.622 0.597 
100 0.769 0.744 
The regression coefficient (b) of a plot of (A-Ao) versus concentration 
was calculated and the concentrations of nitrofurantoin in the urine 
samples. were obtained using Eq. 3.1 as described in Chapter I of this 
Section. 
x. Y-0.0018 0.00747 Eq. 3.1 
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3.3 Results 
The volumes of the urine samples collected at various times in the 
post-administration period were measured (in cn-? ) and the concentrations 
of nitrofurantoin in 1 cm3 of each sample were determined. From the 
products of the volumes and concentrations the amounts of drug 
excreted in each time period were calculated. Successive addition 
of these amounts yielded the cumulative amount excreted. The amount 
of drug excreted during each time period together with the cumulative 
amount excreted were expressed as a percentage of the dose 
administered. The mean values of these percentages are shown in 
Table 3.2, which also shows the apparent viscosity of each formulation 
at a shear rate of 100 s- 
I 
and temperature of 370C. Analysis of 
variance and Duncan's multiple range test were carried out for the 
values obtained for the amount of the drug excreted during the first 
4 and 8 hr and the'cumulative amount excreted (expressed as percentage 
of the dose), according to the methods given for sodium salicylate in 
the previous chapter) and the results of these analyses are shown in 
Table 3.3. The mean values given in Table 3.3 are illustrated 
diagramatically by Fig. 3.1 - 3.3 - 
4.4 Discussion 
The results given In Fig. 3.1 - 3.3 and Tables 3.2 and 3.3 
inditate that nitrofuranto[n is excreted in the urine, and therefore 
absorbed, at both a faster rate and to a greater extent when 
administered as an aqueous rather than as an oily suspension. This 
statement is based on the concept that the only way that the drug 
can get Unto the urine is via the blood (Dittert and Di Santo, 19M. 
With regard to the rate of absorption, the results show that 
when nitrofurantoin was administered tn the two aqueous formulations 
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Table 3.3. Results of the analysis of variance and Duncan's multiple 
range test on the values obtained for the amount of the drug excreted 
during the first 4 hr and 8 hr and the cumulative amount of nitro- 
furantoin excreted (as % dose) after administration of nitrofurantoin' 
suspensions (0.1% w/v) in various formulations to rats in an 8x8 
latin square. 
I 
0.4 hr Formulation(a) HFAEGBCD 
Mean % dose 
excreted (b)(c) 5.1 5.4 7.8 7.8 8.9 9.1 21.7 22.8 
4-8 hr Formu I at ion (a) 




8.3 10.5 10.7 13.1 13.2 13.5 28.2 30.1 
FHABGEDC 
Cumulative Formulation(a) FAEHGBDC 
amount 
excreted 
Mean % dose 
excreted (b) 18.6 20.2 4.2 21.0 21.1 22.6 31.5 31.7 
(c) 
Key: (a) The formulations are as specified on page 146. 
(b) Any two means-not underscored by the same line are significantly 
different (p< 0.01). Any two means underscored by the same line 
are not significantly different. 
(c) As for (b) except that P<0-05- 
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Fig-3-1 Amount of nitrofurantoin excreted (as %. dose) during 
the first 4 hr after oral administration of various su's'pension 
formulati. ons. Each value is the averageý of results obtained in 
8 rats. 















Fig. 3.2 Amount of nitrofurantoin excreted (as % dose) during 
the first 8 hr after oral administration of various suspension 
formulations. Each value is the average of results obtained in 
8 rats. 













Fig-3-3 Total amount of nitrofurantoin excreted (as % dose) 
after oral administration of various suspension formulations. 
Each value is the average of results obtained in 8 rats. 
Key: the formulations are as specified on pagel46- 
x 
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C and D then 70% and 73%, respectively, of the total amount excreted 
appeared in the urine-within 4 hours. After 8 hr the respective 
values were 95% and 90%. In contrast, the ranges of values obtained 
using the oily formulations were 24-41% after 4 hr and 45-66% after 
8 hr. Statistical analysis indicated that these differences between 
the aqueous and oily formulations were highly significant (p <0.01). 
The most likely explanation for this difference is that the delay in 
the GER brought about by the oil (see Chapter 2, Section 1) 
consequently delays the appearance of the drug in the small intestine, 
which is regarded as the chief site for absorption of nitrofurantoin 
(Buzard et a], 1961; Conklin, 1972). These results are in agreement 
with those which-showed that delay in the GER, brought about by 
using a very high viscous aqueous suspension (Seager, 1968; Soci 
and Parrott, 1980) or by the presence of food with a commercial tablet 
(Bates et a], 1974b)-, decreased the rate of nitrofurantoin absorption. 
The above explanation is supported by Heading et al (1973), who found 
that delay in GER slows the absorption of paracetamol, a very weak 
acidic drug witha pKa value of 9-. 5, because of the slower appearance 
of the drug in the small tntestine. 
The variations in the extent of absorption of nitrofurantoin in 
the different formulations are reflected by the total amounts of- 
nitrofurantoi*n that are excreted N the urine (Conklin, 1972; 
Cadwallader et al, -1978).. These amounts, expressed as a percentage of 
the dose, are given N Table . 
3.2. Statistical analysis shows that the 
1.4 - 1.7 fold differences [n the amounts excreted after administration 
of the aqueous formulations, when compared with those excreted after 
administration of the oily products, are significant at p< 0.01. 
This finding is oppost-te to that observed when suspensions of 
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sodium salicylate were compared with aqueous solutions of that drug, 
since the extent of absorption of salicylate was greater from the 
oily formulations (see Chapter I in this Section). This difference 
can be explained on the basis of the pKa values of the two drugs, 
their sites of absorption from the GI tract and the effect of oil on 
the rate of gastric emptying. Thus, the ratio of unionized: ionized 
salicylic acid (pKa = 3), produced when sodium salicylate enters the 
acidic environment in the stomach, will be considerably greater than 
the ratio that will exist in the small intestine. The pH-partition 
theory therefore ind icates that the stomach is a favourable site for 
salicylate absorption (see part 1.3-1, Section 1). Although the areas 
of absorbing surface in the stomach and intestine have a considerable 
influence on the relative absorption of drugs from these two sites, in 
the case of drugs, such as salicylic acid, it is reasonable to suggest 
that absorption from the stomach provides a significant contribution 
to'the total absorption (see Chapter I in this Section). Consequently, 
an increase in the residence time of salicylate in the sto mach is likely 
to favour an increase in the total amount of drug absorbed from a 
parti'cular formulation. Oils are known to delay the rate at which the 
stomach empties (see Chapter 2, Section 1) and oily formulations may, 
therefore, be expected to enhance the extent of. salicylate absorption 
when compared with aqueous formulations. 
In the case of nitrofurantoin (pKa = 7.2) there is a little 
difference in the degrees of Ionization in the stomach and intestine; 
i. e. 99.99% and 94.06%, /respectively. Thus, bearing the area of the 
absorbing surfaces in mind, the small i. ntest[ne is the site for 
optimum absorption of ni'trofurantoin and little contribution to the 
total amount absorbed is provided by absorption from the stomach. In 
(unionized in the. stom. ach (P111) a, nd duodenum (PH6),, 
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fact, Buzard et al (1961) and Conklin (1972) reported that the 
small intestine is the chief absorption site of nitrofurantoin and 
its absorption could not be demonstrated from the stomach. For the 
same reason, Heading et a] (1973) found a significant decrease 
in the extent of paracetamol absorption when GER was delayed. 
Furthermore, nitrofurantoin is degraded by all the tissues of 
the body (except blood) into inactive metabolite (Cadwallader et a], 
1978). This aspect was studied extensively by Buzard et a] (1961), 
who reported that tissues, including the small intestine, are 
capable of destroying nitrofurantoin at a rate ranging from 1.6 to 
7.1 pg/g/min. at body temperature. Cramer (1947), Asnis et al (1952) 
and Beckett and Robinson (1956) reported that nitrofurantoin entering 
into the intestinal tract. would be subject to enzymatic destruction 
by intestinal. flora. In addition, gastric atrophy permits increased 
numbers of micro-organisms to pass into the small intestine. Similarly, 
reduction in intestinal motility results in overgrowth of these flora 
(see part 1.4.3d, Section 1). Bearing the above considerations in 
mind, it is suggested that the decrease in the bioavailability of 
nitrofurantoin is due to the decrease in the gut transit rate brought 
about by the oil. 
Bates et a] 0974b), found that food increased the extent of 
nitrofurantoin absorption from capsules containing macrocrystalline 
drug. Similar results were obtained by Rosenberg and Bates (1976). 
They ascrtbed this effect to the decreasein GER brought about by 
the viscosity or lipid content of the food, and suggested that such 
a decrease in GER would allow a greater fraction of the drug to 
dissolve in the gastric fluids because of an extension of the 
residence time in the stomach. However, Soci and Parrott 0980) 
reported that when nitrofurantoin was administered in a very viscous 
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aqueous suspension the rates of absorption and urinary excretion 
were slowed but the extent of absorption did not decrease. These 
results are in conflict with those of Seager (1968) and Barzegar- 
Mali and Richards (1980) with regard to the extent of absorption. 
Seager (1968) found that the amount of drug excreted by humans in 
6 hr was significantly reduced (p< 0.01) and the biological availability 
of the drug was impaired by inclusion of 5%. w/v methylcellulose in the 
suspension. Barzegar-Jalali and Richards (1980) observed that the 
amount of nitrofurantoin excreted in the urine, expressed as 
percentage of the dose administered to rat., decreased as the viscosity 
of the suspension medium increased and reported an approximately 2 
fold variation between the two extremes of the range of the amount 
excreted and ascribed this result to the delay in GER, which was caused 
bLy the different viscosity enhancing agents. 
The results obtained in this study appear to support those of 
Seager (1968) and Barzegar-Jalali and Richards (1980) and conflict 
with those of Bates et al (. 1974b), Rosenberg and Bates (1976) and 
Soci and Parrott (1980) with regard to the extent of absorption, 
although they do agree with the results of Bates et a] (1974b) and Soci 
and P arrott (1980) with regard to the rate of ab. sorption. However, Bates 
et a] (1974b) were unable to find any significant enhancement in t he 
extent of absorption from a commercial tablet containingmicro- 
crystalline drug an. d Rosenberg and Bates (. 19761 could not find any 
significant enhancement tn the case of commercial nitrofurantoin 
suspension and a microcrystalli. ne tablet (P >0.05). The only 
significant enhancement involved the macrocrystalline drug and those 
dosage forms that gave poor bi'oayailabili, ty in fasting subjects. For 
example, fasting subjects absorbed similar amounts of nitrofurantoi. n 
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from microcrystalline tablet and aqueous suspension, but absorbed 
significantly less drug from the macrocrystalline drug capsule. 
The authors (Rosenberg and Bates, 1976) suggested that the micro- 
crystalline tablet was well formulated. However, when nitrofurantoin 
was assessed in non-fasting subjects, these 3 commercial dosage forms 
were bioequivalent. It is suggested, therefore, that delay in GER 
would have an enhancement effect only with those formulations having 
poor bioavailability in fasting subjects, since it allows a longer 
time for dissolution of these dosage forms in the GI tract and 
consequently a better bioavailability. In the case of suspension and 
well formulated tablet, since dissolution of a significant fraction of 
the drug occurs fairly rapidly, further delay in GER would have no 
effect. This suggestion. is also supported by Soci and Parrott (1980), 
who could not find any significant difference in the extent of 
nitrofurantoln absorption when. GER was delayed using a very viscous 
aqueous suspens ton compared with a simple aqueous suspension as a 
reference (p> 0.05). 
Furthermore, Bates et a] 0974b), Rosenberg and Bates (1976) and 
Soci and Parrott (-1980) conducted their experiments in humans, while 
this study was conducted in the rat. It is possible, therefore, that 
a difference between the species could offset the similarities in 
the absorption (Barr, 1972). The rat differs from other species 
because it does not have a gall bladder (Green, J963; Williams et a), 
1965). It is possible that some absorption of nitrofurantoin could 
take place in the gall bladder itself (Williams et a], 1965), since 
nitrofurantoin is excreted to some extent in the bile (Conklin and 
Wagner, 19711, and this could be a possi. ble explanation of why the 
extent of absorption of ni. trofurantoin, when administered in a 
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suspension, did not decrease significantly when GER was delayed in 
humans. 
It must be pointed out that emýymatic degradation of nttro- 
furantoi'n should be taken into account when a delay in GER occurs 
for any reason, e. g. food, viscosity-enhancing agents or lipids. 
However, Bates et a] (. 1974b), Rosenberg and Bates (1976)'and Soci and 
Parrott (. 1980)- did not take this point into account in their 
assessment of the extent of bioavailability. 
In additton to the species dependent effect mentioned above it 
is possible that the enzymatic degradation of nitrofurantoin could 
also prov[de the. basi. s of a more detailed explanation of the different 
effects observed i. n this study and in previous ones (Seager, 1968; 
Bates-et al, 1974b; Rosenberg and Bates, 1976; Soci and Parrott, 1980; 
Barzegar-Jalali and Richards, 1980). This explanation would depend 
on the fact that a delay in GER would ýIlow a longer period for the 
dissolution of undissolved drug and would also provide, not only a 
longer period for a degradation to occur in, but also a greater 
amount of drug in solution and consequently available for degradation. 
These increased extents of dissolution and degradation would have 
opposing effects with respect to the bioavailability of nitrofurantoin. 
It therefore seems reasonable to suggest that an optimum bioavailability 
would be obtained if the degree of dissolution of the administered 
n[trofurantot. n was sufficient to ensure reasonable absorption when it 
reaches the small intestine. but it should not be excessive otherwise 
an increasing fractton of the dose wi'll be degraded before absorption 
can occur, If this suggestion ts. correct it means that there will be 
a critical rate of dtsaolution for optimum bioavailab-ility. Thus, if 
the actual dissolutton. rate is less than the critical value then a 
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reduction in GER would be expected to enhance the extent of 
nitrofurantoin absorption as Bates et a] (1974b) observed with 
capsules containing macrocrystalline drug, which exhibited an 80% 
increase in the extent of bioavailability when the GER was decreased. 
Furthermore, the closer the actual dissolution or release rate 
approaches the critical value the lower the effect of reduced GER 
would become because the effect of degradation would start to cancel 
the effect of enhanced dissolution rate. Thus, the bioavailability 
of a microcrystalline nitrofurantoin tablet was only increased by 
a statistically insignificant 30% when the GER was decreased by the 
administration of food (Bates et al, 1974b) and that of a micro- 
crystalline suspension was unchanged (Rosenberg and Bates, 1976). 
Extending the suggestion to the presenf results would indicate 
that the oily vehicle delays the GI transit time to such an extent 
that, although release of nitrofurantoin into solution in the aqueous 
gut fluids will have time to occur, the extent of enzymatic 
degradation will be appreciable and consequently the degree of 
absorption of intact drug will be decreased when compared with that 
obtai'ned using an aqueous vehicle. 
There was no significant difference between any of the oily 
formulations, neither during the first 4 and 8 hr nor between the 
total amount excreted, except that the amount excreted during the 
first 8 hr post-administration of formulation (, F), which corresponds 
to the vehicle described by the patent of Stephens and Su (1975), 
was lower than the amounts obtained using the other oily formulations 
(p <0.05) (Table 3 .3 and Fig-3.21. A consideration of the viscosity 
of the formulati'on (Fj (Table 3.2) indicates t hat it has the second 
highest viscosity of all the formulations. However, these remaining 
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formulations show no significant differences in comparison to 
formulation (A), the simple oily suspension, although their 
viscosities. are higher than (A) and include formulation (H), which 
has a higher viscosity than F. In addition, no significant difference 
was observed between the extent of absorption from any of the oily 
formulations including F (P> 0.05) (Table 3-3). These results suggest 
that the viscosity has no additional effect on the extent of 
absorption of nitrofurantoin from the oily vehicles used in this study 
and the effect of the oil on GER is predominant. 
The inclusion of sucrose in the oil (B) had no significant effect 
on the rate and extent of nitrofurantoin absorption (P> 0.05) (Table 
3-3) thus suggesting that the delaying effect of osmotic pressure 
on GER (see Chapter 2, Section 1) had no significant effect in this 
study. This is supported by comparison of the results obtained with 
the two aqueous formulations (C and D). The lack of effect of sucrose 
on nitrofurantoin absorption differs from the situation that was 
observed with salicylate in the previous chapter where osmotic pressure 
appeared to causea significant effect on bioavailability. This latter 
effect was explained on the basis of the high oil/0.1 mole/d& HCI 
partition coefficient of salicylate. In the case of nitrofurantoin this 
partition coefficient i's only 0.48 (see Chapter 2, *Section 4). 
A comparison of formulations A, 8, E, G and H (Tables 3.2 and 
3.3) suggests that neither 0.3% nor 1.0% Cab-o-sil has any significant 
effect (p >0.05) on the bioavallability of nitrofurantoin in the oily 
vehicle: The higher concentration, i. e. 1% w/y, nullified the 
increasing effect of sucrose on the bioavailability of sodium salicylate, 
when given in the formulation which corresponds to formulat ion (H) in 
this study, and the difference was significant (P< 0.05). It was 
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suggested (previous chapter) that this effect was possibly due to 
adsorption of salicylate onto the'large surface-. area. of the Cab-b-sil 
by hydrogen bonding. In vitro studies have confirmed this possibility 
(see Chapter 2, Section 4). However, the absorption of nitro- 
furantoin is not altered by the inclusion of the Cab-o-sil. Neither 
the viscosity (as mentioned above) nor adsorption would-seem to have 
an effect in this study. In fact, in vitro adsorption studies did not 
detect any appreciable adsorption of nitrofurantoin onto Cab-o-sil 
(see Chapter 2, Section 4). 
In summary, the rate and extent of absorption of nitrofurantoin 
was decreased significantly by the use of an oily rather than an 
aqueous vehicle. In. addition, enhanced osmotic pressure and increased 
viscosity did not produce any significant effects on the absorption. 
It is therefore s uggested that the decreased bioavailability is 
caused by the delaying effect of the oil on the GER and this effect 
predominates in all the oily formulations used in this study. 
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CHAPTER 
AMP IC ILL IN 
4A Introduction 
(a) Physico-chemical properties 
Arnpicillin is D-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo- 
4-thia-l-azabicyclo(3. *2.0)heptane-2-carboxylic acid. It is also known 
as (6-(2-amino-2-phenylacetamido)penicillanic acid) and has the following 
chemical structure. 
NH2 HS CH 113 
C- C- N-C CH3 
HoH C=O 81 6H 
It is a free-flowing, white crystalline powder with an odour 
characteristic of penicillin and a bitter taste Ovashkiv, 1973; 
Harvey, 1975; Martindale, 1977b) - 
Ampicillin has 2 pKa values, 2.6 and 7.24 (Ivashkiv, 1973). It 
has an isoelectric point at pH 4.95 and the water solubility-pH profile 
shows a U-shaped curve with the minimum solubility at this pH. (Hou and 
Poole, 1969; Tsuji et a], 1978). Ampicillin is almost insoluble in , 
organic solvents, e. g. alcohol, ether and fixed oils-(Marsh and Weiss, 
1967; Martindale, 1977b). It gave an ethylacetate-water partition 
ratio of 0.044, which is not affected by pH (Hou and Poole, 1969). 
They concluded that ampicillin is more hydrophilic than lipophillc 
and behaves like an ion[c amino actd molecule. 
Ampicillin is an acid stable antibiotic (Saunders, 1974b). Hou 
and Poole (1969) pointed out that ampicillin,. by the presence of its 
side chain amino group, is at least 200 times more acid-stable than 
penicillin G. Gastric destruction is probably not significant in 
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terms of ampicillin stability (Jusko et a), 1978). 
Ampicillin exists in anhydrous and trihydrate forms (Austin et a], 
1965). The solubilities of these forms of ampicillin in 26 different 
solvents at room temperature (21 0 C) have been reported by Marsh and 
Weiss (1967), who quoted values of > 2% w/v for the solubilities in 
HCl (0.1 mole/drO) and 1.0% and 0.756% for the solubilities of the 
anhydrous and trihydrate forms, respectively, in water. Poole et al 
(1968) obtained 1.0% and 0.8% for these latter two values at 37 0 C. 
The significance of the state of hydration of ampicillin will be 
discussed further in part (c) of this introduction. 
(b) Action and uses 
Ampicillin has a w. ide range of antibacterial effects comparable 
with benzylpenicillin. Given orally in doses of 50-100 mg/kg/day, 
ampicillin is freely absorbed and maintains a bactericidal level in 
the plasma for 4 hours or more. It is rapidly excreted, in very high 
concentration, in the urine (Stewart et a], 1961). 
The wide range of the antibacterial effects of ampicillin has 
been reported due to the presence of the NH2 group which increases 
activity against Gram-negative bacilli. It is effective against Staph. 
aureus at concentrations of 0.05 llg/cm', it is acid stable and can, 
therefore, be used orally. However, it is sensitive to penicillinase 
and so is ineffective against organisms, which have developed 
resistance to penicillins by increased production of this enzyme 
(Saunders, 1974b) 
Ampicillin is used in the treatment of infections of the 
respiratory tract and is especially effective where Haemophilus 
influenzae is the causative organism. It is also employed in the 
treatment of infections of the urinary tract due to Escherichia coli 
and Proteus mirabilis. Because ampicillin is excreted in high 
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concentrations in the bile, it has been used in the treatment of 
infections of biliary and intestinal tracts caused by E. coli, 
salmonellae and shigella (Harvey, 1975; Martindale, 1977b). 
The usual oral dose is I to 6g daily in divided doses every six 
hours (Martindale, 1977b).. 
Ampicillin causes the allergic reactions typical of other 
pencillins. The drug may cause nausea and vomiting, diarrhoea and 
stomatitis (Harvey, 1975; Martindale, 1977b). 
(c) Absorption, distribution and elimination 
Ampicillin is relatively stable in the acid gastric secretion and 
is well absorbed from the GI tract after oral administration (Acred et 
a], 1962; Martindale, 1977b; Jusko et a], 1978). The absorption usually 
occurs within two hours after oral administration of ampicillin capsules 
and suspensions. Peak plasma concentration has been reported to be at 
about I to 2 hours after oral administration of the drug (Acred et a], 
1962; Bear et al, 1970; Hultberg and Backelin, 1972). However, large 
variations (20-70 percent of the dose) occur in the actual amount 
absorbed, primarily because of the intrinsic differences in GI absorption 
of ampicillin among subjects (Jusko et a], 1978). 
Ampicillin is eliminated from the body very rapidly with a half- 
li fe of about 1.1 to 1.3 hours in adult patients with normal renal 
function (Dittert et al, 1969; Jusko and Lewis, 1973). Patients with 
reduced renal function showed higher peak concentrations and later 
peak times than those with normal functions (Kirby and Kind, 1967; 
Hultberg and Backelin, 19721. Ampicillin is little metabolised and 
is excreted almost unchanged in high concentrations in bile and urine 
(Harrison and Stewart, 1961; Stewart and Harrison, 1961; Acred et a], 
1962; Ayliffe and Davies, 1965; Martindale, 1977b; Lund et al, 1976; 
Sjoqvist et al, 1980). 
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The bioavallabi'lity. of ampicillin is relatively easy to assess. 
The rapid absorption and elimination of the drug limit the duration 
of blood and urine collection to about 8 hours in normal adults. 
The relati've bioavailability of ampicillin can be assessed using the 
area under the plasma concentration versus time curve after oral 
administration of the drug to normal subjects (Jusko et a], 1978). 
One of the physicochemical properties that has been thought to 
affect the bioavailability of ampicillin is its state of hydration 
Poole et a], 1968).. These latter workers carried out in vivo 
bioavailability studies on commercially available capsule and 
suspension dosage forms containing either the anhydrous or trihydrate 
forms. In spite of the closeness of the aqueous solubilities of the 
two forms they suggested that the enhanced bioavailability of the 
products containing the anhydrous-material could be ascribed to 
differences in. the dissolution rates of the two forms. This suggestion 
was supported by their i'n vitro dissolution rate measurements in water, 
which were later confirmed by Poole and Bahal (1968). However, Hill et 
a] (1972-and -1975). could not detect any differences in the in. vitro 
dissolution rates i'n HCI' (0-053. mole/dm') of the two forms when packed 
loosely in gelatin capsules. They also showed that the solubility of 
-ampicillin was appreciably greater in dilute acid than in water and. 
that the anhydrous forn and the trihydrate were equally soluble in 
the dilute actd. They suggested that the dissolution rate of ampicillin 
in HCl is -more relevant to its bi., oavailability from oral products than 
t he dissolution rate i'n-water. They also suggested that the bioayailability 
differences, that were reported preyiously by Poole et a] 0968), were 
related to formulation factors and not to the hydration state of 
ampicillin. This suggestion was confirmed by the in vivo studies of 
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Hill et a] (1975). Other studies have also revealed that commercial 
capsules containing either fo rm of ampicillin yielded essentially 
identical bioavailabilities (Mayersohn and Endrenyi, 1973; Loo et al, 
1974). In 1973 the FDA suggested the deletion of the term hydrate 
from the official names of ampicillin dosage forms. 
Various reports describing the effect of food on the absorption 
of ampicillin have been published. While absorption is delayed by the 
presence of food in the stomach, this does not affect the total 
amount'of ampicillin absorbed (Foltz et a], 1970). The oral absorption 
of ampicillin has been reported to be good even when taken with food 
(Bear et a], 1970). However, Ali and Farouk (1980) reported that 
Sudanese food causes- a significant reduction in bioavailability of 
ampicillin and suggested that the composition of food is critical in 
this respect. 
The degree of binding of the antibiotic to serum macromolecules 
-governs its antibiotic activity; only the unbound drug is effective. 
In addition, the degree of binding also governs the drug distribution 
in the body (Saunders, 1974b). This aspect has been the subject of a 
number of reports (Acred et al, 1962; Rolinson and Sutherland, 1965; 
Kunin, 1965). Ampicillin shows a lower degree of binding than other 
penicillins and this binding is greater in human serum than in that of 
other species studied (Acred et a], 1962; Rolinson and Sutherland, 
1965). For example, Acred et a] (1962) found that the degrees of 
ampicillin binding in horse, human and bovine sera were 7.9%, 17% and 
17.5%, respectively, whereas the corresponding values for phenoxy- 
methyl penicillin were 39.37%, 51-37% and 68.7%. 
The biopharmaceuticql aspects of ampicillin in different dosage 
forms have been extensively reviewed by Ivashkiv (1973), Saunders 




Ampicillin was obtained from Beecham Pharmaceuticals. Antibiotic 
medium No. 1 CM 327, adjusted to pH 7.9, and nutrient broth CM1 were 
obtained from Oxoid Ltd. Bacillus subtilis (No. 8236) was obtained 
from the N. C. T. C. Details of the sources of other materials and 




The same method was carried out as in the Chapter I of this Section 
except that a6 by 6 latin square pattern of experimental design was 
employed and the sampling times of the blood were 0,1,1,1.5,2,3, 
4,6 and 8 hrs after drug administration. The experimental design is 
shown in Table 4.1 and the 6 formulations are represented by the letters 
A-F. 
The specified amount of the drug was added to the particular 
vehicle, which had been-prepared and left overnighi at room temperature, 
just before dosing the rabbit. Doses of 50 mg1kg body weight were given 
to rabbits weighing 2.15-3.8 kg in a dose-size of 2.5 cm3/kg body weight. 
After collection the blood samples were centrifuged for 5 min and 
the plasma was stored in a refrigerator until required for the 
microbiological assay of ampicillin. This assay was commenced on the 
same day as the bioavailabillty test, Immedlately after the last blood 
-sample had been obtained. 
(ii) Microbiological assay 
A cup-plate assay method was used. this method was very similar 
to that described by Bennett et al (1966) and the medium, bacterial 
suspension and other conditions were as described by Arret et al (1971). 
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Table 4.1. Experimental design 
Rabbit No. Time Period 
3 4 5 6 
1 A B c D E F 
2 B c F .A D E 
3 C F B E A D 
4 D A E B F c 
5 E D A F c B 
6 F E D c B A 
The suspensions used contained ampicillin trihydrate 2% w/v in: 
A Fractionated Coconut Oil (FCO) 
B 30% w/v sucrose in FCO 
C distilled water 
D 30% w/v sucrose in distilled water 
E 30% w/v sucrose + 1.25% w/v Cab-o-sil in FCO 
F 0.5% w/v aluminium stearate (50: 50 mixture of mono- and 
distearate) + 0.7% W/V lecithin + 0.35% hydrogenated castor oil 
+ 30% W/V sucrose in FCO. 
170 
A few drops of nutrient broth were added to the freeze-dried 
sample of B. subtilis and this mixture was used to inoculate a slope 
of the solid antibiotic medium. After incubation at 37 0C for 24 hr 
the slope was washed with sterile distilled water and the washings 
were used to inoculate a larger slope. This was incubated at 370C for 
7 days. The sporing organisms were then washed off and the resulting 
suspension was standardised by adjusting its density to 1/5 of 
Brown's tube No. 1, so that the number of organisms was in the range 




. The suspension was then heated to 80 
0c 
for 10 min in order to kill vegetative organisms. The spore containing 
suspension was finally stored at 40C*until required for the assay. 
Bennett et a] (1966) reporte d that the suspension is stable for 4 weeks 
when stored under such conditions. Three suspensions were prepared 
during the course of this study. 
When an assay was to be performed molten antibiotic agar medium, 
whilst at approximately 50 0 C, was seeded with the standardised B. subtilis 
suspension (2.5 CM3 of suspension in 250 CM3 of agar). The seeded agar 
was allowed to set at room temperature for about I hr. 36 holes of 10 mm 
diameter and 10 mm depth were then made in each plate. 20 of these holes 
were to be filled with 4 replicates of 5 different standard solutions of 
ampici 11 in in plasma and the remaining 16 holes were to be filled with 
the test samples and their replicates. (Single specimens were used for 
the 0 and 8 hr time samples and duplicate specimens were used for each 
of the seven Intermediate time samples). 
Although ampicillin is known to have a low affinity for protein 
binding (Acred et a], J962) the standard solutions Were prepared with 
pooled rabbits' plasma in order to eliminate possible variations in 
antibacterial-activi, ty due to this effect (Bennettet a], 1966). A 
constant volume (0-3 CM3) . of pooled plasma was added to 
0.2 cmI amounts 
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of different concentrations of ampicillin solution in phosphate 
buffer (0.1 mole/dn-? and pH 7.9 + 0-1) to produce 0.5 cn? quantities 
of 5 standard solutions, which contained 0.5,1,2,4 and 8 gCj/CM3' 
respect i ve I y.. 
db 
The standard solutions were made on each day of the study after 
the first or second hourly blood sample had been obtaine'd during the 
bioavailability test. The standard solutions were then stored along 
with the unknown plasma samples in a refrigerator so that they were 
subjected to the same conditions. 
The plasma samples and standard solutions were coded and a constant 
volume of each (50 A was put into the appropriate hole in an agar 
plate. Even though the level of each plate was adjusted by means of a 
spirit-level the distribution of test and standard samples was arranged 
to compensate for any variation in agarthickness, as well as for the 
time factor involved in adding the samples to the plate. The plates 
were then allowed. to stand undisturbed for 2 hr at room temperature to 
allow diffusion of the antibiotic to occur. At the end of this period 
they we re trans'ferred to an incubator and maintained at 37 0C for 16 hrs. 
The diameter of the zones of inhibition around each cup were 
measured, with the aid of calipers, after the incubation period. The 
regression coefficient. (b) of a plot of the mean diameters, given by 
the 4 replicates of each of the 5 standard solutions, versus the 
logarithm of the ampicillin concentration in those solutions was 
calculated for each plate. The unknown concentrations of ampicillin in 
the plasma samples used on that plate were then determined. by means of 
Eq. 4.19 
X (Y - ý) + bR 
b Eq. 4.1 
where X =log concentration, Yx zone diameter and R and ý are the 
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mean values of these parameters. 
4.3 Results 
All zero time plasma samplesyielded, without any exception, no 
detectable activity against the test organism. This is in agreement 
with the findings of Macleod et al (1974). The mean concentrations of 
ampicillin in the plasma samples that were taken from the 6 rabbits at 
various times after oral administration of ampicillin trihydrate 
suspensions are given in Table 4.2. Plots of the mean concentrations 
versus time are shown in F ig. 4.1. 
8 
The values of the 3 bioavailability parameters, i. e. AUCO, 
PC. and PT, are given in Table 4.3. The AUC 
8 
was calculated by using 0 
the trapezoidal rule. 
The statistical analyses of Ahe bioavailability parameters were 
carried out using the methods given. in Chapter 2 of this Section. The 
results of these analyses, which are summarised in Table 4.4, show that 
there are no significant differences between the AUC 
8 
values or the 0 
PT values (P> 0.05) and that only the PC for formulation D differs 
significantly from those of B, F and E (P <0.05). 
Rabbit No. 5 died before carrying out the last experiment for 
formulation B in the time period 6. Therefore the missing values for 
the three bioavailability parameters (PC, PT and AUC 
8) 
were calculated 0 
according to equation 2.1 described in Chapter 2 of this Section. 
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Table 4.2 Mean plasma concentrations of ampicillin (Ag/CM3) following 
oral administration of 50 mg/kg body weight of ampicillin trihydrate, 
as a single dose in different formulations, to 6 rabbits. 
Time(hr) 1 1.5 26 
formuln (aa\)\\ 
A 2.63 2.59 2.42 2,45 3.65 3.57 2.32 1.31 
B 3.35 2.94 2.79 2.99 3.14 2.83 1.49 0.55 
c 4.52 4.77 4.01 3.02 1.60 0.74 0.21 - 
D 4.40 5.86 6.05 4.90 3.27 1.72 0.54 - 
E 2.50 3.26 2.39 2.00 2.10 1.98 0.98 0.73 
F 2.50 3.20 2.53 2.57 2.37 2.48 1.40 0.66 
Key (a) the formulations are as specified in Table 4.1 
Table 4.3 Mean peak plasma concentrations (PC), peak ti ' mes 
(PT) and 
area under the curve (AUC 
8) 
of ampicillin following oral administration 0 
of 50 mg/kg body weight of ampicillin trihydrate, as a single dose in 
different formulations, to 6 rabbits. 
Fo rmu InABcDEF 
(a) 
Paramete r\ 
PC (Ag/cie), 4.9 3.8 5.2 6.4 3.5 3.7 





(gg. hrIc32 ) 20.1 17.4 12.0 18.6 13.2 15.3 
'qapp (b) 17.5 64 0.695 2.32 150 140 
Key: (a) The formulations are as specified in T able 4.1 
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Table 4.4 Results of the analysis of variance and Duncan's multiple 
range test on the values obtained for PT (hr), PC (pg/cm) and 
AUC 8 (pg. hr/cm') of ampicillin after administration of 50 mg/kg 0 
body weight as a single dose of ampicillin trihydrate to rabbits in a 
6x6 latin square. 
PT Formulation(a) c D B F E A 
(h r) Mean (b) 1.00 1.20 1.3 1.80 1.90 2.10 
PC Formulation(a) E F B -A c D 
(gg/crn3 ) Mean (b)- 3.50 3.7 3.8 4.9 5.2 6.4 
AUC 
8 
Formu I at ion (a) cEFBDA 0 
(pg. hr/cm') Mean (b) 12.0 13.2 15.3 17.4 18.6 20.1 
Key: (al The formulations are as specified in Table 4.1. 
(b) Any two means not underlined by the same line are significantly 
different (P< 0.05). Any two means underlined by the same line 
are not signifi. cantly different (P> 0.05).. 
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4.4 Discussion 
The results obtained in this study, although not significantly 
different, P> 0.05, showed that the AUC 
8 
of ampicillin administered 0 
as a simple aqueous suspension (C) was 60%, 64%, 68%, 78% and 90% of 
A, D, B, F and E respectively. In other words, if it is considered 
that the simple oily suspension (A) is 100% bioavailable, then the 
bioavailability of (C) is 60% of (A). Inclusion of 30% w/v sucrose 
in the aqueous suspension (D) enhanced the extent of absorption to a 
degree which is close to that of formulation A. 
A variety of factors could be responsible for the slight 
enhancements in the extent of absorption of ampicillin, as mentioned 
in Chapter 1 in this Section. The most likely explanation is, in fact, 
decrease in the GER brought about by oil or osmotic pressure (see 
Chapter 2, Section 1), because the inclusion of 30% sucrose in the 
aqueous suspension (formulation D) enhanced the extent of absorption 
of ampicillin, as reflected by the AUC 
8, from 12 to 18.6 gg. hr/cn?, 0. 
which is close to the AUC 
8 
of 20.1 pg. hr/CM3 for formulation A(Table 4-3). 0 
Since ampicillin is an amphoteric compound with an isoelectric 
point of 4.95, it follows that its solubility will be greater in the 
gastric fluid than in the mildly acidic intestinal fluid, which has 
a pH closer to the isoelectric point. Thus, a longer gastric residence 
time of ampici II in would improve dissolution and enhance bioavai labi I ity. 
In addition, Kirby and Kind (J967) indicated that appreciable abýorption of 
ampicilli'n occurred from the stomach and Swahn (1976) reported that the 
absorption of radiolabelled ampicillin from the stomach is up to 30% 
of the total amount absorbed. Therefore, if GER is decreased the degree 
of absorption from the stomach might be increased so enhancing the overall 
extent of absorption of ampicillin. 
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If the extent of. absorption of ampicillin is increased by a 
reduction in the GER then one would expect this extent to be reduced 
by an increase in GER as found by Ali and Farouk (1980) who studied 
the effect of Sudanese diet on the bioavailability of ampicillin. They 
indicated that the reduced extent of absorption and PC could be 
attributed to increases in the GER and the total GI motil ity caused by 
the Sudanese diet, which is rich in bran and fibrous substances that 
are known to accelerate gastric emptying and might also increase the 
GI moti lity. They commented"the nett result of this effect will be a 
short drug residence time and consequently less absorption of the 
administered drug. Moreover, this effect will vary accord ing to the 
time of the meals when the drug is administered. Consequently, one 
would expect maximum absorption of the drug if sufficient time is given 
for the drug absorption before such food is taken". They suggested that 
when gastric emptying is delayed, ampicillin will stay in the GI tract 
longer, and hence mre complete absorption will occur. The results 
obtained in the present study are in good agreement with these 
findings and suggestion. 
I. f the enhancement in the extent of ampicillin absorption from 
formulations A and D compared to that from C can be explained solely on 
the basis of the decrease in GER, brought about by oil or by sucrose, 
it leads to the conclusion that the effects of oil on gastric secretion, 
formation of bile salt-mixed micelles, stimulation of the lymph flow 
and the effect of viscosity of the formulation, (Table 4-3), (see 
Chapter I in this Section). are unlikely explanations of the results 
obtained in this study. I. t is suggested, therefore, that delay in the 
GER is the most li. kely e-xplanati. on of the enhancement obtained in the 
extentof ampicillin absorption when the drug is administered in oily 
formulations and formulations possessing high osmotic pressure. 
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The oily formulation E, whose vehicle consists of 1.25% w/v 
Cab-o-si. 1 plus 30% w/v sucrose dispersed in FCO, and formulation F, 
which corresponds to that described by Stephens and Su (1975), allowed 
a greater extent of ampicillin absorption than the simple aqueous 
suspension (formulation C) but provided a lower extent than A, D or B. 
This latter rank or der relationship, i. e. extent of absorption from 
As D and B >extent of absorption from F and E, is paralleled by the 
results obtained in the in vitro dissolution rate studies that are 
described later in this thesis (Chapter 1, Section 4). It is possible, 
therefore, that the in vivo results can be explained to some extent 
on the basis of differences in the rates. of release of drug from 
various formulations. 
In the case of the oily formulation E, it may be suggested that 
the possible adsorption of ampicillin on to the Cab-o-sil may interfere 
with the release of the-drug and so reduce the bioavailability. However, 
this suggestion is unlikely because Poole et a] (1968) detected no 
change in the bioavailability ofampicillin when 0.99% Cab-o-sil was 
included in their aqueous suspension. 
It should be poi. nted out that, unlike salicylate, the inclusion of 
30% W, /v sucrose in the oil, i. e. formulation B, did not enhance the 
extent of ampi-cillin absorption b. ut it did enhance the absorption from 
the aqueous formulation D. It is suggested, therefore, that sucrose 
e- nhances the absorption of ampi. cl-Ilin from the aqueous vehicle by 
virtue of l'ts delaying effect on the GER and has no addIttonal effect on 
the GER over that caused by the oil itself. This suggestion is supported 
by-the fact that AUC-values. of formulations A, B and D are close to each 
other (see Table 4.31. Furthermore, the lack of any enhancement effect 
by sucrose on the extent of ampici. ll*kn absorption in the oily vehicle 
may also be related to the fact that the partition coefficient of 
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ampicill, in between oil and '0.1 mole/dn-P HCI is less than unity, i. e. 
0.052, (see Chapter 2, Section 4) and therefore the role of the 
osmotic effect of sucrose in minimising the uptake of water by the 
GI membrane, and hence maintaining a large volume of available water 
in the GI tract, is not as important as in the case of drugs with oil: 
HCI partition coefficients of more than unity, i. e. salicylate. This 
finding, therefore, is further evidence for the suggestion made to 
explain the enhancing effect of sucrose on salicylate absorption when 
administered in. the oil (see Chapter 2 in this Section). 
Tabl-e 4.4 shows that no significan 
/t 
difference was detected in 
the PT values for all the formulations, p >0.05. This suggests that 
ampicillin is absorbed essentially at the same rate from the oily and 
aqueous formulations. Ampicillin is more hydrophilic than salicylate 
(see Chapter 2, Section 4), and hence one does not expect the oil to 
be a reservoir for this drug. However, the trend toward a slower 
absorption from the oily formulations is likely because of the delay in 
the GER by the oil, which is siqcre-p. ronounced/by the osmotic pressure 
exerted by aqueous formulation D. 
Comparison of the PCs of the aqueous suspensions (C and D) with 
those of the oily ones, Table 4.4 and Fig. 4.1, suggests that higher 
concentrations are provided by the former systems. However, only the 
aqueous one containi'n_g sucrose (, D)- gave a significantly different PC 
value from those obtained with the oily B, E and F formulations 
(P< 0-05)and the PC proyided by formulation A, the simple oily 
suspension, did not differ signi. f[cantly from either of the aqueous 
formulations C and D (p >0-0-51- 
It-should be pointed out that when compartson between the plasma 
concentration versus ti. 'm curves of amplOllin given by the oily and 
aqueous systems i. smade, Fi. g. 4.1 and Table 4.2, it is quite clear 
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that all the oily formulations still maintain a measurable plasma 
concentration at 8 hr post-administration whilst the aqueous ones 
gave zero concentration at that time. In fact, some individual rabbits 
gave zero plasma concentration as early as the 4-6 hr samples. The 
prolonged plasma concentrations of ampicillin, thatare obtained when 
oily vehicles are used, may arise because oil stimulates the evacuation 
of bile from the gall bladder (see parts 1.4.2 b and d in Section 1) and 
it is well known that ampicillin is rapidly excreted in the bile in an 
active form (Stewart and Harrison, 1961; Harrison and Stewart, 1961; 
Acred et al, 1962; Ayliffe and Davies, 1965; Lund et a], 1976) with a 
low susceptibility to the inactivating mechanism within the liver 
(Tuano et a], 1966; Kirby and Kind, 1967). Enhancement of biliary 
recycling by the oil would therefore lead to reabsorption of ampicillin 
and a prolongation of blood levels (see part 1.4.1 c, Section 1). In. 
fact, Ritschel (. 1980a)stated that "drugs entering the bile must be 
considered as drugs administered perorally. Upon emptying of the 
bile into the duodenum, the drugs may be re-absorbed by one of the 
absorption mechanisms into the portal circulation and returned to the 
liver from whence they are re-excreted into bile". Therefore, 
enterohepatic recycling is the most likely explanation of the occurrence 
of the multiphasic blood level curves, with two peaks, that were given 
by the oily formulations (. see part 1.4.1 c, Section 1),. In some cases 
the second peak was reDarded as the peak plasma concentration, as in 
formulation A, since it i. s higher than the first one. An alternative 
explanation of this periodicity is that it could be attributed to the. 
sequential absorption of the drug, first from the stomach and then 
from the small intestine after gastric emptying had occurred. However, 
this latter explanation seems to be unlikely since the aqueous 
formulation D, which should also delay GER, because of its sucrose 
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content, did not show this phenomena, -(i. e. a multiphasic blood level 
curve). Thus, enterohepatic recycling seems to be the most likely 
explanation of this effect. 
The first peak occurred during the first hr and the second one after 
3 hr with all the oily-formulations and in all the rabbits without any 
exception. None of the. aqueous formulations showed this. phenomenon. 
Stewart and Harrison (1961) and Harrison and Stewart (1961) reported 
the rapid and immediate excretion of ampiCillin in the bile. The liver 
I was found to be capable of clearing up 'to 7% of a large dose from the 
blood in I hr producing a concentration in the bile, which may be-40 
times higher than the peak plasma concentration, e. g. 20-160 Pg1ce in 
the bile I hr after dosing. This concentration increased sharply during 
the next 2 hr, and peak values of 160 to 440 pg/cn? were obtained between 
2.5 - 7.5 hr. Re-absorption produced plasma increments of about I Ag/CIO , 
occasionally more. The first. phase of absorption of the orally 
administered drug into the plasma occurred between 1 and 3 hr; the 
second phase, i. e. reabsorption, added small increments to the plasma 
concentration during this time and up to 6 hr. These results of Stewart 
and Harrison agree with those obtained in this study. Ayliffe and 
Davies (1965) also reported that, in patients with normal biliary 
tracts, levels of up to 48-times those in normal serum were obtained 
in gall bladder bile withi. n 4 hrs. These findings provide an explanation 
of the results of Acred et a] (1962), who showed that the concentration 
of ampicillin fell off more rapi dly In the serum than In liver and 
ki'dney, because the presence of bile and urine would favour concentration 
of ampicillin in these two organs. 
Williams et al (19651 have provided an excellent di'scussion of 
the factors affecting the enterohepatic circulation of drugs and the 
consequences of the recycling process and the therapeutic value of 
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such circulation in the treatment of biliary and intestinal tract 
infections has been pointed out (Harvey, 1975; Martindale, 1977b; 
Sjoqvist et al , 1980). 
From the above points and references it*can be concluded that 
prolonged plasma concentrations may be attributed to enterohepatic 
recycling. This conclusion-is supported by Kirby and Kind (1967) 
and by a comparison of the results obtained with formulations A and D. 
Finally, differences in the renal clearance will obviously 
influence the blood levels of ampicillin and the duration of these 
levels. The variation introduced by this effect is minimised by the use 
of cross-over tests. Reduced renal clearance was found to produce 
higher and later peak plasma levels than normal renal function (Kirby 
and Kind, 1967; Hultberg and Backelin, 1972). Therefore, in those 
instances where the normal renal function has not yet been developed, 
as in the newborn (-see part 1.4.3 d, Section 1), the higher and longer 
duration of ampicillin blood levels would be expected to be dangerous 
and even lethal. Evidence supporting this effect has been found in this 
study, because in preliminary work with rabbits weighing less than 
2 kg, a dose of 50 mg/kg body weight was found to be a lethal dose. 
The rabbits died after a period of 2-5 days after dosing. However, a 
dose of 100 Mg/kg body weight was not lethal in rabbits weighing more 
than 2.5 kg. Subsequent studies. were carried out with rabbits 
weighing more than 2 k9 and a dose of 50 mg/kg body weight was used. 
It is recommended that this point should be borne in mind when 
designing bioavailabillity tests for ampicillin preparations. 
In conclusion, delay in the GER, caused by the effect of oil or 
the osmotic effect of sucrose, produced a slight enhancement in the 
extent of ampicillin absorption. This enhancement was not statistically 
significant (P> 0.05) but. was close to the borderline of significance. 
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In addition, although ampicillin appears to be absorbed at essentially 
the same rate from both aqueous and oily formulations, the latter are 
likely to produce prolonged plasma concentrations of ampicillin 
because of the effects of enterohepatic. recycling. 
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SECTION 4 
IN VITRO STUDIES 
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CHAPTER I 
DISSOLUTION MTE STUDIES 
1.1 Introduction 
Details of the usefulness of in vitro release studies are given 
in parts 1.2.2 and 1.2.3 of Section 1. As already mentioned there, the 
development and use of in vitro models to discriminate between 
different formulations and to predict the availability of drugs in 
particular dosage forms is important when physiological functions play 
no significant'part in regard to this aspect. As no apparatus or 
procedure can exactly duplicate in vivo conditions, all dissolution 
studies are relative, and the most important considerations are ones 
of reproducibility, practicality and reasonableness. However, in spite 
of this limitation, in vitro models still serve as a secondary standards 
for the detection of the differences in the release of drugs from 
different dosage forms, and the effect of different pharmaceutical 
additives. 
-in vitro studies on the release of drugs from suspension 
formulations have included methods involving the use of either flask 
stirrer or dialysis methods. The use of a dialysis membrane has been 
advocated by several workers as a device for obtaining the solute 
concentration without disturbing the dissolution process. Depending 
on the apparatus used i-t is possible to carry out dissolution studies 
under sink conditions. The choice of the membrane Is important, for 
it must have a short equilibrium time and adequate physical strength 
and retain solid particles. Obviously, the rate at which solute appears 
on the distal side of the membrane should not*be a function of the 
dialysis rate but of the d[s. solution rate. In other words, within such 
an in vitro model system dissolution must be the rate-limiting step 
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(Swarbrick, 1970). A variety of dialysis methods have been - developed 
to study the in vitro release rate of drugs from tablets and capsules 
(Marlowe and Shangraw, 1967; Barzilay and Hersey, 1968), from 
suspensions (Marty and Hersey, 1975a and b; Shah and Sheth, 1976; 
Barzegar-Jalali and Richards, 1979a) and from solutions (Lamy, 1969; 
Bachynsky et al, 1976). 
The flask-stirrer method was introduced by Poole (1969). It has 
been used by Bates et a] (1969) to obtain an in vitro in vivo 
correlation for salicylamide dosage forms including a commercial 
suspension of the drug and Bates et a] (1973) to compare the dissolution 
rates of nitrofurantoin from a commercial suspension and a tablet 
dosage form. 
Although the sensitivity of the flask-stirrer method has been 
proved to be adequate in detecting differences in the effects of 
suspending agents on the dissolution rate of nitrofurantoin 
suspensions, this was not the case in. another study on aspirin 
suspensions, where a more sensitive dialysis method had to be used 
(Barzegar-Jalali and Richards, 1979a and 1980). In addition, a dialysis 
method was used to study the effect of macromolecules and different 
gums1on the release of salicylic acid and sodium salicylate, respectively, 
from aqueous solutions (Lamy, -1969; Bachynsky et a], 1976). 
The work described in this chapter is concerned with release studies 
on the 3 drugs involved In this thesis, i. e., 'sodium salicylate, nitro- 
furantoin and ampicilli. n, using flask-stirrer and dialysis methods, in 
an attempt to detect the possible effects of the different 
pharmaceut. ical additives, which are involved in the oily vehicles 
patented by Stephens and Su 0975) and Lin and Pramoda (1978), on the 
release characteristics that could be masked by the predominant effect 




Details of the sources of the materials and methods of preparation 
of the suspenions are given in Sections 2 and 
1.2.2 Methods 
(a) Dialysis Method 
In addition to a 4% w/v suspension of sodium-salicylate in FCO 
alone (A) and a 4% w/v solution of the salicylate in distilled water 
the release studies were carried out on sodium salicylate 
suspensions of the same concentration in the following types of 
vehicles. 
Type 1 vehicles 
Aluminium stearate (50: 50 mixture of mono and di-stearates) in the 





E 2.5% w/v 
F3% w/v 
G 3.5% w/v 
H4% w/v 
5% wIv 
Type 2 vehicles 
(Related to the formulation of Stephens and Su (1975)). 
A=0.7% w/v lecithin in FCO 
B 0.35% wIv hydrogenated castor oil in FCO 
C 0.5% w1v aluminium stearate + 0.7% w/v lecithin + 0.35% w/v 
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hydrogenated castor. oil + 20% w/v:. sucrose in FCO. 
0.5% w/v aluminium stearate + 0.35% w/v hydrogenated castor oil 
20% w/v sucrose in FCO. 
Type 3 vehicles 
(Related to the vehicle of Lin and Pramoda (1978)). 
A- 20% w/v sucrose in FCO 
B=0.3% w/v Cab-o-sil + 20% w/v sucrose in FCO 
C-0.5% W/v Cab-o-sil + 20% w/v sucrose in FCO 
D 1% w/v Cab-o-sil + 20% w/v sucrose in FCO 
The dialysis method and apparatus used in this study was based 
on that described by Barzegar-Jalali and Richards (1979a) with minor 
modifications. One end of a 25 cm length of Visking dialysis tubing 
(Scientific Instrument Centre, Ltd. ), having an inflated diameter of 
2.14 cm, was tied off after the tubing had been soaked in HCI (0.1 mole/ 
dm3) for at least 12 hr. Seventy glass beads with an approximate 
diameter of 3 mm were placed in the tube. These beads regulate the 
oscillations of the dialysis sac and markedly improved the reproducibility 
of the results obtained for aqueous suspensions (Barzegar-Jaiali and 
Richards, 1979a). Five cm3 of a suspension were poured into the sac 
and that part of the sac'a. bove the level of its contents wasfiattened 
between the fingers. The sac was then suspended through the central 
neck of a2 d& two-necked round-bottomed-flask, which contained 1495 
cne of 0.1 mole/dO. HCI, and secured by a glass stopper in such a way 
that the surface of the contents of the sac was I cm below the 
surface of the dissolution medium. Use of these volumes allowed sink 
conditions to be maintained because the solubility of sodium salicylate 
in 0.1 mole/dr? HCI is 306.1 ng1J0O cm3 (see Chapter 2, this Section). 
A thermometer and a glass tube connected to a flexible plastic tube were 
inserted through a rubber stopper in the side neck of the flask and into 
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the dialysis medium. The plastic tubing facilitated sampling whilst 
the flask was being shaken. The whole assembly was clamped in a 
shaking water bath (Gallenkamp) maintained at 37 0C+0.10C and 
adjusted to provide an oscillation frequency of 120 +2 cycleý/min. At 
this frequency not only was the dialysis medium well ag'itated but also 
the sac was oscillated in a constant manner, thus ensuring good 
mixing on either side of the membrane and preliminary experiments 
showed that this frequency was low enough to discriminate between the 
release rates of the different formulations. A diagram of the dialysis 
apparatus is given in Fig. I. I. 
Five CM3 samples were taken from the flask at various times and 
immediately replaced by the same volumes of 0.1 mole/dmI HCI. The 
samples were filt ered through a Millipore filter assembly (0.45 pm 
pore size). The absorbance. of the solution was determined using an 
SP 500 Unicam spectrophotometer at 300.5 nm with 0.1 mole/de HCI as 
. the reference solution. 
The corresponding concentration was derived 
from a calibration curve using equation 1.1, which is described in 
Chapter I of the previous Section (i. e. Eq. 1.2). The concentrations 
of the standard solutions used to construct this calibration curve 
and their corresponding absorbances, at 300.5 nm are given in Table 
I. I. The Beer-Lambert law was obeyed over the range of concentrations 
indicated in the table. 
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Fig. 1.1 Dialysis apparatus used for the release studies on sodium 





Suspension or Solution 
Glass beads 
Water bath at 37 oc 
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Table 1.1 Data for calibration curve of sodium salicylate in 
0.1 mole/dm3 HCI at 300.5 nm. 
Concentration M 










(b) Flask-stirrer method 
(i) Nitrofurantoin suspensions 
The suspensions, A-H, described in Chapter 3 of the previous 
Section, were used in this in vitro study. The method was based on 
the apparatus described by Poole (1969) and used by Barzegar-Jalali 
and Richards (1979a). A2 d& wide-mouth, round-bottomed flask, with 
a lid comprising of four side necks and one central neck, was placed 
in a water-bath maintained at 37 + 0.1 OC. A 2-bladed, 8.1 cm 
diameter glass stirrer was placed through the central neck and located 
in a standard position relative to the bottom of the flask, i. e. 
5 cm from the bottom of the flask, and connected to an electric motor 
(Citenco Ltd. ), which rotated the stirrer In a counter-clockwise 
direction at a speed of 60 +2r. p. m. A suitable thermometer (0-5000 
and a plastic cannula for sampling were pl6ced at a constant height, 
angle and position into the dissolution medium through t he side necks. 
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The other side neck was used to introduce the dissolution medium 
(1480 cm3 of 0.1 moleldmP HCI solution) and sample suspension. A 
diagram of the apparatus is shown in Fig. 1.2. 
While the stirrer was in motion 10 cm' of an overnight aged 
suspensions were injected through the side neck from a 10 cnP 
gra I duated syringe. The latter was washed' out with 10 cmý' of 0.1 mole/drO 
HCI and the washings were also added to the flask. Using 10 cre of a 
0.1% w/v nitrofurantoin suspension in 1490 c& of dissolution medium 
provided sink conditions for the drug, because its solubility in 0.1 
mole/drrO HCl at 37 0C is 15-59 mg/100 cm' (see next Chapter). ' 
Exposure-of the nitrofurantoin solutions, i. e. the standard 
solutions -and the solution in the dissolution flask, to light was 
minimised as far as possible by wrapping the containers with aluminium 
foil or with black plastic film. Samples of the dissolution medium 
were obtained at various times in as imilar manner to that used in 
the previous dialysis. method. The absorbance of each solution at 
369 nm was determined using 0.. 1 moleldff? HCI as the reference solution. 
Table 1.2 shows the concentrations of standard solutions of nitro- 
furantoin in 0.1 molejdm3 HCl and their absorbance value at . 
369 nm 
that were used to construct the necessary calibration curve. The 
same equation that is described in Chapter I of the previous Section 
, 
(i. e. Eq. 1.2). was used to calculate the concentrations of nitro- 
fu rantoln in the diffe rent samples. 
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Table 1.2 Data for calibration curve of nitrofurantoin in 
0.1 mole, /d& HCI at 369 nm 
Concentration (-X) 
-(Mg/100 








YI - 0.005 
X 
0.7242 









The suspensions A-F, described in Chapter 4 of the previous 
Section, were studied. The apparatus was the same as that used for 
nitrofurantoin except for the volume of the dissolution medium, which 
was 200 CM3, and the speed of the stirrer was 60 +2r. p. m. 10 cm3 of 
2% w/v freshly prepared suspensions of ampicillin trihydrate were 
injected through the side neck of theAissolution flask from a 10 cmý 
graduated syringe. The latter was washed out with 5 CM3 Of 0.1 mole/dM3 
HCI and the washings were also added to the flask. Sink conditions 
prevailed because the solubility of ampicillin in 0.1 mole/dM3 HCI 
at 37 0C is more than 2% w1v as mentioned in Chapter 4 of the previous 
Section. 2 cm3 samples were removed at specified time intervals and 
each sample was replaced immediately by 2 cm3 of 0.1 mole/dM3 HCI. 
The samples were filtered through a Millipore filter and the ampicillin 
content. of each was determined by the method of Smith et al (1967) 
with minor modifications as follows: 
1 CM3 was diluted to 50 CM3 with a previously prepared pH 5.2 
buffer solution containing copper sulphate. 10 CM3 Of this solution 
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were transferred to a calibrated test tube, which was lightly stoppered 
and placed in a thermostatically controlled bath at 75 0 C. After exactly 
30 min the tube was removed from the bath and rapidly cooled in room 
temperature. The absorbances of the solutions were then measured at 
320 nm using unheated buffered ampicillin solution as the blank. The 
concentrations were derived from a calibration curve prepared by 
carrying out the above procedure on known dilutions of a standard 
ampicillin preparation. Table 1.3 shows the data used in obtaining such 
a curve. Eq. 1.2 in Chapter 1 of the previous Section was again used to 
calculate the concentrations of the unknown samples. 
The. buffer solution was prepared by mixing 464. cml of 0.1 mole/dM3 
citric acid solution and 536 cm' of 0.2 mole/dm' disodium hydrogen 
phosphate solution. The pH was adjusted, if necessary, to 5.2 + 0.05 with 
either of the above mentioned solutions. To 15 cm' of a 0.393 w/v 
copper sulphate pentahydrate solution, the mixed buffer at pH 5.2 was 
added to a volume of 1 dm'. One CM3 of this solution contains 15 Ag 
of copper. 
Table 1.3 Data for calibration curve of ampicillin trihydrate in 
0.1 mole/d M3 HCI at 320 nm. 
Concentration 
Mg/100 CM3 


























(a) From dialysi, s method 
The amount of salicylate released, expressed as a percentage of the 
total amount originally added to the system, was calculated from the 
drug concentration in each sample and plotted against the sampling time 
to give a dialysis, or release rate curve. The mean values of these 
percentages for each formulation are shown in Table 1.4. Each value is 
the mean obtained. from 3 experiments. The release rate curves for these 
values are shown in Fig.. 1.3 1.5. Fig. 1.3 shows the lower and higher 
concentrations of aluminium stearate, i. e. 0.5% w/v and 5% w/v. All 
the other concentrations lie between these two curves but have been 
omitted from the figure for the sake of clarity. 
The time required for 30% and 50% of the salicylate to appear in 
solution outside the-dialysis sac (t 30% and t 50% 
) were. calculated from 
the individual release rate curves for each formulation and were used 
as indices for estimation. of the release rate. Analysis of variance 
and Duncan's test were carried out to distinguish the differences 
be tween the mean 
t 30% values. Details of the analysis were described in 
Chapter 2 of the previous Section. The results of the analysis can be 
summarised as shown in Table 1.5 where any two means not underlined by' 
the same line are significantly different (P <0.05 or p <01) and any 
two means underlined by the same line are not significantly different. 
The results given in Table 1.5 show that the sensitivity of the 
method in discriminating between-the different formulations is not as 
good as might be expected from a simple comparison of the mean values 
of t 30%. This reduction in sensitivity is brought about by the 
relatively low reproducibility of the release of salicylate from some 
of the systems. It is considered that this low reproducibility is 















M (0 - 
z -Z 
j 




































C) C) CD C) C5 C=) C) 
CrN 00 rlý %D LA -T 





* ý:, * z i












tn > 1, ý c * a ) Z, ro CD U 
a) Cl. Q) 
CL cr) (U Q- 
CL c 4J th 
0 
4J (D 4-J 
m 4J 
c 0) C%j 
> . 0 G 
0 
0 0 L) 
tn - Q. "I 
th th 
4- C: (1) 
0 a) C: 
4J th 0 




0 4-J > 
cu 
0 c - ý: 
,5 ; 
4-1 E 
0 s- L- 
o 0 












C) C3 Cý C) CD CD 
OD fl-. LIN -: r 
































4- 0 tf) 
0 4- 3 
0 
41 2 















C: 3 C: ) CZ) CD C: ) CD C: ) 
r-ý %D Lr% _: r m C, 4 
pasÄteip : jugD. Ja. d 
Table 1.4 Percent 
(a) 
salicylate released at various times from different 
formulations using the dialysis method. 
Ti me 
(min) 5 10 20 30 45 60 90 
Formul 
(b) 
A 13.2 19.2 27.8 35.2 4o. 6 43.9 48.6 
B 19.2 25.6 36.8 49.3 . 
68.4 85.8 98.5 
1A 10.8 17.4 24.3 28.1 32.8 36.0 4o. 8 
IB io. 4 17.0 22.8 27.5 32.2 35.8 40.4 
Ic 9.0 14.4 20.6 25.8 29.0 31.9 36.8 
1D 8.4 13.7 19.4 23.6 27.9 32.9 36.0 
IE 7.5 12.7 18.7 23.9 28.9 31.7 35.7 
1F 6.1 10.8 17.3 22.3 27.1 30.4 34.9 
IG 5.0 9.0 15.2 19.9 24.1 26.4- 30.1 
1H 5.5 8.8 14.6 18.1 21.2 23.9 28.7 
if 3.4 8.2 14.0 17.8 21.6 24.1 28.1 
2A 13.0 18.8 27.4 35.0 4o. o 43.4 47.7 
2B 11.8 19.5 28.0 34.7 39.2 42.2 46.9 
2. C 5.4 9.3 15.9 22.3 31.9 4o. 9 56.8 
2D 7.3 11.9 18.3 24.4 32.2 38.5 51.0 
3A 7.9 11.7 19.2 26.6 34.7 43.3 56.3 
3B 6.9 11.0 19.4 26.6 35.9 44.4 58.9 
30 6.6 10.3 17.6 24.5 34.1 43.5 55.6 
3D 5.6 9.3 15.8 21.5 30.1 38.1 48.5 
(a) Each value is the average of the results from three experiments. 
(b) Key to Formulations: A- simple suspension in FCO, B- aqueous 
solution, Type 1 vehicles (A-1) contain various concentrations of 
aluminium stearate in FCO, Type 2 (A-D) and Type 3 (A-D) vehicles 
are based on those of Stephens and Su (1975) and Lin and Pramoda 
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the complexity of the mechanisms that will influence the overall 
release process. These mechanism are described in Section 1.4a of this 
Chapter. 
A cumulative correction to account for the previously removed 
samples was not made when determining the percentage of drug released 
because, as can be seen from the following calculations,. which make 
use. of data obtained for the simple suspension in the oil (A), the 
corrected and uncorrected values are approximately equal after 7 samples 
are removed. Eq. 1.4, which was described by Bates et a] (1966a), was 
used to calculate the corrected values. - 
n-I 
CC+ 5- (C Eq. 1.4 
n n, meas. 1500 s, meas' 
5=1 
Where C 
n, meas. . 
denotes the spectrophotometrically measured 
concentrati on (expressed as a% in this case), Cn is the concentration 
(% in thi. s case) of the n 
th 
sampling expected in th Ie 
dialysis medium 
if the previous samples had not been removed and F(Cs, meas. ) is the 
Sul 
sum of concentrations (% in this case) measured spectrophotometrically 
from'sample Ito (n-1) sample. A corrected value (Cn) of 49.2% is 
obtained when Eq. ' 1.4 is applied to the data provided by formulation A 
after 7 samples have been removed. As can be seen from Table . 
1.4 the 
uncorrected value (Cn meas. 
) is 48.6%, which is only 0.6% less than 
the corrected value and in the case of the aqueous solution (B) the 
di fference is only 0.95%. In the case of the 1st, 2nd, 3rd, 4th, 5th. and 
6th samples the differences between corrected and uncorrected values 
will be less than 0.6% and 0.95% in the oily and aqueous systems, 
respectively. 
(b) From flask-stirrer method 
Tables 1.6 and 1.7 show the mean percentages of drug dissolved 
at different times in the flask-stirrer method when using nitro- 
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Table 1.6 Percent 
(a ) 
nitrofurantoin dissolved at various times from 
different formulations using the flask-stirrer method. 




5 20.0 21.8 79.8 80.3 11.9 5.6 
. 
12.6 
10 4o. 5 38.7 84.2 86.2 20.5 lo. 4 25.9 19.3 
20 68.1 51.5 86.9 88.4 31.5 16.0 46.0 29.0 
30 77.1 65.4 88.6 90.1 38.5 26.5 57.2 4o. o 
45 82.7 74.8 88.6 90.3 49.3 39.4 66.5 46.8 
60 84.2 84.1 88.9 90.1 57.2 51.2 73.9 55.9 
Note 
(-a)-Each value is the average of the results from 3 experiments. 
(b) The formulations are 0.1% w/v nitrofurantoin in (A) FCO, (B) 20% w/v 
sucrose in FCO, (C) 0.25% w/v xanthan gum in distilled water, (D) 20% w/v 
sucrose + 0.25% w/v xanthan gum in distilled water, (E) 1% w/v Cab-o-sil 
in FCO, (F). 0.5% w/v aluminium stearate + 0.7% w/v lecithin + 0.35% w/v 
hydrogenated castor oil + 20% w/V sucrose in FCO, (G) 0.3% w/v Cab-o-sil 
+ 20% w/v sucrose in FCO-and (H) 1% w/v Cab-o-sil + 20% w/v sucrose in FCO. 
Table 1.7 Percent 
(a) 
ampicillin dissolved at various times from different 
formulations using the flask-stirrer method. 




5 67.6 35.5 80.6 81.3 13.2 15.1 
10 80.5 47.6 99.9 99.4 20.3 28.6 
20 97.3 63.4 101.2 100.9 29.6 43.0 
30 99.0 69.5 35.3 55.2 
45 98.1 82.3 46.3 69.8 
60 98.6 
. 
92.1 55.3 79.9 
Note 
(-aTEach value is the average of the results from 3 experiments. 
(b) The formulations are 2% w/v'ampicillin trih drate in (A) FCO, (B) 
30% w/v sucrose in FCO, (C) distilled water, (Dý 30% w1v sucrose in 
distilled water, (E) 30% w/v sucrose + 1.25% w1v Cab-o-sil in FCO and 
(F) 0.5% w/v aluminium stearate+ 0.35% w/v hydrogenated castor oil + 
0.7% w/v lecithin + 30% w/v sucrose in FCO. 
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furantoin and ampicillin for each formulation, respectively. Plots 
of these percentages against sampling times, to give the dissolution 
rate curves for each formulation of nitrofurantoin and ampicillin, 
are. given in Fig. 1.6 and 1.7, respectively. Only, formulations D and F 
(Fig.. 1.6) and C and E (Fig. 1-7) are shown and the rest of formulations 
lie between these two curves but have been omitted from. the figures for 
the sake of clarity. However, their t 50% values are given in Tables 
1.10 and 1.11 for nitrofurantoin and ampicillin, respectively. A 
cumulative correction was only made with ampicillin, using Eq. 1.4 
1 
, mentioned 
in the previous method, since the corrected and uncorrected 
values are approximately equal in the case of nitrofurantoin.. 
The time required for 50% of the drug to appear in solution, i. e. 
t 50%, calculated from individual dissolution rate curves for each 
formulation, was used as an index of the dissolution rate of nitro- 
furantoin and ampicillin. Analysis of variance and Duncan's test were 
carried out to distinguish the significance or otherwise of the 
differences between the mean t50% values. Details of the analysis are 
described in Chapter 2 of the previous Section. The results are 
summarised in Table 1.8. 
The results given in Table 1.8 show that the sensitivity of the 
flask-stirrer method in discriminating between the different 
formulations of both drugs was affected adversely by the low 
reproducibility of the results. In fact. the reproducibility appeared 
to be less satisfactory than with the dialysis method and probably 
resulted from the varying degrees of dispersion of different samples 
of a given formulation when it was added to t he dissolution medium. 
1.4 Discussion 
(a) Dialysis mthod 
The simplest test formulation that was used in this method was the 
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Fig 1.6 Plot of percent of nitrofurantoin dissolved versus time 
for an aqueous suspension containing 20% w/v sucrose plus 
0.25% W/v xanthan gum (D) and an oily formulation 










5 10 20 30 45 60 
Fig 1.7 Plot of percent of ampicillin dissolved versus time for 
a simple aqueous suspension (C) and an oily suspension 













Table 1.8 Summary of the results of t. he statistical analysis of 
t 50% 
values for nitrofurantoln and ampicillin formulations. 
(i) for ni-trofurantoin 
Mean values 
Of t50% in 
rank order DCABGEHF 
1% level 2.4 2.5 12.3 17.2 23.5 47.3 48.4 59.9 
5% level cG 
for ampicillin 
Mean values. 





3.00 3.00 3.6 12.3 25.7 51.0 
CDABFE 
where the underlinings have the same meani. ng as before. 
(see. Tables 1.6 and 1.7 for keys to nitrofurantoin and ampicillin 
suspensions, respectively. ) 
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aqueous solution of sodi'um salicylate (formulation B). However, even 
in this system the overall release rate of the drug cannot be ascribed 
solely to the rate of dialysis of a single species in solution, because 
other reactions will be occurring as indicated by the simplified 
scheme in Fig. 1.8. 
n Sol Inside Dialysis Dialysis Outer Dissolution 
Sac Membrane Medium 




SA in. sol n Dialysis SA in soln 
dissolution precipitation 
Solid SA 
Fig. 1.8 Reactions occurring during dialy5is of sodium salicylate 
solution into an acidic dissolution medium (NaS = sodium salicylate 
and SA - salicylic acid). NOTE. The effects of dissociation of the 
salicylic acid and its sodium salts are ignored in this scheme. 
Thus, the obseryed rate of release will be influenced not only 
by the dialysis rates of salicylate ion and undissociated salicylic 
acid, but also by the rate of dissolution of any particles of 
precipitated salicylic acid. If this precipitation produces fine 
particles, then-subsequent dissolution will be fairly rapid and 
the release rate will not be decreased markedly (Munzel, 1971). 
In fact, this aqueous solution provided the most rapid release rate of 
all the systems that were studied and gave man t30% and t50% values 
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of 14.3 and. 28.6 min, respectively (see Tables 1.5 and 1.9). 
The mechanism of release of drug from the oily suspensions of 
sodium salicylate is likely to be more complex than from the aqueous 
solution, because (a) partition of salicylate between oily and aqueous 
phases must occur, (b) the oil can act as a reservoir for salicylic 
acid, formed by hydrolysis of the sodium salt and (c) some of the acidic 
aqueous dis. solution medium penetrates through the dialysis membrane into 
the sac, particularly when sucrose is used as an ingredient in the oily 
vehicle. In addition, the release of water soluble compounds, such as. 
sucrose into the aqueous dissolution medium, the sedimentation of 
sodium salicylate to the bottom of the oily vehicle inside the dia. lysis 
sac and the possibility of emulsification inside the dialysis sac may 
affect the release of salicylate. 
In spite of the additional processes involved when oil alone is 
used as the suspension vehicle (formulation A) the initial rate of 
release of salicylate, as indicated by the 
t 30% value, is not much 
slower than from the aqueous solution B. The mean 
t 30% values are 22.2 
min for A and 14.3 min for B but the statistical analysis of the results 
(see Table 1.5) indicated that this difference was insignificant at 
p> 0.05. It is possible that precipitation of salicylic acid from the 
aqueous solution B may be partly responsible for this similarity in the 
initial rates of release. However, the release rate from the oily 
suspension decreased at longer times in comparison with the aqueous 
solution and the 
t 50% values were > 90 min for A and only 28.6 min for 
B. This differen ce may arise from the effect of the oil in formulation 
A acting as a reservoir for salicylic acid and so interfering with the. 
apparent rate of appearance of salicylate in th e aqueous dissolution 
medium. The difference in the later release of drug agrees with the 
results of Marty and Hersey (1975b), who found that the release rates 
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tt Table 1.9 Apparent viscosities, 30% and 50%_values for sodium 
salicylate formulations. 
Type of t 30% 71app t 50% 
vehicle (FnN s m-2) (c) (min)(b) (a) (min)(b) 
A 22.2 17.5 9 0' 
. 
B 14.3 0.695 28.6 
1A 34.0 37 
1B 37.1 50 
Ic 45.3 59 
1D 50.7 69 
1E 51.5 81 
1F 58.3 92 > go 
IG 89.2 lo4 
1H 99.7 144 
110 176 
2A 22.7 23 
2B 22.9 40 
-2C 42.2 120 76.5 
2D 41.1 105 87.5 
3A 36.7 51 75.0 
3B 35.3 83 71.0 
3C 38.6 98 76.5 
3D 44.4 131 > 90 
(a) Formulations are as specified on pages 188 and 189. 
(b) Each value is the mean of 3 experiments. 
(c) 77 
app, apparent viscosity, 
from Table 1.2, Section 2. 
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of aqueous solutions of drugs were more rapid than those of oily 
suspensions in a dialysis system. This difference also indicates 
that the dialysis rate is not the rate limiting step in the release 
process and the method appears, therefore, to satisfy the conditions 
given by Swarbrick (1970) and Shah and Sheth (1976) for the 
determination of drug release rates from dosage forms using dialysis 
techniques. 
Table 1.9 shows that, with few exceptions, a rank order correlation 
exists within each type of formulation (i. e. Types 1,2 or 3) between 
t 30% and the apparent viscosity of the different vehicles. In fact the 
correlation coefficient (r) for the values given by all the formulations 
is o. 8127 (P<0.001). This rank order suggests that although the gels 
are affected by the presence of water, as mentioned in Section 2, the 
viscosity of the systems still retards the release of drug, at least in 
the early stages. This finding is in agreement with that reported by 
Buckwalter and Dickison (1948 and 1958) who found that increase in the 
concentration of aluminium stearate in the oil delayed the absorption 
of penicillin from an i. m. depot injection. They suggested that this 
is because of the entrapment of the drug particles within the gels. 
Although this suggestion seems to be in agreement with the results 
obiained in the present in vitro release studies viscosity appeared to 
play an insignificant role in the. in vivo absorption studies on the-oily 
vehicles (see Chapter 2, Section 31. (See also Chapter 1, Section 5 for 
further details on the correlation between in-vivo and in vitro 
results). 
It should be pointed out that, in addition to the poor 
reproducibility of the results that lowers the sensitivity of this 
dialysis method in discriminating between the release behaviour of the 
different formulations the model may be criticised due to the problems 
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that arise when there is an osmotic imbalance between the sac contents 
and the external dialysis medium, particularly with the formulations 
where sucrose is involved. It is possible that it may be desirable to 
add some aqueous fluid (0.1 mole/dm' HCO to the oily sample inside 
the dialysis sac to allow partitioning of drug from the oily to the 
aqueous phase before dialysis, because it is likely that, the 
partitioning process is relevant to drug release in vivo (Kakemi et al, 
1972a and b). Unfortunately, addition of the aqueous phase may cause 
a further complication. in the system, particularly if emulsification 
occurs on stirring (Marty and Hersey, 1975a and b). 
However, in the case of sucrose containing formulations (2C and D 
and 3A, B, C and D) osmotic imbalance between the inside and outside the 
dialysis sac caused the influx of appreciable volumesof the aqueous 
phase. In the earlier stages these formulations exhibited slow release 
rates compared with A and some other oily vehicles, (Table 1.9) probably 
because of their high viscosities. However, with the exception of 
formulation 3D the behaviour of which might be due to its very high 
viscosity and the adsorptive capacity of its Cab-o-sil content, these 
sucrose containing formulations were the only oily suspensions that 
gave t 50% values of< 90 min. (see Table 1-9). These increases in 
release rate in the later stages were accompanied by the influx of 
aqueous phase, the volume of which was about the same as that of the 
oily liquid, i. e. 5 cm', after 90 min. In the presence of water these 
oily vehic les form globules of different sizes (see part b of this 
discussion). Thus, the influx of water will not only affect the 
viscosity of the oily vehicle but will also enhance the rate of partition 
of drug between oil and water because of the increase in interfacial 
area between these two phases. 
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The results obtained from these in vitro studies suggest that 
the release of salicylate from a suspension of its sodium salt in 
FCO can be influenced by the inclusion of: 
(a) aluminium stearate, which retards the release, particularly when 
its concentration is 1.5% w/v or more, 
(b) sucrose, which tends to give rise to a faster release in the later 
stages, and 
(c) Cab-o-sil, which tends to nullify the effects of sucrose, when 
used in a concentration of 1% wIv. 
Other conclus-ions that can be drawn from these results include 
the fact that the inclusion of 0.7% w1v lecithin or 0.35 w/v 
hydrogenated castor oil in the oily vehicle does not appear to have 
any significant effects on the release process as shown by a comparison 
of the results obtained for formulations 2A and 2B, respectively, with 
that for the simple oily suspension (A). In fact these three oily 
formulations were the only ones that gave t30% values that were not 
significantly different to that given by the aqueous solution of sodium 
salicylate (B). The t50% values were, of course, all much greater than 
that of B. The insignificant effect of 0.7% w/v lecithin is also 
indicated by a comparison to the t30% values obtained for formulations 
2C and 2D. 
Finally, there appears to be little difference in the in. vitro 
release of salicylate from formulations that correspond to those 
patented by Stephens and Su (1975) and Lin and Pramoda (1978), as shown 
by a comparison of systems 2C and. 3C, provided that the concentrati. on of 
Cab-o7sil in Lin and Pramoda's formula does not exceed 0.5% w/v, because 
if 1.0% is used the increased rate of release, produced by sucrose in 
the later stages of release, is not so readily apparent. 
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(b) Flask-stirrer method 
(i) Nitrofurantoin formulations 
The results given in Table 1.8 show that the two suspensions in 
aqueous vehicles C and D produced rapid release of the drug and gave 
very close t50% values. Both vehicles contained 0.25% w/v xanthan gum 
but D also contained 20% w/v-sucrose. The presence of sucrose there- 
fore appeared to have little effect on the release of nitrofurantoin 
from the aqueous suspensions. This is to be expected-because the 
agitation of the dissolution medium will cause rapid dispersion and 
dilution of the dissolved sucrose. 
The release of nitrofurantoin from the oily formulations was often 
poorly reproducible and this poor reproducibility was probably 
associated with the behaviours of the vehicles when they were placed in 
the dissolution medium. In addition, the variety of behaviours shown by 
the different vehicles was considered to be a major factor that 
contributed to the significant differences that were detected in the 
t50% values from some of the vehicles. 
In general the main difference in behaviours-depended on the 
presence or absence of sucrose in the formulations. Thus, the 
formulations that did not contain sucrose, i. e. A (FCO only) and E (1% 
Cab-o-sil in FCO), tended to form oi. ly layers on the surface of the 
dissolution medium. Under the influence of the agitation of the aqueous 
medium droplets of oil could be seen to become detached from the oily 
layer and then coalesce with it, particularly in the case of A. The 
higher viscosity of the layer formed by E reduced the tendency to form 
these droplets and was probably. responsible for the significant increase 
value for this formulation over that of A, p< 0.01. The in the t50% 
release of nitrofurantoin from the simple suspension in FCO (A) was 
fairly rapid as would be expected from the low oil: 0.1 mole/dM3 HCl 
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partition coefficient of this drug (see next chapter). Because of 
the low reproducibility of the results, the mean t50% value. for 
this simple oily suspension did not differ statistically from the mean 
values for the aqueous suspensions C and D, P> 0.05. 
In the cases of sucrose containing formulations, i. e. B (20% 
sucrose in FCO), G, (0.3% Cab-o-sil + 20% sucrose in FCO), H (1.0% 
Cab-o-sil + 20% sucrose in FCO) and F, which corresponded to Stephens 
and Su's patent (1975), the oily vehicle tended to form relatively 
large pear-shaped globules, in which the sucrose and other solid 
ingredients sedimented inside the globules leaving a clear oily layer 
at the top of the globule. The sizes of these globules ranged from 
approximately 1-10 mm and their overall densities caused them to fall 
to the bottom of the dissoljjtion flask (see Fig. 1.2). As the sucrose 
was removed from the globules by dissolution into the aqueous phase 
they gradually disappeared and the oil then formed a layer on the, 
surface of the aqueous phase. The lifetimes of these globules therefore 
appeared to depend on the dissolution rate of sucrose, which in turn 
will depend-on the viscosity of the oily liquid inside the globules. 
Thus, the lifetime of the globules formed by B (20% sucrose in FCO) was 
only of the. order of 5 minutes so that an oily layer was formed on the 
surface of the dissolution medium in a relatively short time. The 
viscosity of this layer was presumably similar to that of FCO alone and 
the release of nitrofurantoin from. formulation B would therefore be 
expected to be not too inuch slower than from a suspension in FCO alone 
(A). In fact, the-t50% value for B was about 5 min longer than that for 
A and the two values were not statistically different, P> 0.05 (see 
Table 1.8). 
The lifetimes of the globules produced by the remaining sucrose 
containing formulations fell into the order G <H <F. G and H also 
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contain Cab-o-sil in 0.3% and 1% concentrations, respectively. The 
resultant higher viscosities will delay the loss of sucrose from the 
globules and the release of nitrofurantoin not only from the globules 
but also from the oily layer that is eventually produced on the surface 
of the dissolution medium. In fact, the globule forming tendencies of 
these two formulations caused by their sucrose contents. do not seem to 
be as important as the effect produced by including 1% Cab-o-sil, 
because formulations E and H gave very similar t50% values (see Tables 
1.8 and 1.10). 
Table 1.10 Apparent viscosities and t50% values for oily 
nitrofurantoin formulations 
Formulations t50% (b) I? 
app 
(C) 
(a) (min) mN s m- 
2 
A 12.3 17.5 
B 17.2 51 
E 47.3 58 
G 23.5 83 
F 59.9 120 
H 48.4 131 
Key: 
(a)-See Table 1.6 for key to formulations. 
(b) Each value is the mean of 3 experiments. 
(c) japp, apparent viscosity, from Table 1.2, Section 2. 
These two formulations both contain 1% Cab-o-sil but only H contains 
20% sucrose. Although the apparent viscosities of these two vehicles 
are markedly different (see Table 1.10), it is likely that the 
viscosities of the oily layers produced by both of them will be 
similar when the sucrose has been removed from H. The increase in 
viscosity of an oily layer produced by 0.3% Cab-o-sil does not appear- 
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to be sufficient to lead to a significant decrease in the release rate 
of nitrofurantoin because the t value of formulation G did not 50% 
differ significantly from that of B, P> 0.05. 
Finally, although the apparent viscosity of formulation F, which 
corresponds to the patent of Stephens and Su (1975), was less than that 
of H (see Table 1.10) the lifetime of the globules was greater in F. 
This increase in globule'slifetime appears to be responsible for the 
higher mean t50% value for F compared to H, and the difference between 
these values was significant, P< 0.05 (see Table 1.8). 
One final point concerning the aqueous suspensions of nitro- 
furantoin (C and D) is that the maximum amount of drug released 
appeared to be about 90% and this value remained constant over the last 
few sampling times. This may suggest that some nitrofurantoin remains 
in the oily vehicle but the low oil: 0.1 mole/dm' HCI partition 
coefficient does not support this suggestion. The decomposition of 
nitrofurantoin under the influence of light offers an alternative 
explanation. Such decomposition. was confirmed by preliminary studies 
and although the dissolution experiments were carried out in the dark 
as far as possible, exposure to light could not be avoided completely. 
Thus, some decomposition of dissolved nitrofurantoin is likely to occur 
and may reduce the rate of apparent dissolution of the drug particularly 
in the latter stages when the concentration of nitrofurantpin in solution 
is high and when the rate of dissolution is decreasing. 
(ii) Ampicillin formulations 
The results obtained with these forinulations (Table 1.7 and 1.8) 
parallel those obtained with the nitrofurantoin ones. This is not 
surprising because both drugs possess low oil: 0.1 mole/dM3 HCl 
partition coefficients(see next chapter). Thus, the aqueous suspensions 
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(C and D) gave the lowest t50% values and the inclusion of 30% 
sucrose in D did not cause any apparent effect. The t50% value for 
the suspension. in FCO alone could not be distinguished statistically 
from those of the aqueous formulations,. P> 0.05, and neither could 
that for th. e oily suspension B, which contained 30% sucrose. The low 
lipophilicity of ampicillin trihydrate was v. isually apparent in these 
systems bedause the solid particles could be seen to be released from 
the FCO in formulation A and fall through the dissolution medium in 
the same way as they did with the aqueous suspensions. It is, therefore, 
not surprising that the t50% value for this formulation should be very 
similar to those of the aqueous suspensions C and D. 
The formulation F, which corresponds to Stephens and Su's patent 
(1975) gave a significantly longer t50% value than the simple oily 
suspension A, p<0.01, but was not- statistically distinguishable at 
p> 0.01 from formulation B, which contained sucrose. This latter 
difference was significant however at the 5% level. It should be pointed 
out that the sucrose content of the appropriate ampicillin formulations 
was 30% rather than 20% as in the previous nitrofurantoin suspensions. 
Finally, the longest t50% value was given by formulation E, which 
contained 30% sucrose plus 1.25% Cab-o-sil, so that not only was the 
sucrose content higher than that in the nitrofurantoin suspensions but 
also the Cab-o-sil content was increased. This formulation had a very 
high apparent viscosity, as shown in Table 1.11. The values given in 
this table also show that there is an approximate rank order 
relationship between t5 0% and 'qapp. 
Like the nitrofurantoin formulations, the ampicillin suspensions 
B, F and E formed large pear-shaped globules and the lifetimes of 
these appeared to be a major factor in determining the release of 
ampicillin. 
219 
Table 1.11 Apparent viscosities and t 50% values for oily ampicillin 
formulations 
Formulation t oý (b) 
71app (c) 
(a) ý min) (mN s m-2) 
A 3.6 17.5 
B 12.3 64 
F 25.7 14o 
E 51.0 150 
Key: 
(a) See Table 1.7 for key to formulations. 
(b) Each value is the mean of 3 experiments. 
(c) '? app, apparent viscosity, from Table 1.2, Section 2. 
In addition, the dispersion of the vehicles into these globules and the 
formation of oily layers on the surface of the dissolution medium in an 
uncontrollable manner was probably responsible for the poor 
reproducibility of the results. Although this poor reproducibility may 
be a criticism of the method used to determine the release of drug it 




SOLUBILITY,, PARTITION COEFFICIENT AND ADSORPTION STUDIES 
2.1 Introduction 
Since the absorption of drugs occurs normally from solution 
(Morrison and Campbell, 1965; Cadwallader, 1974), aqueous solubility 
and, consequently, the amount of drug in solution are of importance 
with respect to drug activity. However, lipid solubility is equally 
important since the*absorption involves the passage of the drugs 
through biological membranes, which are lipoidal in nature (see 
part 1.3-1, Section 1). A guide to the lipophilic nature of a drug 
is provided by its partition coefficient between oil or a fat-like 
solvent, such as chloroform, and aqueous phase, which is either water, 
dilute HCl or an aqueous buffer approximating the pH of the absorption 
site.. The effect of lipid solubility on absorption was studied by 
Schanker (1960) for a series of barbituric acid derivatives. Each 
compound had about the same pKa value and an almost perfect rank order 
correlation was found to exist between their partition coefficients 
and extents of absorption. 
Physical adsorption involves the removal of drug molecules from 
solution and their transfer to the surface of an "active" solid, such 
as charcoal, alumina, various clays or colloidal silicon dioxide. The 
molecules are held on the surface by van der Waal's forces oe hydrogen 
bonding. An equilibri um between drug in solution and adsorbed drug is 
usually observed. When adsorption is irreversible, a chemical 
adsorption (chemisorption) rather than a physical adsorption is 
suggested. 
A number of pharmaceutical adjuvants and antidiarrhoeal 
medications may function as "active" solids or adsorbents. The ability 
of certain adsorbents to interfere with drug absorption is well known. 
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The use of charcoal as a non-specific antidote in drug poisoning 
is based on its adsorption properties and its consequent ability to 
remove a portion of the drug from the GI fluids. The poor serum levels 
of lincomycin obtained upon co-administration with attapulgite-pectin 
suspension have been attributed to an adsorption process (Monkhouse 
and Lach, 1972). Sorby (1965) showed that human urinary'levels of 
promazine are significantly decreased when the drug is adsorbed on to 
attapulgite and charcoal prior to administration. 
With the above points in mind the purpose of this work was to 
study the solubility of the drugs in both 0.1 mole/dO HCI and the oil, 
their partition coefficient between the oil and HCl and their 
adsorption from solution on to Cab-o-sil. 
2.2 Experimental 
2.2.1 Materials 
Details of the sources of materials and the methods of preparation 
of Cab-o-sil dispersion are given in the previous sections of this 
thesis. 
2.2.2 Methods 
(a) Solubility studies in 0.1 mole/dml and FCO 
An excess amount of sodium salicylate or nitrofurantoin were 
added to 100 cmP of the particular solvent and kept at 370C for a 
week with occasional shaking. Samples were taken periodically from 
the supernatant solution to predict the equilibrium solubility, 
filtered through a 0.45 Millipore filter and then diluted to an 
appropriate extent with the particular solvent. The concentration of the 
drug (solubility) was calculated from the previously rnade calibration 
curves in the appropriate solvent. Calibration curves in the HCI are 
given in the previous chapter. Tables 2.1 and 2.2 show the concentrations 
of standard solutions of sodium salicylate and nitrofurantoin in FCO 
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and their absorbance values at 298 nm and 363 nm, respectively, that 
were used. to construct the necessary calibration curves. The 
concentrations of the test solutions were calculated by means of 
Eq. 2.2 and 2.3. Equilibrium solubility was attained in 3 days in all 
cases. The experiment was carried out in the dark with nitrofurantoin. 
Table 2.1 Data for calibration curve of sodium salicylate in FCO at 
298 nm. 
Concentration 



















Table 2.2 Data for calibration curve of nitrofurantoin in FCO at 
363 nm. 
concentration M Absorbance (Y) 
mg/100 cm, 
0.2 0.182 
o. 4 0.381 
o. 6 0.582 
o. 8 0.766 
1.00 0.962 
Xy+ mo8g Eq. 2.3 
0.9725 
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(b) Oil/0.1 mole 
W HCI partition coefficient 
50 cm3 of solutions containing 100 mg of sodium salicylate or 
ampicillin or 1 mg of nitrofurantoin in 100 cn? of 0.1 mole/dO HCI 
were equilibrated with 50 caP of FCO for 24 hr in a 250 cm' glass 
stoppered conical flask kept at 37 0C in a shaking water bath and 
agitated at 100 oscillations per min. The experiment was carried out 
in the dark with. nitrofurantoin. The drug concentrations in the HCI 
were determined according to the appropriate method given in the 
previous chapter. Preliminary studies showed that equilibrium was 
attained within 5 hr in all'cases. The apparent p artition coefficient 
of each drug was calculated by means of the following equation: 
App. partition coefficient'-- 
Cl - C2 
Eq. 2.4 C2 
where ClAs the original concentration of the drug in the HCI and 
C is the equi I ibrium concentration in the HCI. 2 
(c) Adsorption studies 
0.5 g quantities of Cab-o-sil were placed in 100 CM3 glass 
stoppered conical. flasks containing 50 cm' of sodium salicylate or 
nitrofurantoin solutions of specified concentrations in FCO (see 
Tables 2.4 and 2.5 respectively). The flasks were shaken in a 370C 
shaking water bath at 100 oscillations per min for 24 hr. Preliminary 
experiments had shown that equilibrium was attained in less than 
5 hr. The drug concentrations In the supernatant solutions were 
determined after centrifugation at 8000 r. p. m. for 10 min using 
Eqs. 2.2 and 2.3 mentioned above. The experiment was carried out in 
the dark with nitrofurantoin. 
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2.3 Results 
Table 2.3 shows the solubilities of the drugs in the 0.1 mole/dM3 
HCI and FCO together with their oil/HCl partition coefficients. 
Corrections of the absorbances of the aqueous solutions of the drugs 
to account for the effect of water soluble components of the oil were 
not made, because preliminary experiments showed that these effects were 
negligible. 
The adsorption data for sodium salicylate and nitrofurantoin on to 
the Cab-o-sil are shown in Tables2.4 and 2.5, respectively. 
Table 2.3 Solubilities and partition coefficients of sodium salicylate, 
nitrofurantoin and ampicillin. Each value is the average of 
experiments. 
Solubility (mg/100 cml) apparent 
0.1 moWdm' FCO partition coefficient H 
Sodium salicylate 306.1 16.85 38.60 
nitrofurantoin 15-59 4.47 0.48 
ampicillin >2000 (a) <3 0.052 
(a) Marsh and Weiss (1967) 
225 
Table 2.4 Adsorption data for sodium salicylate on to Cab-o-sil 
from solution in FCO. Each value is 'the average of 
2 experiments. 
Co c X/m eq 
mg/100 crn3 mg/100 ce m9/9 
0.5 0.. 47 0.03 
1 0.89 0.11 
1 -5 1.27 0.23 
2 1.55 o. 45 
3 2.19 0.81 
4 2.76 1.24 
5 3.40 1.6o 
7 4.41 2.59 
10 6. o4 3.96 
15 8. go 6. lo 
C0 is the original concentration of drug in solution 
c is the equilibrium concentration of drug in solution 
x eys the amount of drug adsorbed by mass m of the adsorbent. 
Table 2.5 Adsorption data for nitrofurantoin on to Cab-o-sil from' 
solution in FCO. Each value is the average of 2 experiments. 
c0 ceq xjm 
mg/100 cm, mg/100 CM3 P-2/--2 
0.2 0.20 0.0 
0.4 0.395- 0.005 
o. 6 0.590 0.01 
o. 8 0.78 0.02 
1 0.97 0.03 
1.5 1.46 0.04 
2.00 1.97 0.03 
. 4.00 3.95 0.05 
c0, c. eq ,x and m 
have the same meaning as in Table 2.4 
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2.4 Discussion 
Contrary to the partition coefficient expected on the basis of 
the solubilities of sodium salicylate in FCO and 0.1 mole/dm3 HCI, 
the relatively high apparent oil/HCI partition coefficient (Table 2-3) 
ind i cates the effect of conversion of this drug to the very lipophilic 
salicylic acid in the acidic medium. This effect will also occur i'n 
the stomach and would be a possible explanation, besides the delay in 
the GER caused by the oil, for the slower absorption rate in vivo 
(see Chapter 1, Section 3) and for the slower release rate in vitro 
(previous chapter). 
The solubilitlesand partition coefficientsof nitrofurantoin and 
ampicillin are shown in Table 2.3. A solubility of 15.59 mg/100 cap 
of nitrofurantoin in 0.1 mole/dml HCl is very close to that found by 
Bates et a]. (1974a) (15.4 mg/100 cm3). However, its solubili ty in FCO 
(4.47 mg1IOO c& ) is nearly double that found byý the same authors 
(2-07 mg/100 cm3) for its solubility in peanut oil. The apparent oil/ 
HCI partition coefficient of nitrofurantoin is less than unity, 0.48. 
Ampicillin. is almost insoluble in all organic solvents (Marsh and 
Weiss, 19671. Its ethylacetate-water partition coefficient is 0.044 
(Hou and Poole, 1969)-. Its solubility in FCO was found to be<3 mg/100 
crO and the apparent oiljHC[ partition coefficient is 0.052, Table 2.3. 
The adsorption studies indicate that sodium salicylate is 
significantly adsorbed on to Cab-o-sil from solution in FCO (Table 2.4) 
but no appreciable adsorption of nitrofurantoln occurs on to this 
suspending agent (Table 2-5). 
It has been reported that the use of colloidal silicon dioxide as 
a viscosity modifier is largely attributed to the ability of the very 
small silica particles to form a network structure throughout the medium 
by interparticle hydrogen bonding via the silanol groups on the silica 
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surface. In addition to these particle interactions there is possible 
bonding between the silanol groups and other components that are also 
capable of hydrogen bond formation (Marshall and Rochester, 1975). The 
amount of drug adsorbed per gram of Cab-o-sil will consequently depend 
on the strength of any interactions, such as hydrogen bond formation, 
between the drug and the surface silanol groups relative to the 
competing effects of silanol groups on other particles or of compounds, 
such as fatty acids, that are present in FCO. The relative numbers of 
these competing agents will also be important. For example, Sherriff 
and Enever (1979) showed that methyl salicylate could bond to the 
silanol groups of Cab-o-sil when n-dodecane was used as the dispersion 
medium but not when I-dodecanol was used, because in the latter systems 
there was such an excess of hydroxyl groups from the I-dodecanol 
relative to the silanol groups that the probability of silanol-l- 
dodecanol interactions was even higher than that of silanol-silanol 
interaction. Thus, there was no chance for methyl salicylate to be 
adsorbed. 
, Increase in the number of surface silanol groups, i. e. by using more 
Cab-o-sil, will obviously lead to relatively greater adsorption of a 
fixed amount of drug. Thismay provide a likely explanation of the fact 
that 1% Cab-o-sil nullified the enhancing effect of sucrose on the 
bioavailability of sodium salicylate whilst 0.3% Cab-o-sil allowed the 
effect to be retained (see Chapter 2, Section 3). 
The adsorption of salicylate by Cab-o-sil. may also be responsible 
for some of the effects observed in the in vitro studies as indicated 
in the previous chapter. 
The negligible adsorption of nitrofurantoin by Cab-o-sil (Table 2-5) 
indicates that the effects of this, suspending agent in the in vivo and 
in vitro studies were unlikely to involve any adsorption phenomena. 
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SECTION 
IN VIVO - IN VITRO CORRELATIONS 
AND CONCLUDING REMARKS, 
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CHAPTER 1 
CORRELATION OF IN VIVO AND IN VITRO RESULTS 
It is suggested, as indicated in Section 3, that the differences 
obtained in the bioavailabilities of the three drugs studied were mainly 
due to the decrease in the GER brought about by the oil or by the high 
osmotic pressure produced by sucrose, although other possible 
physiological factors mentioned in that section might also be involved. 
The effects of all the physiological functions, particularly GER, masked 
the inherent effect of the suspending agents and the viscosity of the oily 
vehicles for the range of concentrations studied. Therefore, it is not 
surprising that the lack of factors similar to these physiological effects 
in the in vitro dissolu tion and release studies resulted in poor 
correlation between the in vivo and in vitro parameters (see part 1.2-3, 
Section 1). However, there are instances where some correlations were 
observed, as will be seen later in this chapter. 
1.1 Sodium salicylate 
It was suggested in Chapter 2, Section 3 that the results obtained 
in vivo cannot be correlated with the viscosity of the formulations and 
that the effect of the oil on the GER predominates. In fact, analysis of 
the results in Table 1.1 shows that of the three in vivo parameters, i. e. 
9 AUCO, PC and PT, only PT _gives any reasonable 
degree of correlation with 
viscosity as indicated by Eq. 1.1 - 1.3 respectively. 
9 Eq. 1.1 AUC 
0 
100.92 - 0.0722 -? app 
r 0.426, p>0.1 
PC 13.1958 - 0.0107 Tapp Eq. 1.2 
r-0.4454, p'. p 0-1 
PT 2.493 + 0.0164 71 app Eq. 1.3 
r 0.7409, p< 0.05 
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Table 1.1 In vivo and in vitro parameters for sodium salicylate 
formulations together with the viscosities of the various 





-2 (mN Sm 
AUC 9 
0 







A 17.5 89.8 12.7 2.7 22.2 
C 50 96.9 12.8 3.2 37.1 
B 51 106 14.7 2.7 36.1 
D 83 102 13.9 4.6 38.6 
G 105 92 12.7 5.5 41.1 
F 120 99 13.8 4.0 42.2 
E 131 86 12.0 4.25 44.4 
H 144 85 11.4 4.5 99.7 
(a) Formulations are as specified in Table 2.1, Section 3. 
(b) 11, pp,. apparent viscosity, 
from Table 1.2, Section 2. 
1 
The latter correlation (i. e. PT with viscosity) probably arises from the 
fact that salicylate is absorbed fairly well from the. stomach (see 
Chapter l, ' Section 3) and that an increase in the viscosity would decrease 
the rate of movement of drug molecules to the absorbing membrane (Levy and 
Jusko, 1965). The effect of viscosity on the in vitro release rate of 
salicylate is shown by the existence of a correlation between viscosity 
and the t30% as shown by Eq. 1.4: 
t30% - 13-160 + 0; 3651 'Yapp Eq. 1.4 
ra0.7113, P< 0.05 
Analysis of the results also showed that the three in vivo 
parameters did not correlate with the in vitro parameter t30% (Pý*0-1)* 
However, in spite of this lack of correlation formulation E (i. e. 1% w/v 
Cab-o-sil + 20% w/v sucrose in FCO) which gave the lowest but one AUC9 0 
value, also gave the highest but one t30% value, i. e. almost the slowest 
release rate. Two possible explanations might be suggested to account for 
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this correlation, i. e. the high viscosity of this formulation (Table 1.1) 
and the possible adsorption of salicylate on to the Cab-o-sil. However, 
because of the poor correlation between viscosity and AUC9 (Eq. 1.1) and 0 
the marked adsorption of this drug on to Cab-o-sil, as indicated by the 
adsorption studies (see Chapter 2, Section 4) , it is suggested that the 
decreased. in vivo and in vitro availabilities of sodium salicylate when 
administered in this formulation are most likely due to the adsorption of 
the drug on to Cab-o-sil. 
Finally, the rapid abýorption of salicylate from the aqueous solution 
compared with that from the oily suspension (Chapter 1, Section 3) 
correlates well with the rapid in vitro release rate of this drug from the 
I 
former formulation (Chapter 1, Section 4). This latter correlation reflects 
the action of oil as a reservoir for a drug with high oil/0.1 mole/dn-P HCl 
partition coefficient, e. g. salicylic acid. 
1.2 Nitrofurantoin 
It was suggested in Chapter 3 of Section 3 that the significant 
reduct. ion in the rate and extent of nitrofurantoin absorption when 
administered in oily rather than aqueous suspensions is due to the effect 
of the oil on the GER and that the viscosity of the vehicle played an 
insignificant role. In factanalysis of the results given in Table 1.2 
supports this suggestion by showing poor correlations between viscosity 
and either the amount of drug excreted (as % dose) during the first 4 hr 
and 8 hr periods or the total amount excreted, as indicated by Eq. 1.5 
1.7, respectively. 
% dose 'excreted (4 hr) - 17-746 - 0.1006 V Eq. 1.5 app 
r0- 5907, p>0-I 
% dose excreted (8 hr) z 23.238 - 0.1009 7? Eq. 1.6 app 
r 0.5453, p >0-1 
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% dose (Total) = 27.62 - m642 Eq. 1.7 
ru-0.5105, P> 0.1 
However,. viscosity appears to play a significant role in the in 
vitro dissolution studies, as indicated by the existence of a correlation 
between t50% and viscosity (Eq. 1.8) 
-- 2-756. o + 0.444 11 Eq. 1.8 t50% app 
r=0.824ý, p <0.02 
Table 1.2 In vivo and in vitro parameters for nitrofurantoin formulations 




(mN s m-2) 
Nitrofurantoin excreted (% dose) 
4hr 8hr Total 
t50% 
(min) 
A 17.5 7.8 10.7 20.2 12.3 
C 33 21-7. 30.1 31.7 2.4 
D 37 22.8 28.2 31.5 2.5 
B 51 9.1 13.1 22.6 17.2 
E 58 7.8 13.5 20.2 47.3 
G 83- 8.9 13.2 21.1 23.5 
F 120 5.4 8.3 18.6 59.9 
H_ 131 5.1 10.5 21.0 48.4 
(a) Formulations are as specified on page 1ý6. 
In addition, t50% showed reasonable degrees of correlation with the in 
vivo parameters as indicated by Eq. 1-9 - 1.11. 
% dose excreted (4hr) z 17.627 - 0.2455 t50% Eq. 1.9 
r=- 0-776, p <0-05 
% dose excreted (8hr) = 23.244 - 0.2733 t50% Eq. 1.10 
r=-0.7302, p. <0.05 
% dose excreted (Total) = 28.071 - 0.1764 t50% Eq. 1.11 
r=-0.7556, P. <0.05 
These correlations are perhaps surprising in view of the previous 
comments that the in vivo parameters do not show any relationship to 
viscosity whereas the in vitro parameter t50% does show some correlation 
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with viscosity. The only explanation that can be suggested to account 
for this apparent contradiction is that dissolution, whether in vivo or 
in vitro, is influenced not only by the viscosity of the formulation but 
by additional factors, e. g. possible effects of the formulation components 
on the solubility of the nitrofurantoin, adsorption of nitrofurantoin on 
to sucrose particles in the oily formulations or complexation with sucrose 
in solution in the aqueous phase. The correlation between the in vitro 
dissolution rate and the in vivo parameters is supported by the work of 
Groning (1981) who studied the bioavailability of nitrofurantoin after 
oral administration of dosage forms with different onsets of release. The 
author found that a delay in the release of merely a few hours leads to 
a statistically significant reduction in the bioavailability of active 
ingredients. After administration of coated tablets, where release was 
delayed for up to 5 hr, only 8.3% of the dose was excreted in the'urine, 
whereas with rapidly disintegrating tablets, 34.5% of the dose under-went 
renal elimination. The author indicated that nitrofuranto in is only 
optimally available from the GI tract over a limited period and that with 
dosage forms of nitrofurantoin, which are subject to passage through the 
GI tract, only that part of the active ingredient which is released from 
the preparation within the first few hours of administration is optimally 




and PT Yal-ues correlate poorly with viscosity as indicated 0 
by Table . 1.3 and*Eq. 1.12 and 1.13. However, the existence of a 
reasonable correlation between PC and viscosity (Eq. 1.14) is probably 
due, as for salicylate, to the gastric absorption of ampicillin, so that 
the higher the viscosity the slower absorption of the drug (Levy 
and Jusko, 1965). The effect of viscosity on the in vitro dissolution and 
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Table 1.3 'In vivo and in vitro parameters for ampicillin together with 
the viscosities of the various vehicles 
Formulation 'Tapp AUC PT PC t 50% 
(a) (mN s m-2 gg hr/cm? (h r) gg/CM3 (min) 
C 0.695 12.0 1.0 5.2 3.0 
D 2.32 18.6 1.2 6.4 3.0 
A 17.5 20.1 2.1 4.9 3.6 
B 64 17.4 1.3 3.8 12.3 
F 140 15.3 1.8 3.7 25.7 
E 150 13.2 1.9 3.5 51.0 
(a) Formulations are as specified in Table 4.1, Section 
release of ampicillin is shown by the existence of correlation between 
t50% afid viscosity (Eq. 1.15). 
AUC 8 17-155 - 0.0169 71 Eq. 1.11 0 app 
r - 0.3642, p> 0.1 
PT = 1.334 + 0.003456 Yapp Eq. 1-. 13 
r = 0.5322, p >0.1 
PC = 5.463 - 0.0141 7app Eq. 1.14 
r =-0.851, P< 0.05 
t50% " 0.373 + 0.2573 Tapp Eq. 1.15 
r = 0.917, P< 0.01 
Analysis of the results also showed that the three in vivo parameters did 
8 
not correlate with the in vitro parameter t 50% 
(p> 0.1 for AUC 
0 and 
PT and 
P >0.05 for PC). 
Although there is a poor correlation between t50% and the in vivo 
parameters, the slower release rates of ampicHlin from the formulations 
E and F(i. e. ', 1.25% Cab-o-sil + 30% sucrose in FCO and the formulation 
patented by Stephens and Su, (1975), respectively)-are paralleled by the 
lower bioavailabilities of this drug from these 2 formulations. in vivo 
(see Chapters 4 and 1 in Sections 3 and 4, respectively). 
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In conclusion, these in vivo - in vitro correlation studies 
indicate and confirm the suggestion made in Section 3 that the viscosity 
enhancing agents have no significant effect on the bioavailability of the 
3 drugs studied when administered in an oily vehicle, since the major 
effect of the oil in decreasing GER masks the other effects of viscosity. 
However, viscosity did affect, and correlated with, the in vitro 
dissolution and release rates of these drugs. Finally, it is suggested 
that the correlations found between PT or PC and viscosity in the cases 
of salicylate and ampicillin, respectively, are related to the 
appreciable gastric absorption of these 2 drugs, because their rates of 
absorption are likely to be affected by the rates at which they arrive 




CLINICAL SIGNIFICANCE OF THE RESULTS AND SUGGESTIONS FOR FURTHER WORK 
The results of the present investigations suggest that the 
bioavailability of drugs in perorally administered suspensions is 
greatly affected by the physicochemical properties of the vehicle 
and the subsequent action of this vehicle on the physiological functions 
as well as the properties of the drug. For-example, oils and osmotic 
pressure decrease the GER, which is very important in the case of acidic 
drugs, e. g. salicylate and nitrofurantoin, and for an amphoteric drug, 
such as ampicillin. In addition, the incr eased bile secretion caused by 
the presence of oil, is Suggested to be responsible for enhancement of the 
enterohepatic recycling process for drugs that are excreted extensively in 
the bile in active form with minimum metab olism by the liver cells, such 
as ampicillin. Furthermore, the effects of oil and osmotic pressure on 
the bioavailability of the acidic drugs appeared to depend, in turn, on 
the degree of acidity of these drugs and their oil/HCI (0.1 mole/do 
partition coefficients. For example, in the case of sodium salicylate, 
which forms salicylic acid (pKa - 3) as a result of the acidic medium 
of the stomach, a decrease i. n GER caused an increase in the extent of 
drug absorbed and the blood level remained rather high for a longer 
period of time when administered in oily suspension rather than aqueous 
solution. However, the reduction in the rate of absorption is due 
partly to the action of the oil as a reservoir that controls the 
release of salicylic acid and partly to the delay in the appearance of 
salicylate in the small intestine because of the decrease in the GER. 
Another important conclusion is that the inclusion of sucrose in 
the oily vehicle increased the extent of absorption of drugs with oil/ 
HCI (0.1 mole/do) partition coefficients of more than unity due to its 
osmotic pressure effect on the uptake of water by the GI membrane and 
0 
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not to any additional decrease in GER over that caused by the oil 
itself. Evidence for this conclusion arises from the fact that this 
was the case with sodium salicylate with an apparent oil/HCI partition 
coefficient of 38.6, whereas with ampicillin, with a partition co- 
efficient ofO. 052, there was no enhancement in the extent of absorption 
when sucrose was included in the oily vehicle, although. 30% w/v was used 
instead of 20% w/v. However, inclusion of 1% w/v Cab-o-sil nullified the 
enhancement effect of sucrose on the extent of absorption-of sodium 
salicylate. Adsorption of salicylate on to the large surface area of 
Cab-o-sil was found in in vitro studies and it is suggested that this 
adsorption decreased the availability of salicylate in vivo and the 
in vitro release rate. 
. 
The extent of absorption of ampicillin was enhanced by inclusion 
of sucrose in the aqueous Vehicle (distilled water) to a -value close to 
those given by the simple oily vehicle and the oil with sucrose. It is 
concluded that sucrose exerts its action on GER in aqueous systems but 
produces no additional decrease over that caused by the oil itself, unless 
there is a certain concentration beyond which an additional decrease in 
GER will be observed. It is obvious, therefore, that this point should be 
borne in mind for future work. At is recommended, therefore, that more 
attention should be paid to the osmotic pressure, since this effect 
might modify the absorption of drugs from their dosage forms. 
However, with very weakly acidic and less water soluble drugs, e. g. 
ni * trofurantoin (pKa- = 7.2), opposite results are apparently obtained, i. e. 
a reduction in the extent of absorption as a result of the decrease in 
GER. together with a decrease in the rate of absorption as indicated by 
the percentage of the dose excreted in the urine. The reasons for these 
differences have already been discussed. The inclusion of sucrose in 
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oily vehicles or increasing their viscosities did not give any further 
change in the bioavailability of nitrofurantoin thus suggesting that 
the effect of the oil is predominant. 
The studies presented in this thesis relate only to a small number 
of drugs and a small range of the viscosity of the oily vehicle. 
Extension of these studies to include other drugs with-different 
solubilities and pKa values would be required before the relation between 
the effects of oil or osmotic pressure and the properties of a drug, 
that are implied by the results obtained to date, could be substantiated. 
Since the effects of viscosity and osmotic pressure were masked by the 
predominant effect of the oil, it would be worthwhile studying a wide r 
range of viscosities and higher concentrations of sucrose in the oil to 
detect any critical values beyond which these two effects might appear. 
It is suggested that the effect of oil on the bioavailability of 
the drugs studied is mostly due to its action in decreasing GER. 
However, studies on the other actions of the oil (see Chapter 1, Section 
3) and the significance of these actions in relation to the GER is 
desirable. These aims could be achieved as follows. 
(i) Comparative studies in which the drug is administered orally in 
water alone, in an aqueous, formulation containing either an anti- 
cholinergic drug, bile salts or both, or in oil. 
(Ji) Comparative studies using aqueous and oily vehicles together with 
a non-aqueous vehicle, Atch. has no effect on GER, such as glycerol or 
liquid paraffin (Roberts, 1931). 
(iii) Compara. tive studies in which a drug in an oily vehicle is 
administered directly into the duodenum as well as orally. 
(. iv) Studies using oily vehicles possessing longer hydrocarbon chains 
fatty acids than FCO, since these should have a greater effect on GER 
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and are absorbed via the lymph. 
It should be borne in mind that although a prolonged gastric 
residence time, brought about by the effects of oily vehicles or the 
osmotic pressure of a suspension or solution, may be an advantage in 
terms of bioavailability, clinical efficacy and economy of use of a 
given dosage form it might be a disadvantage if the drug concerned 
causes gastric irritation. However, oily vehicles may give an additional 
advantage in overcoming this problem by providing a protective layer on 
the gastric mucosa and hence minimising this shortcoming. If oily 
vehicles do provide a means 6f enhancing the extent of absorption of 
certain drugs and prolonging blood (plasma or serum) level curves at 
measurable' drug concentrations then such formulations may be of value 
in the treatment of chronic diseases, such as chronic rheumatism by 
salicylate, by allowing a reduction in either the dose or its frequency 
of administration. 
It should also be pointed out that the suggestions made in the 
preceding paragraph must be qualified by the fact that the in vivo 
studies in this thesis were limited to rabbits and rats. Extrapolation 
of the results obtained with these animals to humans is questionable. 
The performance of similar studies on humans is, consequently, an 
obvious suggestion for further work in this field in order to obtain a 
more reliable indication of the clinical significance of the oil and, 
osmotic pressure. Furthermore, the volume of oil used in the present 
st udies is relatively high when compared with the dose volumes that 
would be used normally in humans. Thus, the results obtained in this 
study may have more significance in relation to the effects of fatty 
meals on drug'bioavailability. 
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Finally, the results presented in this thesis suggest that the 
use of traditional in vitro dissolution rate tests in studies on 
orally administered formulations, which contain ingredients that 
have a marked effect on physiological functions, such as gastric emptying 
rate and-bile secretion, is of limited value because the tests are 
unable to take these effects into account. Thus, correl. ations between 
in*vivo and in vitro parameters cannot be established and the dissolution 
rate te sts cannot therefore be used to predict the effects of formulation 
changes on drug bioavailabilities. 
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